Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 i 
CONFIDENTIAL REVISION HISTORY 
Revisions to KX01-AK-002 protocol v2.0_26 Apr 2016 (Amendment 1 protocol) 
Current Version and Date:  v3.0_26 Sep 2016 (Amendment 2) 
Change  Rationale  Affected Protocol Sections 
Revised the length of time a female 
subject must be amenorrheic in the definition of postmenopausal (from 18 months to 12 months).
 
Revised the length of time before 
study treatment during which a highly effective means of contraception must be used (from 
[ADDRESS_717108] 30 days or 
1 menstrual cycle, whichever is 
longer ). To align with current guidelines. 
A minimum of 1 menstrual cycle 
prior to dosing is sufficient for 
subjects using highly effective 
contraception.  x Synopsis / Inclusion Criteria
x Section 9.3.[ADDRESS_717109] was taken in a previous clinical trial as exclusionary in this study (from 14 days to 30 days).
 Clinical trial subjects are followed 
for safety up to [ADDRESS_717110] study 
visit. x Synopsis / Exclusion Criteria
x Section 9.3.2
Specified KX2 -391 1% as study 
drug.  
Included treatment area borders as 
part of the application site. Clarification.  x Section [IP_ADDRESS]
x Section 9.4.4
Added measurement of height as 
part of the screening physical 
examination.  BSA may need to be calculated 
for interpretation of PK data, so 
height measurement is needed. x Table 1
x Table 2
x (new) Section [IP_ADDRESS].4
x Section [IP_ADDRESS].5
Heading name [CONTACT_548045] ‚Äú‚Ä¶ and Exposure to study 
Drug t hrough Breastfeeding‚Äù.  
Specified pregnancies include those 
occurring in a subject or in the female partner of a male subjec
t. 
Revised withdrawal from study to 
discontinuation  from treatment. Correction; section text makes no 
reference to exposure through 
breastfeeding.  
Clarification . 
Clarification.  x Section [IP_ADDRESS]
Stipulated that pi[INVESTIGATOR_2517]-related 
changes or scarring should be 
followed until resolution or deemed stabilized
 by [CONTACT_737]. Additional  safety monitoring. x Section [IP_ADDRESS].8
Revised language about reporting of 
significant treatment -emergent 
laboratory abnormalities.  Clarification . x Section [IP_ADDRESS].1
x Section [IP_ADDRESS].2
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  ii 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v2.0_26 Apr 2016 (Amendment 1 protocol) 
Current Version and Date:  v3.0_26 Sep 2016 (Amendment 2) 
Change  Rationale  Affected Protocol Sections 
Stipulated that s ubjects with a 
history of HIV, chronic hepatitis C, 
or chronic hepatitis B infection will 
be excluded from the study.  The effect of KX2-[ADDRESS_717111] these chronic infections for which they 
are on treatment i
s unknown. x Synopsis / Exclusion Criteria 
x Section 9.3.2 
Added additional ECG 
measurements for Cohort 2 . Additional safety monitoring.  x Table 2 
x Section [IP_ADDRESS].6 
Corrected miscellaneous 
punctuation/grammar errors.  Administrative.  x Throughout protocol 
  
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  iii 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change  Rationale  Affected Protocol Sections  
Added a second cohort with a 3 -day 
dosing regimen.  If the 5 -day treatment regimen  
(Cohort 1) has sufficient activity and safety, a 3
-day regimen 
(Cohort  2) will be evaluated. x Throughout protocol 
x Table 1 
x (new) Table [ADDRESS_717112] of In-Text Tables 
Added a secondary objective.  To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Objectives 
x Section 8.2 
Made sustained response an 
exploratory objective; removed it as a primary endpoint and 
revised 
exploratory endpoints and analyses 
to align with  it as an exploratory 
objective ; revised wording to 
describe analysis of recurrence 
rates.  Sustained response is more 
appropriate as exploratory because it is assessed post
-
Day 57; clarification x Synopsis  
- Objectives 
- Statistical Methods / Study 
Endpoints 
- Activity Analyses 
x Section 8.3 
x Section [IP_ADDRESS].1 
x Section [IP_ADDRESS].3 
x Section [IP_ADDRESS] 
Revised the number of subjects in 
the study.  To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Number of subjects 
x Section 9.1 
x Section 9.1.1 
Revised PK sampling timepoints. To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Pharmacokinetic 
Assessments 
x Table 4 
Removed refere nce to a Safety 
Management Plan; revised text 
regarding reporting of SAEs , deaths, 
and life -threatening events, and 
corresponding follow-up 
information . Clarification.  x Section [IP_ADDRESS] 
Revised statistical-related text to 
reflect increased number of subjects ba
sed on the addition of Cohort 2 ; 
revised text regarding  interim 
analysis.  To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis 
 - Analysis Sets 
 - Activity Analyses 
 - Safety Analyses 
 - Interim Analysis 
 - Sample Size Rationale 
x Sections [IP_ADDRESS] - [IP_ADDRESS] 
x Section [IP_ADDRESS] (entirety) 
x Section 9.7.[ADDRESS_717113] the 
intended effects of the study drug. x Synopsis / Exclusion Criteria 
x Section 9.3.2 
Increased the duration of the study 
period overall and enrollment To accommodate addition of a x Synopsis / Study Period and 
Phase of Development 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  iv 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change  Rationale  Affected Protocol Sections  
period. 3-day regimen (Cohort 2). x Synopsis / Duration of 
Participation and Treatment 
Increased the number of sites 
conducting the study.  
 
  With addition of additional sites, specified that enrollment among sites would be monitored to avoid 
imbalance.
 To accommodate increased 
number of subjects due to 
addition of Cohort 2; to facilitate 
enrollment.  
 
Clarification.  x Synopsis / Sites 
x Section 6 
 
  
x
 Synopsis / Study Design 
x Section 9.1 
x Section 9.4.3 
Revised description of study 
treatment.  Clarification.  x Table 3 
Specified  ‚Äúduring the Treatment  
Period ‚Äù with regard to withdrawal 
of subjects who become pregnant. Clarification of timeframe.  x Section [IP_ADDRESS] 
Revised text regarding collection 
and following of adverse events. 
 
Removed reference to Screening Disposition CRF/eCRF.
 Clarification of timeframe; only 
study drug -related AEs will be 
followed.  
There is no Screening Disposition 
CRF/eCRF in the study.  x Section [IP_ADDRESS].1 
Removed Appendix 1 and 
renumbered remaining appendix; 
added appropriate literature citation for reference.
 Investigators are familiar with the 
method for skin typi[INVESTIGATOR_007]; 
questionnaire and scoring system in Appendix [ADDRESS_717114] of Appendices 
x Section [IP_ADDRESS].2 
x Section [IP_ADDRESS].8 
x Section 10 
x (original) Appendix 1 (deleted) 
Revised text regarding removal of 
subjects from the therapy or 
assessment; modified some of the 
reasons for discontinuation.  Clarification.  x Section 9.3.3 
Modified text regarding restrictions 
on the use of concomitant 
medication/therapi[INVESTIGATOR_014] /topi[INVESTIGATOR_547917]; referred 
the reader to an  FDA draft guidance. Per recommendation of the 
Investigator s and subject matter 
experts ; to provide further 
guidance to the investigators.  x Synopsis / Concomitant 
Drug/Therapy 
x Section [IP_ADDRESS] 
Revised description of the Final 
Visit; specified when the Final Visit is for those who do not have complete response at Day 57.
 
 Clarification.  x Table 1 / Footnote c 
x Section 9.1.3 
x Section 9.1.4 
Specified that use of sunblock in the 
treatment area will be recorded in To be able to evaluate the activity 
of study drug in the presence and x Section [IP_ADDRESS] 
x Section [IP_ADDRESS].8 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  v 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change  Rationale  Affected Protocol Sections  
the Concomitant Medication CRF. 
 
Removed text regarding subjects not 
changing their use of concomitant 
medications.  absence of sunblock. 
 
Subjects will be able to change 
concomitant medications per the 
Investigator‚Äôs instructions.  
Removed use of body charts for 
identifying the location and shape of the treatment area.
 Not needed; this will be done 
with the acetate sheets.  x Section 9.1.1 
x Section 9.1.2 
Specified minimum timeframe 
during which subjects cannot touch 
or wet the treatment area after study 
treatment application; removed 
information regarding shower times; revised text about instructions to the subjects for care of the treatment area
. Clarification.  x Section [IP_ADDRESS] 
Revised description of sun 
exposure.  Clarification.  x Synopsis / Inclusion Criteria 
x List of Abbreviations and 
Definition of Terms 
x Section 9.3.1 
Revised description of Medical 
History.  Clarification.  x Section [IP_ADDRESS].1 
Revised description of the Final 
Visit ; specified when the Final V isit 
is for those who do not have 
complete response at Day 57.  Clarification.  x Table 1 / Footnote c 
x Section 9.1.3 
x Section 9.1.4 
Removed exclusionary use of 
moisturizers or emollients on the face or scalp within 12 hours prior to Visit
 1. Not necessary to exclude before 
Visit 1.  x Synopsis / Exclusion Criteria 
x Section 9.3.2 
Revised Medical Monitor signatory. Administrative.  x Protocol Signature [CONTACT_548046], in addition 
to pi[INVESTIGATOR_371], will be assessed at 
the visits cited.  Clarification.  x Section [IP_ADDRESS].8 / 
Pi[INVESTIGATOR_547918].
 Clarification to align with 
streamlined procedures.  x Section 9.1.1 
Revised text to ensure the signing of 
ICF prior to study procedures. Clarification.  x Section 5.3 
Revised the definition of the 
Evaluable Set.  Clarification.  x Synopsis / Number of Subjects 
Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 vi 
CONFIDENTIAL Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change  Rationale  Affected Protocol Sections  
Revised definition of ICH.  Clarification to align with recent 
ICH organizational changes.  x Investigator Signature [CONTACT_3490]
x Title Page
x List of Abbreviations and
Definition of Terms
x Section 5.1
Corrected 
typographical/punctuation/grammar errors.
 Administrative.  x Throughout protocol
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003] [COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 viii 
CONFIDENTIAL INVESTIGATOR SIGNATURE [CONTACT_36619]: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face 
or Scalp  
Investigational Product 
Name: [CONTACT_548047]2-391 Ointment 1% 
UTN Number: U1111-1173-[ADDRESS_717115] this study in accordance with all stipulations of 
the protocol and in accordance with Interna tional Council for Harmonisation of Technical 
Requirements for Registration of Pharmaceutic als for Human Use (ICH) and all applicable 
local Good Clinical Practice (GCP) guidelines, including the Declaration of Helsinki. 
<Name, degree(s)>  
Investigator Signature [CONTACT_1782] 
<Name [CONTACT_548048]>  
Study Site 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 1  
CONFIDENTIAL 
 1 TITLE PAGE 
 
CLINICAL STUDY PROTOCOL  
Study Protocol 
Number: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face or 
Scalp  
Sponsor : [LOCATION_002]: 
Kinex Pharmaceuticals, Inc.  
[ADDRESS_717116], New Jersey [ZIP_CODE], US  
Tel:  [PHONE_3096] -272-[ADDRESS_717117] Name: [CONTACT_548047]2-391 Ointment 1% 
Indication: Actinic keratosis on the face or scalp 
Phase: 2a 
Approval Date:   v1.0 
v2.0 
v3.0 23 Jan 2016 (original protocol) 
26 Apr 2016 (Amendment 1) 
26 Sep 2016 (Amendment 2) 
UTN Number: U1111-1173-5677 
GCP Statement: This study is to be performed in full compliance with International Council 
for Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) and all applicable local Good 
Clinical Practice (GCP) and regulations.  All required study documentation 
will be archived as required by [CONTACT_12721].  
Confidentiality 
Statement:  This document is confidential.  It contains proprietary information of Kinex 
Pharmaceuticals, Inc. (the Sponsor).  Any viewing or disclosure of such 
information that is not authorized in  writing by [CONTACT_55360].  Such information may be used solely for the purpose of 
reviewing or performing this study.  

Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 2  
CONFIDENTIAL 
 2 CLINICAL PROTOCOL SYNOPSIS 
Compound No.  KX2-391 
Name [CONTACT_3261]: N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) acetamide 
Study Protocol Title 
A Phase 2a, Open -Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects 
with Actinic Keratosis on the Face or Scalp  
Investigators 
, MD, Lead Principal Investigator  
[INVESTIGATOR_547919] [ADDRESS_717118] out, approximately  24 months 
Phase 2a  
Objectives 
Primary Objective: 
‚Ä¢ To evaluate the activity of KX2- 391 Ointment 1% administered topi[INVESTIGATOR_547920] (AK) by [CONTACT_547992], defined as 100% 
clearance at Day 57 
Secondary Objectives:  
‚Ä¢ To assess the activity of KX2-391 Ointment 1% during Days 1-57 
‚Ä¢ To assess the safety and tolerability of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp 
‚Ä¢ To assess the pharmacokinetics (PK) of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp 
‚Ä¢ To assess dose regimens by [CONTACT_456105] 5-day treatment with 3- day treatment in terms of the activity 
and safety of KX2-391 Ointment 1% in subjects with AK on the face or scalp 
Exploratory Objective s: 
‚Ä¢ To determine recurrence rates up to [ADDRESS_717119]- Day 57 for subjects who show response at 
Day 57 
‚Ä¢ To determine sustained response rates at [ADDRESS_717120]- Day 57 for subjects who show response at 
Day 57 
Study Design 
This study will be an open -label, multicenter, activity, safety, tolerability, and PK study of KX2 -391 
Ointment 1% administered topi[INVESTIGATOR_547921] 2 sequential 
cohorts :  a 5-day dosing regimen (Cohort 1) and a 3-day dosing regimen (Cohort 2). 
The study consists of Screening, Treatment, and Follow-up Periods. 
In Cohort 1, eligible subjects will receive 5 consecutiv e days of topi[INVESTIGATOR_35786], to be applied at the [COMPANY_003]
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 3  
CONFIDENTIAL 
 study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be 
collected on Day  1 and Day 5.  Subjects will return for Follow-up visits until Day 57.  Thereafter, only 
Day 57 complete responders will continue Recurrence Follow -up Visits every 3 months for an additional 
12 months after Day 57.  Activity (lesion counts) and safety evaluations will be performed. 
The Sponsor will review accumulating data.  If the 5-day regimen (Cohort 1) has sufficient activity and 
safety to warrant evaluating a 3-day regimen, enrollment of Cohort 2 will start after there are 60 evaluable 
subjects  or up to 80 subjects are enrolled (whichever comes first) in Cohort 1.  For the most part, protocol 
procedures for Cohort [ADDRESS_717121]/be:  
1. Males and females ‚â•18 years old  
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
x is a continuous area measuring [ADDRESS_717122] be postmenopausal (>[ADDRESS_717123] 12 months of amenorrhea), 
surgically sterile (by [CONTACT_547993], bilateral oophorectomy or tubal ligation) or otherwise incapable 
of pregnancy for at least 1 year; or, if of childbearing potential, must be using highly effective 
contraception for at least 30 days or 1 menstrual cycle, whichever is longer, prior to treatment with 
KX2- 391 Ointment 1% and must agree to continue to use highly effective contraception for at least 
[ADDRESS_717124] dose of KX2-391 Oi ntment 1%.  Highly effective contraceptio n includes 
oral hormonal contraceptives, hormonal contraceptiv e implant or patch, or intrauterine device.  
Abstinence and double barrier methods do not qualify as highly effective methods of contraception. 
5. Males who have not had a vasectomy must agree to u se barrier contraception from Screening through 
[ADDRESS_717125] dose of KX2-391 Ointment 1%. 
6. All subjects must agree not to donate sperm or eggs or attempt conception from Screening through 
[ADDRESS_717126] dose of KX2-391 Ointment 1%. 
7. Females of childbearing potential must have a negative serum pregnancy test at Screening and a 
negative urine pregnancy test on Day 1 prior to administration of study treatment. 
8. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x no physical examination (PE) findings that the Principal Investigator (PI) determines would 
interfere with interpretation of study results 
x screening electrocardiogram (ECG) without clinically significant abnormalities  
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 4  
CONFIDENTIAL 
 x clinical chemistry, hematology, and urinalysis resu lts that are within the reference ranges; clinical 
laboratory values outside the reference ranges th at are considered by [CONTACT_978] [INVESTIGATOR_547923]  
9. Willing to avoid direct sun or ultraviolet (UV) light exposure to the face or scalp  
10. Able to comprehend and are willing to sign an informed consent form (ICF)  
Exclusion Criteria 
Eligible subjects must not have/be:  
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924] 
2. Malignancy within 5 years prior to Screening except basal or squamous cell carcinoma not on the 
treatment area that were treated with curative intent and are without recurrence 
3. Used any of the following systemic therapi[INVESTIGATOR_547925] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 28 days (intra-artic ular and inhaled steroids are allowed) 
x methotrexate or other anti-metabolites; 28 days 
x immunosuppressants or immunomodulators; 28 days 
4. Used any of the following topi[INVESTIGATOR_547926] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 14 days 
x analgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
5. Had any of the following on the treatment area within 90 days (or until the site has healed, whichever 
is longer) before Visit 1: 
x ingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
x 5-fluorouracil (eg, 5-FU; Efudex) 
x imiquimod (eg, Aldara; Zyclara) 
x diclofenac with or without hyaluronic acid (eg, Solaraze) 
6. Surgical or destructive modalities on the t reatment area within 30 days (or until the site has healed 
following treatment, whichever is longer) before Visit 1: 
x cryotherapy 
x electrodesiccation 
x laser, light (eg, photodynamic therapy, intense pulsed light) or any other energy-based therapy  
x chemical peels (eg, tricholoracetic acid) 
x dermabrasion 
x surgical removal (eg, curettage, excision) 
7. Currently, or has experienced any of the following on the treatment area within the specified period 
before Visit 1: 
x cutaneous malignancy; 180 days 
x sunburn; 28 days 
x body art (eg, tattoo, pi[INVESTIGATOR_77219]); currently 
8. A history of sensitivity and/or allergy to an y of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psoriasis, ec zema) or condition (eg, scarring, open wounds) that, 
in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which 
Clinical Study Protocol Amendment [ADDRESS_717127], whichever is longer, before 
dosing 
13. A known history of human immunodeficiency virus (HIV), chronic hepatitis C, or chronic hepatitis B 
infection 
Study Treatment 
50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_231704] 5 consecutive days (Cohort 1) or 
3 consecutive days (Cohort 2) to the 25 cm2 treatment area (2 mg/cm2; 0.5 mg KX2-391 total). 
Duration of Participation and Treatment 
‚Ä¢ Planned enrollment period for each cohort:  approximately 3 months (90 days) 
‚Ä¢ Planned subject participation is approximately 64 weeks:  
o Screening Period:  up to 28 days 
o Treatment Period:  For Cohort 1, 5 consecutive treatment days (Days 1-5); for Cohort 2, 
3 consecutive treatment days (Days 1-3) 
o Follow-up Period:  Visits at Days 8, 15, 29, and 57 
o Recurrence Follow- up Period:  only for complete responders at Day 57, visits every 3 months for 
12 months after Day 57 (ie, at 3, 6, 9, and [ADDRESS_717128]-Day 57). 
Length of stay:  On Day 1 (Visit 2 , Cohorts 1 and 2) and Day 5 (Visit 6, Cohort 1) or Day 3 (Visit 4, 
Cohort 2) , subjects may stay for approximately [ADDRESS_717129] PK 
blood sample is collected.  
Concomitant Drug/Therapy 
Use of any non -study drug treatment for AK lesions on the treatment area is prohibited until Day 57 .  Any 
lesion in the treatment area that is treated during the Recurrence Follow-up Period will be considered as a 
recurrence.  
Assessments 
Activity Assessments  
The Investigator will perform a count of AK lesions for all subjects a t Visits 1 and 2, Visits 7 through 10, and 
for Day 57 complete responders, also at Visits 11 through 14. 
Safety Assessments  
Safety will be assessed by [CONTACT_547994] (AEs), serious adverse events (SAEs), laboratory 
evaluation of hematology, biochemistry, and urinalysis values, measurement of weight and vital signs, 
evaluation of ECGs, and the performance of physical examinations.  
Subjects will be queried for spontaneously reported AE s at each study visit, before assessment of local 
skin react ions (LSRs).  AEs will be reported separately from LSRs. 
Subject -reported LSRs will not be reported as adverse events.  
Other Assessments  
The LSR assessment is the Investigator‚Äôs (or trained designee ‚Äôs) assessment of the following signs on the 
treatment area:  erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration.  
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 6  
CONFIDENTIAL 
 These signs will be assessed using a grading scale ranging from 0 (not present)  
to 4 (worst).   In addition to LSRs, hypo- and hyper- pi[INVESTIGATOR_547927].  Application site reactions not classified as LSRs (eg, pruritus, 
pain, infection) will be reported as adverse events.   All application site reactions and LSRs will be 
followed to re solution, or if resolution is unl ikely, to stabilization.  LSRs will be reported separately from 
AEs.  
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 (Visit 7), 
Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717130]- Day 57).  Before 
study medication application on Day 1, the Investigator or a qualified staff member must obtain 
standardized photography of each subject‚Äôs treatment area before application of study medication.  
Pharmacokin etic Assessments 
PK samples will be collected at the following timepoints  for Cohort 1: 
‚Ä¢ Day 1:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
‚Ä¢ Day 5:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose 
PK samples will be collected at the following timepoints for Cohort 2: 
‚Ä¢ Day 1:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
‚Ä¢ Day 3:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
Pharmacodynamic, Pharmacogenomic, and Other Biomarker Assessments 
Not applicable  
Bioanalytical Methods 
Plasma concentrations of study drug will be measured using a validated liquid chromatography/tandem 
mass spectrometry (LC -MS/MS) assay. 
Statistical Methods 
Study Endpoints  
Primary Endpoint  
x Activity will be evaluated by [CONTACT_547995].  Complete response rate will be defined as 
the proportion of subjects achieving 100% complete clearance of all treated AK lesions on the face 
or scalp at Day 57.   
Secondary Endpoints  
‚Ä¢ Activity:   Reduction in lesion counts during Days 1-57 
‚Ä¢ Safety:  Evaluation of AEs and clinical laboratory data ; the results of other safety assessments (vital 
signs, physical examinations, ECGs) will also be evaluated. 
‚Ä¢ Pharmacokinetic:  Determination of C max and where applicable, AUC t, C min, and accumulation  
ratio R 
Exploratory Endpoint s 
‚Ä¢ Recurrence rate will be defined as the proportion of subjects who achieved 100% complete clearance 
at Day 57 (Visit 10) with any identified AK lesions on the treatment area at 3, 6, 9, and [ADDRESS_717131]-Day 57. 
‚Ä¢ Sustained response rate will be defined as the proportion of subjects who achieved 100% complete 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 7  
CONFIDENTIAL 
 clearance at Day 57 (Visit 10) without any identified AK lesions on the treatment area at [ADDRESS_717132]-Day 57.  
Analysis Sets  
‚Ä¢ Per-Protocol Set:  the group of protocol-eligible subjects who receive 5 days (Cohort 1) or 3 days 
(Cohort 2) of study treatment and complete at least one scheduled post-treatment evaluation. 
‚Ä¢ Evaluable Set:  the group of subjects who receive 5 days (Cohort 1) or 3 days (Cohort 2) of treatment 
and complete most evaluations including the Day 57 Follow-up Visit. 
‚Ä¢ Safety Analysis/Full Analysis Set:  the group of subjects who receive at least one dose of study 
treatment. 
‚Ä¢ PK Analysis Set: the group of subjects who receive study treatment and complete at least one 
scheduled post-treatment PK evaluation. 
Activity Analyses  
AK lesion counts will be summarized  by [CONTACT_547996] 1 (pretreatment) and at each subsequent timepoint 
for subjects in the Full Analysis Set  and the Per-Protocol Set. 
A 95% confidence interval (CI) for the complete clearance (response rate) at Day 57 will be estimated by 
[CONTACT_547997]. 
Recurrence rates for all subjects who achieved co mplete clearance at Day 57 will be estimated by 
[CONTACT_547998]. 
A 95% CI for the sustained response rate at [ADDRESS_717133] one dose of KX2-391 Ointment 1% will be included in the s afety 
analyses.  Treatment -emergent AEs (TEAEs) are defined as either those AEs with an onset after dosing or 
those pre -existing AEs that worsen after dosing.  For AEs, verbatim terms on the case report 
form/electronic case report form (CRF/eCRF) will be m apped to preferred terms (PTs) and system organ 
classes (SOCs) using the Medical Dictionary for Regulatory Activities (MedDRA; v 16. 0 or higher).  
Subject incidence of AEs will be displayed by [CONTACT_2946].   The incidence of AEs will be summarized by 
[CONTACT_9084].  Adverse events will also be summarized by [CONTACT_926], relationship to study drug , and cohort.  
Subject incidence of SAEs will also be displayed  by [CONTACT_9084] .  Laboratory parameters will be summarized 
using descriptive statistics at baseline and at each subseque nt timepoint by [CONTACT_9084] .  Changes from baseline 
will also be summarized  by [CONTACT_9084].  In addition, shift tables (ie, low-normal- high at baseline versus low-
normal -high at follow-up in a 3-by- 3 contingency table) will be provided to assess changes in laboratory 
values from baseline to follow -up in each cohort. 
Local skin reactions, pi[INVESTIGATOR_371], and scarring as reported by [CONTACT_737], will be displayed and 
summarized by [CONTACT_547999]. 
Similar to the activity analyses, any contrast between the [ADDRESS_717134] de viation (SD), median, minimum, and maximum.  
Categorical variables will be summarized by [CONTACT_374560].  All raw data obtained from the CRF/eCRF, as well as any derived data will be included in 
data listings.  
Sample Size Rationale 
For either cohort, a  sample size of [ADDRESS_717135] a 100% complete clearance rate at 
Day 57 greater than 20% with 80% power, based on a two -sided (alpha=0.05) binomial test, assuming a 
response rate of 35%, and less than a 25% dropout rate.  This corresponds to a two -sided 95% CI with a 
half-width of less than 15% (ie, lower boundary of the CI above 20%).  The sample size of Cohort 2 may 
be adjusted, depending on the results of Cohort 1.  
FINAL   v3.0_26 Sep 2016  
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 9  
CONFIDENTIAL 
 Table 1 Schedule of Procedures/Assessmen ts in Study KX01-AK-002 (Cohort 1) 
Period Screening Treatment Follow-up Recurrence Follow-up a 
Visit 1 2 3 4 5 6 7 8 9 10 b/ 
Early 
Term  11, 12, 13, [ADDRESS_717136] -Day 57c 
Visit time window (days) None None None None None None ¬±2 ¬±2 ¬±2 ¬±2 ¬±14 
Informed consent X           
Inclusion & exclusion criteria X Xd          
Demographics X           
Medical/surgical history X           
AK history/AK treatment history X           
Fitzpatrick skin-type scale X           
Vital signse X     X X X X X  
Prior and concomitant medications/therapi[INVESTIGATOR_014] X Xd X X X X X X X X X 
Physical examination, including weight and 
heightf X         X  
Treatment area identification X Xd           
AK lesion count X Xd     X X X X X 
ECGg X      X   X  
Clinical chemistry, hematology, and urinalysish X      X   X  
Pregnancy test  X Xd,i     X   X  
PK blood samples  Xj    Xj      
Study medication application  X X X X X      
AEsk X X X X X X X X X X Xl 
LSRs  Xd Xd Xd Xd Xd X X X X  
Pi[INVESTIGATOR_547928] X X X X  
Standardized photography X Xd     X   X X 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 10  
CONFIDENTIAL 
 Table 1 Schedule of Procedures/Assessmen ts in Study KX01-AK-002 (Cohort 1) 
AE = adverse event; AK = actinic kerato sis; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local skin react ion; PK = pharmacokinetic; 
Term  = Termination. 
a For Day [ADDRESS_717137] be fasted for laboratory assessments. 
i For females of childbearing potential; urine pregnancy test on Day 1 before study medication application.  All other pregnancy tests are performed with serum. 
j PK assessments on Day 1 and Day 5 at 0 hour (just before study medication application) and at 0.5 (¬±5 min), 1 and 4 hours (¬±10 min) after study drug application.  
k Before LSR assessment, subjects will be queried for spontaneously reported AEs. 
l Only AEs in the selected treatment area will be recorded. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 Page 11 
CONFIDENTIAL Table 2 Schedule of Procedures/Assessments in Study KX01-AK-002 (Cohort 2) 
Period Screening Treatment Follow-up Recurrence Follow-up a 
Visit 1 2 3 4 5 b 6 b 7 8 9 10c/ 
Early 
Term  11, 12, 13, [ADDRESS_717138] -Day 57d 
Visit time window (days) None None None None ¬±2 ¬±2 ¬±2 ¬±2 ¬±14 
Informed consent X 
Inclusion & exclusion criteria X Xe 
Demographics X 
Medical/surgical history X 
AK history/AK treatment history X 
Fitzpatrick skin-type scale X 
Vital signsf X X X X X X 
Prior and concomitant medications/therapi[INVESTIGATOR_014] X Xe X X X X X X X 
Physical examination, including weight and 
heightg X X 
Treatment area identification X Xe 
AK lesion count X Xe X X X X X 
ECGh X Xh Xh X X 
Clinical chemistry, hematology, and urinalysisi X X X 
Pregnancy test X Xe,j X X 
PK blood samples Xk Xk 
Study medication application X X X 
AEsl X X X X X X X X Xm 
LSRs Xe Xe Xe X X X X 
Pi[INVESTIGATOR_547929] X X X X
Standardized photography X Xe X X X 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 12  
CONFIDENTIAL 
 Table 2 Schedule of Procedures/Assessments in Study KX01-AK-002 (Cohort 2) 
AE = adverse event; AK = actinic kerato sis; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local skin reaction; PK = pharmacokin etic; 
Term  = Termination. 
a For Day [ADDRESS_717139] be fasted for laboratory assessments. 
j For females of childbearing potential; urine pregnancy test on Day 1 before study medication application.  All other pregnancy tests are performed with serum. 
k PK assessments on Day 1 and Day 3 at 0 hour (just before study medication application) and at 0.5 (¬±5 min), 1 and 4 hours (¬±10  min) after study drug application.  
l Before LSR assessment, subjects will be queried for spontaneously reported AEs. 
m Only AEs in the selected treatment area will be recorded. 
Clinical Study Protocol Amendment [ADDRESS_717140] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..................................17  
5 ETHICS......................................................................................................................... ...18 
5.1 Institutional Review Boards/Independent Ethics Committees ..............................[ADDRESS_717141] Information and Informed Consent ...........................................................19  
6 INVESTIGATORS AND STUDY PERSONNEL ..........................................................19  
7 INTRODUCTION ...........................................................................................................19  
7.1 Indication ...............................................................................................................19  
7.1.1  Mechanism of Action ...................................................................................20  
7.1.2  Clinical Experience with KX2-391 ..............................................................20  
7.2 Study Rationale ......................................................................................................21  
8 STUDY OBJECTIVES ....................................................................................................21  
8.1 Primary Objective ..................................................................................................21  
8.2 Secondary Objectives.............................................................................................21  
8.3 Exploratory Objectives ..........................................................................................22  
9 INVESTIGATIONAL PLAN ..........................................................................................22  
9.1 Overall Study Design and Plan ..............................................................................22  
9.1.1  Screening Period ..........................................................................................23  
9.1.2  Treatment Period ..........................................................................................24  
9.1.3  Follow-up Period .........................................................................................24  
9.1.4  Recurrence Follow-up Period ......................................................................24  
9.2 Discussion of Study Design, Including Choice of Control Groups .......................25  
9.3 Selection of Study Population ................................................................................25  
9.3.1  Inclusion Criteria .........................................................................................25  
9.3.2  Exclusion Criteria ........................................................................................26  
9.3.3  Removal of Subjects from Therapy or Assessment .....................................27  
9.4 Treatments..............................................................................................................28  
9.4.1  Treatment Administered ..............................................................................28  
9.4.2  Identity of Investigational Products .............................................................29  
 Chemical Name [CONTACT_548049]2-391 .........................29  
 Labeling for Study Drug ......................................................................29  
 Storage Conditions ...............................................................................30  
Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 Page 14 
CONFIDENTIAL  Administration of Investigational Products .........................................[ADDRESS_717142] ..........................................31  
9.4.6  Blinding........................................................................................................31  
9.4.7  Prior and Concomitant Therapy ...................................................................31  
 Prior Therapy .......................................................................................31  
 Concomitant Medication/Therapy .......................................................31  
 Prohibited Medication/Therapy ...........................................................32  
9.4.8  Prohibitions and Restrictions during Study Period ......................................33  
9.4.9  Treatment Compliance .................................................................................33  
9.4.10  Drug Supplies and Accountability ...............................................................33  
9.5 Study Assessments .................................................................................................34  
9.5.1  Assessments .................................................................................................34  
 Demography .........................................................................................34  
 Baseline Assessments ..........................................................................34  
[IP_ADDRESS].1  Medical/Surgical and Actinic Keratosis History ...........................34  
[IP_ADDRESS].2  Fitzpatrick Skin-Type Classification .............................................34  
[IP_ADDRESS].3  Prior Medications ...........................................................................35  
[IP_ADDRESS].4  Height .............................................................................................35  
 Activity Assessments ...........................................................................35  
[IP_ADDRESS].1  Actinic Keratosis Lesion Count .....................................................35  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Assessments .............................................................36  
[IP_ADDRESS].1  Pharmacokinetic Assessments .......................................................36  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Assessments ...................................................................................36  
 Safety Assessments ..............................................................................36  
[IP_ADDRESS].[ADDRESS_717143] ................................37  
[IP_ADDRESS].[ADDRESS_717144] ...................39  
[IP_ADDRESS].3  Laboratory Measurements .............................................................40  
[IP_ADDRESS].4  Vital Signs ......................................................................................41  
[IP_ADDRESS].5  Physical Examinations ...................................................................41  
[IP_ADDRESS].6  Electrocardiograms ........................................................................42  
[IP_ADDRESS].7  Pregnancy Testing ..........................................................................42  
[IP_ADDRESS].[ADDRESS_717145]..........................................................................................................44  
 Reporting of Serious Adverse Events ..................................................44  
 Reporting of Pregnancy .......................................................................45  
 Reporting of Other Events of Interest ..................................................46  
[IP_ADDRESS].1  Reporting of Adverse Events Associated With Study Drug 
Overdose, Misuse, Abuse, or Medication Error ............................46  
 Expedited Reporting ............................................................................46  
 Breaking the Blind ...............................................................................46  
 Regulatory Reporting of Adverse Events ............................................46  
9.5.4  Completion/Discontinuation of Subjects .....................................................46  
9.5.5  Abuse or Diversion of Study Drug ..............................................................47  
9.5.6  Confirmation of Medical Care by [CONTACT_548000] ..................................47  
9.6 Data Quality Assurance .........................................................................................47  
9.6.1  Data Collection ............................................................................................47  
9.6.2  Clinical Data Management ..........................................................................48  
9.7 Statistical Methods .................................................................................................48  
9.7.1  Statistical and Analytical Plans ....................................................................48  
 Study Endpoints ...................................................................................48  
[IP_ADDRESS].1  Primary Endpoints .........................................................................48  
[IP_ADDRESS].2  Secondary Endpoints .....................................................................49  
[IP_ADDRESS].3  Exploratory Endpoints ...................................................................49  
 Definitions of Analysis Sets.................................................................49  
 Subject Disposition ..............................................................................50  
 Demographic and Other Baseline Characteristics ...............................50  
 Prior and Concomitant Therapy ...........................................................50  
 Activity Analyses .................................................................................50  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Analyses ...................................................................51  
[IP_ADDRESS].1  Pharmacokinetic Analyses .............................................................51  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Analyses .........................................................................................51  
 Safety Analyses ....................................................................................51  
[IP_ADDRESS].1  Extent of Exposure .........................................................................51  
[IP_ADDRESS].2  Adverse Events ..............................................................................51  
[IP_ADDRESS].3  Laboratory Values ..........................................................................52  
[IP_ADDRESS].4  Vital Signs ......................................................................................52  
[IP_ADDRESS].5  Electrocardiograms ........................................................................52  
Clinical Study Protocol Amendment 2 KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016 Page 16 
CONFIDENTIAL [IP_ADDRESS].6  Physical Examinations ...................................................................52  
[IP_ADDRESS].7  Pregnancy Tests .............................................................................52  
[IP_ADDRESS].8  Other Analyses ...............................................................................52  
9.7.2  Determination of Sample Size .....................................................................53  
9.7.3  Interim Analysis ...........................................................................................53  
9.7.4  Other Statistical/Analytical Issues ...............................................................[ADDRESS_717146] OF IN-TEXT TABLES 
Table 1  Schedule of Procedures/Assessm ents in Study KX01-AK-002 
(Cohort 1) .....................................................................................................9  
Table 2  Schedule of Procedures/Assessm ents in Study KX01-AK-002 
(Cohort 2) ...................................................................................................[ADDRESS_717147] OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Terms 
AE adverse event 
AK actinic keratosis 
AUC area under the plasma concentration-time curve  
CFR Code of Federal Regulations 
CI confidence interval 
Cmax maximum plasma concentration 
Cmin minimum (trough) plasma concentration 
CRA clinical research associate 
CRF case report form 
CRO contract research organization 
ECG electrocardiogram 
eCRF electronic case report form 
GCP Good Clinical Practice 
ICF informed consent form 
ICH International Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
LC-MS/MS liquid chromatography/tandem mass spectrometry 
LSR local skin reaction 
MedDRA Medical Dictionary for Regulatory Activities 
PE physical examination 
PI [INVESTIGATOR_547930] 
R accumulation ratio 
SAE serious adverse event 
SCC squamous cell carcinoma 
SD standard deviation 
SOC system organ class 
SOP standard operating procedure 
TEAE treatment-emergent adverse event 
US [LOCATION_002] 
UV ultraviolet (light) 
 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 18  
CONFIDENTIAL 
 5 ETHICS 
5.1 Institutional Review Boards/Independent Ethics Committees 
The protocol, any protocol amendments, infor med consent form (ICF), and appropriate 
related documents must be reviewed and approve d before subjects are screened for entry by 
[CONTACT_3551] (IRB) or Indepe ndent Ethics Committee (IEC) constituted and 
functioning in accordance with International Council for Harmonisation (ICH) E6 (Good 
Clinical Practice [GCP ]1), Section 3, and any local regulations (eg, Federal Regulations, Title 
21 Code of Federal Regulations [CFR] Part 56 ).  Documentation of IRB/IEC compliance 
with the ICH E6 and any local regulations rega rding constitution and review conduct will be 
provided to the Sponsor. 
A signed letter of study approval from the IRB/IEC chairman must be sent to the Principal 
Investigator (PI) with a copy to the Sponsor be fore study start and the release of any study 
drug to the site by [CONTACT_4885] (ICH E6, Section 4.4).  If the IRB/IEC decides 
to suspend or terminate the study, the Investig ator will immediately send the notice of study 
suspension or termination by [CONTACT_1201]/IEC to the Sponsor. 
Study progress is to be reported to IRB/IECs annually (or as required) by [CONTACT_425826], depending on local regulatory obligations.  If the Investigator is required to report 
to the IRB/IEC, he/she will forward a copy to the Sponsor at the time of each periodic report.  
The Investigator(s) or the Sponsor will subm it, depending on local regulations, periodic 
reports and inform the IRB/IEC of any reportable adverse events (AEs) per ICH guidelines and local IRB/IEC standards of practice.  Upon co mpletion of the study, the Investigator will 
provide the IRB/IEC with a brief report of the outcome of the study, if required. 
5.[ADDRESS_717148] operating procedures (SOPs) of the 
Sponsor (or designee), which are designed to en sure adherence to GCP guidelines as required 
by [CONTACT_716]: 
‚Ä¢ Principles of the World Medical Assoc iation Declaration of Helsinki (2013) 
‚Ä¢ ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance, US 
Department of Health and Human Services, Food and Drug Administration, April 1996.  
‚Ä¢ Title 21 of the [LOCATION_002] CFR (US 21 CFR) regarding clinical studies, including Part 
[ADDRESS_717149] the nature of the study, its pu rpose, the procedures i nvolved, the expected 
duration, the potential risks and benefits involved, any potential discomfort, potential alternative procedure(s) or course( s) of treatment available to the subject, and the extent of 
maintaining confidentiality of the subject‚Äôs reco rds.  Each subject must be informed that 
participation in the study is voluntary, that he/s he may withdraw from the study at any time, 
and that withdrawal of consent will not affe ct his/her subsequent medical treatment or 
relationship with the treating physician. 
This informed consent should be given by [CONTACT_15276] a standard written statement, written in 
nontechnical language.  The subject should understand the statement before signing and 
dating it, and will be given a copy of the signed  document.  If a subject is unable to read, an 
impartial witness should be present during the entire informed consent discussion.  After the 
ICF and any other written information to be provided to subjects is read and explained to the 
subject, and after the subject provides verbal consent to the subject‚Äôs participation  in the 
study and has signed and personally dated th e ICF, the witness should sign and personally 
date the consent form.  The subject will be asked to sign an ICF and all authorizations required by [CONTACT_1769] (eg, Protected Health Information in North America) before any study-specific procedures are performed.  No subject can en ter the study before his/her informed consent 
has been obtained. 
An unsigned copy of an IRB/IEC-approved ICF must be prepared in accordance with 
ICH E6, Section 4, and all applicable local regulations.  The original, signed ICF for each subject will be verified by [CONTACT_548001]. 
6 INVESTIGATORS AND STUDY PERSONNEL 
This study will be conducted by [CONTACT_548002], Inc. at approximately 8 to 16 i nvestigational sites in the [LOCATION_002] (US). 
The name [CONTACT_548050] [CONTACT_548003] o rganizations (CROs) will be listed in the 
Regulatory Binder provided to the site. 
7 INTRODUCTION 
7.1 Indication 
In this study, the activity, safety, and pharm acokinetics (PK) of KX2-391 Ointment 1% will 
be evaluated in adult subjects with a clinical diagnosis of stable, clinically typi[INVESTIGATOR_547931] (AK) on the face or scalp. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 20  
CONFIDENTIAL 
 7.1.1 Mechanism of Action 
KX2-391 (also referred to as KX01) is a synt hetic and highly selective inhibitor of Src 
tyrosine kinase signaling and tubulin polymer ization. KX2-[ADDRESS_717150] overall response in  these early studies has been ‚Äòstable disease‚Äô 
in 25-30% of patients. 
KX2-391 promotes the induction of p53, G2/M arrest of proliferating cell populations and 
subsequent apoptosis via the stimulation of Ca spase-[ADDRESS_717151] clinical activity in dermatology indications 
such as actinic keratosis.  Potent inhibition of the growth of primary human keratinocytes and 
several melanoma cell lines in vitro (50% growth inhibition [GI
50 values] ‚â§50 nM), suggests 
that KX2-391 has the potential to inhibit the proliferative expansion and promote apoptosis 
of abnormally proliferating cells in the epi[INVESTIGATOR_547932]. 
KX2-391 has also been observed to inhibit T cell migration and endothelial tubule formation 
in vitro, suggesting additional potential therapeutic benefits for conditions where pathology is supported by [CONTACT_548004], inflammation, and/or angiogenesis. 
Information regarding KX2-391 nonclinical studies is provided in the Investigato r‚Äôs 
Brochure. 
7.1.2 Clinical Experience with 
KX2-391  
KX2-391 Ointment 1% has been administered  to humans in ongoing study KX01-AK-01-
US.  Based on preliminary PK data from this study in AK lesions on the forearm, the systemic exposure to KX2-[ADDRESS_717152] ication site reactions and systemic toxicity. 
KX2-391 has been administered orally to a pproximately 120 patients with malignancy. 
The Kinex studies of oral KX2-391 are as follows: 
KX2-391 was evaluated in a Phase I clinical trial, Study No. KX01-01- 07, entitled ‚ÄúA 
Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase I Study to Evaluate Safety, Tolerability, and Pharmacoki netics of KX2-391 in Patients with Advanced 
Malignancies That Are Refractory to Conventional Therapi[INVESTIGATOR_014]‚Äù.  
KX2-391 has been evaluated in Study No. KX01-002- 09, entitled ‚ÄúA Phase II, Open -Label, 
Single-Arm Study Evaluating the Safety, Ef ficacy and Pharmacokinetics of KX2-[ADDRESS_717153] Not Received 
Prior Chemotherapy.‚Äù  
KX2-391 was evaluated in Study No, KX01-03- 11, ‚ÄúA Phase 1b Rising Multi ple-Dose 
Clinical Study to Evaluate Safety, Tolerabili ty and Activity of Oral Monotherapy with 
KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy‚Äù.  
7.2 Study Rationale 
Actinic keratoses represent the initial intra-epi[INVESTIGATOR_547933] a (SCC).  Squamous 
cell carcinoma is the second leading cause of skin cancer deaths in the US, with up to 65% of 
SCC arising from pre-existing actinic keratoses.2,3  The risk of progression has been 
determined to be between  0.025% and 16% per year,2,4 and the calculated lifetime risk of 
malignant transformation for a patient with AKs followed up for 10 years is between 6.1% and 10.2%.
5  The rationale behind treating every AK is  based on the difficulty in predicting 
which single AK will progress to squamous cell carcinoma.6,7  Suchniak et al8 reported 36% 
of lesions previously diagnosed clinically as AKs being in fact SCC, with 14% being in situ SCC.  Ehrig et al
9 showed that 4% of AKs clinically diagnosed by [CONTACT_17685]-certified 
dermatologists were in fact SCC and 5% were  considered occult early stage of cutaneous 
malignancy.  Spontaneous regression has been  reported in up to 25.9% of AKs over a 
12-month period, although 15% later reappeared.10,11,[ADDRESS_717154] cosmetically acceptable 
outcomes.  Current approved/marketed trea tment has shown up to approximately 60% 
efficacy, with a recurrence rate of approximately 35%. 
8 STUDY OBJECTIVES 
8.1 Primary Objective 
The primary objective of the study is: 
‚Ä¢ To evaluate the activity of KX2-391 Ointment 1% administered topi[INVESTIGATOR_547934], defined as 100% 
clearance at Day 57 
8.2 Secondary Objectives 
The secondary objectives of the study are: 
x To assess the activity of KX2-391 Ointment 1% during Days 1-57 
x To assess the safety and tolerability of KX2-391 Ointment 1% in subjects with AK on 
the face or scalp 
x To assess the PK of KX2-391 Ointment 1% in subjects with AK on the face or scalp 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 22  
CONFIDENTIAL 
 x To assess dose regimens by [CONTACT_456105] 5-da y treatment with 3-da y treatment in terms 
of the activity and safety of KX2-391 Ointment  1% in subjects with AK on the face 
or scalp 
8.3 Exploratory Objectives 
The exploratory objectives of the study are: 
x To determine recurrence rates up to [ADDRESS_717155]-Day 57 for subjects who 
show response at Day 57 
9 INVESTIGATIONAL PLAN 
9.1 Overall Study Design and Plan 
This study will be an open-label, multicenter, activity, safety, tolerability, and PK study of 
KX2-391 Ointment 1% administered topi[INVESTIGATOR_547935] 2 sequential c ohorts:  a 5-day dosing regimen (Cohort 1) and a 3-day dosing 
regimen (Cohort 2). 
The study consists of Screening, Treatment, and Follow-up Periods. 
Cohort 1:  
Eligible subjects will receive 5 consecutive days  of topi[INVESTIGATOR_35786], to be applied at the 
study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 and Day 5.  Subjects will return for Follow-up visits until Day 57.  
Thereafter, only Day 57 complete responders w ill continue Recurrence Follow-up Visits 
every 3 months for an additional 12 months afte r Day 57.  Activity (lesion counts) and safety 
evaluations will be performed. 
Cohort 2: 
Eligible subjects will receive 3 consecutive days  of topi[INVESTIGATOR_35786], to be applied at the 
study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 and Day 3.  Subjects will return for Follow-up visits until Day 57.  
Thereafter, only Day 57 complete responders w ill continue Recurrence Follow-up Visits 
every 3 months for an additional 12 months afte r Day 57.  Activity (lesion counts) and safety 
evaluations will be performed. 
For both cohorts, subjects may stay for approx imately [ADDRESS_717156] PK blood sample is coll ected on Days 1 and 5 (Cohort 1) or Days 1 and 3 
(Cohort 2). 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 23  
CONFIDENTIAL 
 The Sponsor will review accumulating data.  If the 5-day regime n (Cohort 1) has sufficient 
activity and safety to warrant evaluating a 3- day regimen, enrollment of Cohort 2 will start 
after there are 60 evaluable subjects or up to 80 s ubjects are enrolled (whichever comes first) 
in Cohort 1.  For the most part, protocol proc edures for Cohort [ADDRESS_717157] dose of study drug.  All screening assessments/evaluations, as presented in Table [ADDRESS_717158] provides informed 
consent and eligibility criteria are met. 
Treatment Area Identification 
At Screening (Visit 1), the Investigator will se lect a continuous treatment area affected with 
AK on the face or scalp for each subject that: 
x measures 25 cm
2 
x contains 4 to 8 AK lesions that are clinically typi[INVESTIGATOR_547936]. 
At Visit 1, the Investigator and an investigational center staff member will identify the 
treatment area by:  
x Examining the face or scalp and locating e ach AK with a dot of removable marker. 
x Using an [ADDRESS_717159] 2 anatomical landmarks on the acetate sheet.  Example of landmarks 
could be bony prominences, scars, moles, seborrheic keratosis, and veins. 
x Indicating the location of AK lesions with  permanent marker dots on the acetate 
transparency sheet. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 24  
CONFIDENTIAL 
 x Outlining the treatment area on the transparency sheet with the permanent marker. 
x Removing marker dots on the face/scalp with  alcohol swabs or water (after taking the 
screening photo). 
9.1.2 Treatment Period 
The inclusion/exclusion criteria will be review ed again prior to treatment on Day 1, to 
re-confirm subjects‚Äô eligibility to participate in the study . 
Subjects in Cohort 1 will be treated for 5 cons ecutive days (Days 1-5 [Visits 2-6]) during the 
Treatment Period.  Visits 2 through 6 should be scheduled to occur at approximately the 
same time each day. 
Subjects in Cohort 2 will be treated for 3 cons ecutive days (Days 1-3 [Visits 2-4]) during the 
Treatment Period.  Subjects will not return on Day 4 (Visit 5) or Day 5 (Visit 6).  Visits 2 
through 4 should be scheduled to occur at approximately the same time each day.  
At Visit 2 (Day 1), prior to study drug application, the Investigator and any appropriate 
investigational staff member(s) (Investigator-tra ined designee) will confirm the location of 
the treatment area using the Visit 1 acetate sheet.  The Investigator should re-mark the 
treatment area borders as needed so the study evaluations may be effectively completed. 
Once the treatment area has been re-ident ified at Visit 2, photographs will be taken 
(Section [IP_ADDRESS].8) .  50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_231704] 
5 consecutive days (Cohort 1) or 3 consecutive days (Cohort 2) to the 25 cm2 treatment area 
(2 mg/cm2; 0.5 mg KX2-391 total).  See Section [IP_ADDRESS] for a detailed description of study 
medication application. 
Pharmacokinetic blood sampling, activity, safety assessments, and local skin reaction (LSR) 
assessments (see Section 9.5 for details) will be performed ( Table 1 and Table 2 ).  
Pi[INVESTIGATOR_547937] (or a 
trained designee). 
Standardized photography will be performed at  designated visits throughout the study 
(Table 1 and Table 2 ). 
9.1.[ADDRESS_717160]-Day 57 (ie, at 3, 6, 9, and [ADDRESS_717161]-Day 57) to assess recurrence of AK lesions .  These subjects will continue to undergo 
scheduled activity and safety assessments ( Table 1 and Table 2 ). 
For subjects who have complete response at Day [ADDRESS_717162] their Final Visit at the visit when the AK recurrence is identified.  
9.2 Discussion of Study Design, Including Choice of Control Groups 
This is a nonrandomized, open-label study.   No control group has been included. 
9.3 Selection of Study Population 
Eligible subjects will be adults (‚â•18 years of age) with a clinical diagnosis of stable, 
clinically typi[INVESTIGATOR_547938]. 
9.3.1 Inclusion Criteria 
Inclusion criteria will be rev iewed at Screening (Visit 1). 
Subjects must meet all of the following criteria to be included in this study: 
1. Males and females ‚â•18 years old  
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
x is a continuous area measuring [ADDRESS_717163] be postmenopausal (>[ADDRESS_717164] 12 months of 
amenorrhea), surgically sterile (by [CONTACT_548005], bilateral oophorectomy or tubal 
ligation) or otherwise incapable of pregnancy fo r at least 1 year; or, if of childbearing 
potential, must be using highly effectiv e contraception for at least 30 days or 
1 menstrual cycle, whichever is longer,  prior to treatment with KX2-391 Ointment 1% 
and must agree to continue to use highly effective contraception for at least [ADDRESS_717165] dose of KX2-391 Ointment  1%.  Highly effective contraception 
includes oral hormonal contraceptives, hormona l contraceptive implant or patch, or 
intrauterine device.  Abstinence and double barrier methods do not qualify as highly effective methods of contraception. 
5. Males who have not had a vasectomy must agree to use barrier contraception from 
Screening through [ADDRESS_717166] dose of KX2-391 Ointment 1%. 
6. All subjects must agree not to donate sper m or eggs or attempt conception from 
Screening through [ADDRESS_717167] dose of KX2-391 Ointment 1%. 
7. Females of childbearing potential must have a negative serum pregnancy test at 
Screening and a negative urine pregnancy test on Day 1 prior to administration of study 
treatment. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 26  
CONFIDENTIAL 
 8. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x no physical examination (PE) findings that th e Principal Investigator (PI) determines 
would interfere with interpretation of study results 
x screening electrocardiogram (ECG) without  clinically significant abnormalities  
x clinical chemistry, hematology, and urinalysis results that are within the reference 
ranges; clinical laboratory values outside the reference ranges that are considered by 
[CONTACT_978] [INVESTIGATOR_547939]  
9. Willing to avoid direct sun or ultraviolet (UV) light exposure to the face or scalp  
10. Able to comprehend and are willing to sign an informed consent form  
9.3.2 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from this study: 
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924] 
2. Malignancy within 5 years prior to Screenin g except basal or squamous cell carcinoma 
not on the treatment area that were treated  with curative intent and are without 
recurrence 
3. Used any of the following systemic therapi[INVESTIGATOR_547940] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 28 days (intra-articu lar and inhaled steroids are allowed) 
x methotrexate or other anti-metabolites; 28 days 
x immunosuppressants or immunomodulators; 28 days 
4. Used any of the following topi[INVESTIGATOR_547941] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 14 days 
x analgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
5. Had any of the following on the treatment area within 90 days (or until the site has 
healed, whichever is longer) before Visit 1: 
x ingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
x 5-fluorouracil (eg, 5-FU; Efudex) 
x imiquimod (eg, Aldara; Zyclara) 
x diclofenac with or without hyaluronic acid (eg, Solaraze) 
6. Surgical or destructive modalities on the treatm ent area within 30 days (or until the site 
has healed following treatment, wh ichever is longer) before Visit 1: 
x cryotherapy 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 27  
CONFIDENTIAL 
 x electrodesiccation 
x laser, light (eg, photodynamic therapy, intense pulsed light) or any other energy-based 
therapy 
x chemical peels (eg, tricholoracetic acid) 
x dermabrasion 
x surgical removal (eg, curettage, excision) 
7. Currently, or has experienced any of the following on the treatment area within the 
specified period before Visit 1: 
x cutaneous malignancy; 180 days 
x sunburn; 28 days 
x body art (eg, tattoo, pi[INVESTIGATOR_77219]); currently 
8. A history of sensitivity and/or allergy to any of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psorias is, eczema) or condition (eg, scarring, open 
wounds) that, in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which exposes the subj ect to an unacceptable risk by [CONTACT_160823] 
10. Other significant uncontrolled or unstable medic al diseases or conditions that, in the 
opi[INVESTIGATOR_689], would expose the subject to unacceptable risk by [CONTACT_160823] 
11. Females who are pregnant or nursing 
12. Participated in an investigational drug tria l during which an investigational study 
medication was administered within [ADDRESS_717168], whichever is longer, before dosing 
13. A known history of human immunodeficiency virus (HIV), chronic hepatitis C, or 
chronic hepatitis B infection 
9.3.[ADDRESS_717169] from the study for any of 
the reasons listed below:  
x Occurrence of AEs 
x Occurrence of pregnancy  
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 28  
CONFIDENTIAL 
 x Use of a prohibited concomitant medication or treatment (see Section [IP_ADDRESS] ) 
x Conditions that, in the opi[INVESTIGATOR_689] , would make the subject‚Äôs 
continued participation in the study in advisable (actual condition must be 
documented) 
x Noncompliance (Investigator must describe) 
x Withdrawal of consent (subject asked, but not required to give a reason) 
x Other (Investigato r must describe) 
If the study is terminated by [CONTACT_1034], the Inve stigator will promptly explain to the subject 
involved that the study will be discontinued and provide appropriate medical treatment and 
other necessary measures for the subject. 
9.[ADDRESS_717170] in the study is KX2-391 Ointment 1%. 
9.4.[ADDRESS_717171]  Strength Size of 
Treatment 
Area Quantity study 
medication/ 
KX2- 391 Number 
Applications 
and Frequency Study Days 
Administered  
KX2 -391 Ointment 1% 1% 25 cm2 50 mg of study 
drug = 0.5 mg 
of KX2- 391 1 application 
daily for 
5 consecutive 
days (Cohort 1) 
or 3 consecutive 
days (Cohort 2) Days 1 -5 (Cohort 1) 
Days 1 -3 (Cohort 2) 
 
9.4.2 Identity of Investigational Products 
 Chemical Name [CONTACT_548049]2-391 
x Study drug code:  KX2-391 Ointment 1% 
x Drug Product:  KX2-391 free base ointment formulated with glyceryl 
monostearate and propylene glycol 
x Chemical name:  N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) 
acetamide   
x Molecular formula:  C 26H29N3O3 
x Molecular weight:  431.53 g/mole 
x Structural formula:   
 
 Labeling for Study Drug 
Investigational product will be packaged and labeled in a manner consistent with the study 
and will be designed by:  
[CONTACT_548006], Inc. 
[ADDRESS_717172] will be  in accordance with US regulations and will 
include (but will not be limited to) the following information: 
‚Ä¢  For clinical study use only 
‚Ä¢ Name [CONTACT_49256] 
‚Ä¢ Chemical name/drug identifier 
‚Ä¢ Lot number/batch number 
‚Ä¢ Storage conditions, expi[INVESTIGATOR_547942] w ith labeled storage conditions. Temperature 
monitoring is required at the storage location to ensure that the study drug is maintained 
within an established temperature range.  The Investigator is responsible for ensuring that the temperature is monitored throughout the tota l duration of the trial and that records are 
maintained; the temperature should be monitored continuously by [CONTACT_548007], a mechanical recording device, such as a calibrated chart 
recorder, or by [CONTACT_3177], such that minimu m and maximum thermometric values over a 
specific time period can be recorded and retrieved as required. 
 Administration of Investigational Products 
The study medication is for external topi[INVESTIGATOR_453609] e on the treatment area.  An investigational 
center staff member will perform the study medic ation applications.  Th e staff member must 
wash her/his hands before and after each study medication application. 
50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_547943] a 25 cm2 treatment area.  This 
amount contains a total of 0.5 mg KX2-391 free  base.  KX2-391 Ointment 1% will be 
applied once daily for 5 consecutive days (Cohort 1) or 3 consecutive days (Cohort 2) (see 
Table 3 ). 
The staff member will weigh the appropriate amount of study medication into a weighing 
boat (or equivalent) using a calibrated scale.  The amount of study medication applied will be 
calculated by [CONTACT_548008].  The amount of study medication weighed will be as 
close to the intended dose as possible. 
A study staff member will perform and document a scale accuracy check at least every day 
before weighing study medication. 
KX2-391 Ointment 1% will be applied to the subject‚Äôs treatment area using a fingertip 
protected with a powder-free finger cot or examin ation glove.  The study medication will be 
gently and evenly rubbed over the treatment area, including its borders, until no visible 
accumulation is evident. The time when the study medication application is completed 
(Application Completion Time) will be recorded. 
Clinical Study Protocol Amendment [ADDRESS_717173] application and are not 
allowed to apply any topi[INVESTIGATOR_547944] (see Section [IP_ADDRESS] ).  Instructions 
will be sent home with the subject clarifying on how to care for the treatment area. 
9.4.3 Method of Assigning S ubjects to Treatment Groups 
This is an open-label study with 2 sequential cohorts.  Each site will enroll subjects for 
Cohort 1 (5-day regimen) first, and will not a ssign any subjects to Cohort 2 (3-day regimen) 
until being notified.  The Sponsor will review accumulating data on Cohort 1 to decide if, 
when, and where to start Cohort 2.  In addi tion, the Sponsor study team will monitor the 
enrollment status closely and ensure that any individual site does not enroll too many subjects. 
9.4.4 Selection of Doses in the Study 
The dose of 50 mg of KX2-391 Ointment 1% applied to a 25 cm
2 area on the face or scalp 
for 5 or 3 consecutive days is based on a previ ous study using the same dose regimen for the 
treatment of AK on the forearm (study KX01-AK- 01-US).  Preliminary data show that this 
regimen had an acceptable LSR and safety profile, with efficacy outcomes considered to warrant further investigation. 
9.4.[ADDRESS_717174] 
Section [IP_ADDRESS] provides detailed instructions for admini stering KX2-391 Ointment 1% in 
this study.  Study medication should be applied at about the same time each day. 
9.4.6 Blinding 
The study will not be blinded. 
9.4.7 Prior and Concomitant Therapy 
 Prior Therapy 
All medications (prescription and nonprescription including vitamins and dietary 
supplements), treatments, and therapi[INVESTIGATOR_547945] [ADDRESS_717175] be recorde d in the case report form/electronic case report 
form (CRF/eCRF).  A complete AK treatment hist ory will be recorded on the AK Treatment 
History CRF/eCRF (see Section [IP_ADDRESS].1 ). 
 Concomitant Medication/Therapy 
Concomitant medication/therapi[INVESTIGATOR_547946]. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 32  
CONFIDENTIAL 
 Any medication (including nonprescription medications) or therapy administered to the 
subject during the course of the study (startin g at the date of informed consent) will be 
recorded on the Concomitant Medication CRF/eCRF. 
Use of sunblock or any topi[INVESTIGATOR_547947]/eCRF. 
The Investigator will record any AE on the Adverse Events CRF/eCRF for which the 
concomitant medication/ther apy was administered.  
Subjects will refrain from receipt of any th erapy in accordance with the inclusion/exclusion 
criteria. 
 Prohibited Medication/Therapy 
Use of any non-study drug treatment for AK lesions on the treatment area is prohibited until Day 57.  AK lesions located outside the treatm ent area may be treated by [CONTACT_240765]-directed 
treatment only, eg, cryotherapy or biopsy, as determined by [CONTACT_737].  A list of prohibited medications follows. 
Prohibited drug products and treatments that migh t influence or mask the effects of treatment 
until Day 57 include:  immunomodulators or im munosuppressive therapi[INVESTIGATOR_014], cytotoxic drugs, 
interferon/interferon inducers, topi[INVESTIGATOR_547948], 5-FU, ingenol mebutate, 
imiquimod, diclofenac, topi[INVESTIGATOR_547949], topi[INVESTIGATOR_547950] c acid, bichloroacetic 
acid, trichloroacetic acid, acid-containing therapeutic products, benzoyl peroxide, 
chemodestruction, medicated/therap eutic topi[INVESTIGATOR_547951], photodynamic 
therapy, psoralen plus UVA or UVB therapy, artificial tanner, excessive or prolonged 
exposure to UV light source.
13 
During the Recurrence Follow-up Period, lesion-di rected treatment such as cryotherapy or 
biopsy, and topi[INVESTIGATOR_547952].  Any lesion in the treatment area that is treated during the Recurrence Follow-up Period will be considered as a recurrence. 
Subjects are prohibited from applying any t opi[INVESTIGATOR_49186], including but not limited to, 
lotions, creams, and ointments to the treatmen t area up until the end of Visit 10 (Day 57), 
except when those medications are prescribed by [CONTACT_548009].  All other routinely used  topi[INVESTIGATOR_547953] [ADDRESS_717176] unrestricted use of nonmedi cated topi[INVESTIGATOR_547954].  After Day 57, all routinely used topi[INVESTIGATOR_547955]. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 33  
CONFIDENTIAL 
 Any subjects who start systemic therapi[INVESTIGATOR_256957] e treatment of AK will be withdrawn from 
the study. 
Any subjects who start topi[INVESTIGATOR_547956]. 
The decision to administer a prohibited medication/treatment is done with the safety of the 
study subject as the primary consideration. 
9.4.[ADDRESS_717177] be fasted for laboratory 
assessments (see Section [IP_ADDRESS].3 ); otherwise there are no food, water, beverage, or physical 
activity restrictions during the study. 
9.4.[ADDRESS_717178] will be kept during the study.  The 
clinical research associates (CRAs) will rev iew treatment administ ration throughout the 
course of the study. 
9.4.10 Drug Supplies and Accountability 
The Investigator and study staff will be responsible for the accountability of all clinical 
supplies (dispensing, inventory, and record keep ing) following the Sponsor‚Äôs instructions.  In 
this matter, the Investigator and study staff must adhere to GCP guidelines, as well as national requirements. 
Under no circumstances will the Investigator allo w the study drugs to be used other than as 
directed by [CONTACT_3181].  Clinical supplies will be dispensed only by [CONTACT_548010] y individual who is not enrolled in the study. 
An accurate and timely record of the receipt of all clinical supplies and dispensing of study 
drug to the subject must be maintained.  This includes, but is not limited to: 
x documentation of receipt of clinical supplies 
x study drugs dispensing/return reconciliation log, including amount and date of 
dispensing 
x study drugs accountability log 
x all shippi[INVESTIGATOR_3087]  
x documentation of study drug returned to the Sponsor 
All forms will be provided by [CONTACT_1034] (or its designee).  Any comparable forms that the 
investigational site wishes to use must be approved by [CONTACT_1034].  A copy of the drug accountability record must be provided to the Sponsor at the end of the study. 
Clinical Study Protocol Amendment [ADDRESS_717179], for inspection by [CONTACT_429] (or its designee) or a representative of a he alth authority.  If applicable, all unused 
study drugs and empty containers, are to be retu rned to the Investigator by [CONTACT_548011].  On completion 
of drug accountability and reconciliation procedure s by [CONTACT_548012], st udy drug that is to be returned to the 
Sponsor, if necessary must be boxed and sealed  and shipped back to the Sponsor following 
all local regulatory requirements. 
The CRA(s) will review drug accountability duri ng monitoring site visits and at the 
completion of the study. 
9.5 Study Assessments 
9.5.1 Assessments 
All assessments and timing of the assessmen ts should be performed according to the 
Schedule of Procedures and Assessments ( Table 1 and Table 2 ). 
 Demography 
Subject demographic information will be coll ected at the Screening Visit.  Demographic 
information includes date of birth (or age), sex, race/ethnicity. 
 Baseline Assessments 
[IP_ADDRESS].1 M EDICAL /SURGICAL AND ACTINIC KERATOSIS HISTORY  
Medical and surgical history and current medi cal conditions will be recorded at Screening 
(Visit 1).  All pertinent medical history must be noted in the CRF/eCRF.  A complete AK medical history will also be recorded. 
Medical history will include:  
x Significant medical and surgical history;  childhood diseases and common colds are 
not required unless it is ongoing at Screening 
x A complete AK history from the time of initial diagnosis 
x A complete AK treatment history including  all commercial and investigational 
products, including medical therapi[INVESTIGATOR_547957], and other prescribed 
and nonprescription therapi[INVESTIGATOR_547958].  
[IP_ADDRESS].2 F ITZPATRICK SKIN-TYPE CLASSIFICATION  
The Fitzpatrick Skin-Type is a skin classification system14 which measures 2 components 
(genetic disposition and reaction to sun exposure).  Skin-types range from very fair (Type I) 
to very dark (Type VI). 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 35  
CONFIDENTIAL 
 Subjects‚Äô skin will be typed using this cla ssification system at Screening (Visit 1). 
[IP_ADDRESS].3 P RIOR MEDICATIONS  
Prior medications taken within 28 days before Day 1, including nonprescription remedies, 
vitamins, etc, will be recorded at Screening (Visit 1). 
[IP_ADDRESS].4 H EIGHT  
Height will be measured only during the screening physical examination. 
 Activity Assessments 
[IP_ADDRESS].1 A CTINIC KERATOSIS LESION COUNT  
The Investigator will perform a count of AK lesions (lesion count) for all subjects at Visits 1 
and 2, Visits 7 through 10, and for Day 57 complete responders, also at Visits 11 through 14. 
The AK lesion count is the Investigator ‚Äôs assessment of the number of AK lesions in the 
treatment area.  A subject must have [ADDRESS_717180] with the AK lesion count.  
This is not a comparison with the AK lesion count at any other timepoint. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 36  
CONFIDENTIAL 
 
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker 
Assessments 
[IP_ADDRESS].1 P HARMACOKINETIC ASSESSMENTS  
Blood samples (3 mL at each timepoint) for PK an alysis of KX2-391 will be collected at the 
following timepoints ( Table 4 ): 
Table 4 Blood Sample Collection Times for Pharmacokinetic Analyses  
Application Day  Time (hours)   
 0 
predose 0.5 
postdose 1 
postdose 4 
postdose 
Window  ¬±5 minutes ¬±10 minutes ¬±10 minutes 
Both cohorts: Day 1 (Visit 2)  Xa X X X 
Cohort 1:  Day  5 (Visit 6) Xa X X X 
Cohort 2:  Day  3 (Visit 4) Xa X X X 
a Prior to application of study treatment. 
Approximately 24 mL will be collected for  measurement of plasma concentrations of 
KX2-391. 
The actual times of PK sampling will be recorded. A description of collection, handling, and ship pi[INVESTIGATOR_547959]. 
Plasma concentrations of KX2-391 will be analyzed to determine C
max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Plasma concentrations of study drug will  be measured using a validated liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) assay. 
[IP_ADDRESS].2 P HARMACODYNAMIC , PHARMACOGENOMIC , AND OTHER BIOMARKER ASSESSMENTS  
Not applicable 
 Safety Assessments 
Safety assessments will include recording all AEs and serious adverse events (SAEs). 
Safety assessments also include laboratory evaluation of hematology, biochemistry, and 
urinalyses; periodic measurement of weight, vita l signs, ECGs, and performance of PEs, as 
detailed in the sections below and shown in  Table [ADDRESS_717181]-reported LSRs will not be reported as adverse events.  Treatments administered for 
LSRs will be recorded on the Concomitant Medications CRF. 
[IP_ADDRESS].[ADDRESS_717182].  For this study, the study drug is KX2-391 Ointment 1%. 
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after dosing or  
x those pre-existing conditions that worsen after dosing 
The criteria for identifying AEs are: 
‚Ä¢ any unfavorable and unintended sign (incl uding an abnormal laboratory finding), 
symptom, or disease temporally associated wi th the use of an investigational product, 
whether or not considered related to the investigational product 
‚Ä¢ any new disease or exacerbation of an existing disease  
‚Ä¢ any deterioration in nonprotocol-required mea surements of a laboratory value or other 
clinical test (eg, ECG or x-ray) that result s in symptoms, a change in treatment, or 
discontinuation from study drug 
‚Ä¢ recurrence of an intermittent medical conditi on (eg, headache) not present at baseline 
All AEs, regardless of relationship to study drug  or procedure, should be collected beginning 
from the time the subject signs the study IC F through the final contact [CONTACT_548013]-up 
Period on Day 57.   For subjects participating in the Recurrence Follow-up Period, only AEs 
at the treatment area will be collected. 
Subjects with study drug-related AEs will be followed until resolution, resolved with 
sequelae, or under medical care.  All SAEs must be followed to resolution or, if resolution is 
unlikely, to stabilization. 
All AEs observed during the study will be reported on the CRF/eCRF. 
Laboratory Adverse Events 
A treatment-emergent abnormal laboratory test re sult should be considered as a treatment-
emergent AE (TEAE) if the identified labor atory abnormality leads to any type of 
intervention whether prescribed in the protocol or not. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 38  
CONFIDENTIAL 
 An abnormal laboratory result should be considered by [CONTACT_548014]: 
x results in the withdrawal of study drug 
x results in withholding of study drug pending some investigational outcome 
x results in the initiation of an inte rvention, based on medical evaluation (eg, 
potassium supplement for hypokalemia) 
x results in any out of range laboratory value that in the Investigator ‚Äôs judgment 
fulfills the definitions of an AE with regard to the subject ‚Äôs medical profile  
x increases in severity compared with baseline 
Abnormal laboratory values should not be listed as  separate AEs if they are considered to be 
part of the clinical syndrome that is being reported  as an AE.  It is the responsibility of the 
Investigator to review all laboratory findings in  all subjects and determine if they constitute 
an AE.  Medical and scientific judgment should be  exercised in deciding whether an isolated 
laboratory abnormality should be classified  as an AE.  Any laboratory abnormality 
considered to constitute an AE should be reported on the Adverse Event CRF/eCRF. 
For significant treatment-emergent laboratory abnormalities meeting criteria as SAEs, the 
study site must submit an SAE report to the Sponsor or designee using the SAE reporting procedures described in Section [IP_ADDRESS] .  However, if a significant treatment-emergent 
laboratory abnormality is accompanied by, and is  part of the syndrome of, a serious clinical 
event or diagnosis, it is the clinical event/d iagnosis that should be reported as the SAE and 
not the significant treatment-emergent laboratory abnormality. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015].  An ECG abnormality in a subject with symptoms may 
meet the criteria for an AE as described in this protocol.  In these instances, the AE 
corresponding to the symptomatic ECG abnormality will be recorded on the Adverse Events CRF/eCRF. 
For symptomatic ECG abnormalities meeting criteria as SAEs, the study site must submit an 
SAE report, including the ECG report to the Sponsor, or designee, using the SAE reporting procedures ( Section [IP_ADDRESS] ). 
Assessing Severity of Adverse Events 
Every effort must be made by [CONTACT_548016].  
Adverse events will be graded for severity as follows: 
Mild An event that is easily tolerated by  [CONTACT_102], causing minimal discomfort 
and not interfering with everyday activities 
Moderate An event that is sufficiently discomforting to interfere with everyday 
activities 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 39  
CONFIDENTIAL 
 Severe An event that prevents normal everyday activities  
Investigators will assess severity for all AEs (f or both increasing and decreasing severity).  
The criteria for assessing severity are different from those used for seriousness (see Section [IP_ADDRESS].2 ). 
Assessing Relationship to Study Treatment 
Items to be considered when assessing the relationship of an AE to the study treatment are: 
x temporal relationship of the onset of the event to the initiation of the study treatment 
x the course of the event, especially the effe ct of discontinuation of study treatment or 
reintroduction of study treatment, as applicable 
x whether the event is known to be associated  with the study treatment or with other 
similar treatments 
x the presence of risk factors in the study s ubject known to increase the occurrence of 
the event 
x the presence of nonstudy treatment-related factors that are known to be associated 
with the occurrence of the event 
Classification of Causality 
The relationship of each AE to the study drug will be recorded on the CRF/eCRF using the 
following criteria: 
Definitely Related:   A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administ ration, and which cannot be explained by 
[CONTACT_548017]:   A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, unl ikely to be attributed to concurrent or 
underlying disease or other drugs or conditions  
Possibly Related:   A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, but wh ich could also be explained by [CONTACT_548018]:   A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which makes  a causal relationship improbable, and in 
which other drugs, conditions or concurrent  or underlying disease provide plausible 
explanations 
[IP_ADDRESS].[ADDRESS_717183] medical occurrence that at any dose: 
‚Ä¢ results in death 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 40  
CONFIDENTIAL 
 ‚Ä¢ is life-threatening (ie, the subject was at immediate risk of death from the AE as it 
occurred; this does not include an event that, had it occurred in a more severe form or 
was allowed to continue, might have caused death) 
‚Ä¢ requires inpatient hospi[INVESTIGATOR_1081] 
‚Ä¢ results in persistent or significant disability/incapacity 
‚Ä¢ is a congenital anomaly/birth defect (in th e child of a subject who was exposed to the 
study drug) 
Other important medical events that may not be  immediately life-threatening or result in 
death or hospi[INVESTIGATOR_313], when based on appropriate medical judgment, may jeopardize the subject or may require intervention to pre vent one of the outcomes in the definition of 
SAE listed above should also be considered SAEs.  Medical and scientific judgment should 
be exercised in deciding whether expedited reporting is appropriate in such situations. 
In addition to the above, other events of inte rest, which include pregnancy and overdose, are 
to be captured using the SAE procedures described in Section [IP_ADDRESS] , but are to be 
considered as SAEs only if they met one of the above criteria.  All events of these types are 
to be reported on the Adverse Events CRF/eCRF whether or not they meet the criteria for SAEs. 
The following hospi[INVESTIGATOR_547960] ‚ÄúAE‚Äù (ie, 
there is no untoward medical occurrence) associated with the hospi[INVESTIGATOR_059]: 
‚Ä¢ hospi[INVESTIGATOR_547961] (where the condition requiring the 
hospi[INVESTIGATOR_547962] t study drug administration) 
All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization. 
[IP_ADDRESS].3 L ABORATORY MEASUREMENTS  
Blood will be collected for clinical laboratory te sts at Screening (Visit 1), Day 8 (Visit 7), 
and Day 57 (Visit 10) ( Table 1 and Table 2 ).  Collection of blood and urine (including 
samples for pregnancy testing, where applicable)  will be conducted at the clinic site.  
Approximately [ADDRESS_717184] be documented for all 
laboratory samples. 
Microscopic urinalysis will be conducted only when clinically indicated based on dipstick 
results (laboratory protocol) or as determined by [CONTACT_737].  When conducted, microscopic urinalysis results will be recorded on the CRF/eCRF. 
The clinical laboratory tests to be measured during the study are provided in  Table 5 . 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 41  
CONFIDENTIAL 
 Table 5 Clinical Laboratory Tests 
Category Parameters 
Hematology  red blood cells (RBC), hemoglobin, hematocrit, platelets, and white 
blood cells (WBC) with differential (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils),  mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentrati
on (MCHC), RBC distribution width (RDW) 
Chemistry  
 Electrolytes chloride, potassium, sodium, bicarbonate (HCO 3) 
 Liver function tests alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), gamma glutamyl transpeptidase (GGT), direct 
bilirubin, total bilirubin  
 Renal function tests blood urea/blood urea nitrogen, creatinine 
 Other Albumin, calcium, cholesterol, glucose, lactate dehydrogenase  (LDH) , 
phosphorus, total protein, triglycerides, uric acid  
Urinalysis  (dipstick)a hydrogen ion concentration (pH), specific gravity, protein, glucose, 
ketones, leukocyte esterase, nitr ite, bilirubin, urobilinogen, blood 
Pregnancy Testing  serum pregnancy test, urine pregnancy test (where applicable)  
a Microscopic urinalysis will be conducted only when clinically indicated based on dipstick results 
(laboratory protocol) or as determined by [CONTACT_737]. 
A laboratory abnormality may meet the criteria to  qualify as an AE as described in this 
protocol (see Section [IP_ADDRESS].1 ).  In these instances, the AE  corresponding to the laboratory 
abnormality will be recorded on the Adverse Event CRF/eCRF. 
For laboratory abnormalities meeting the criteria of SAEs (see Section [IP_ADDRESS].2 ), the site 
must electronically transmit the SAE report including the laboratory report to the Sponsor using the SAE form (see Section [IP_ADDRESS] ). 
[IP_ADDRESS].4 V ITAL SIGNS 
Vital sign (pulse rate, systolic and diastolic blood pressure, respi[INVESTIGATOR_697], and body 
temperature) measurements will be taken after the subject has been seated for at least 
5 minutes at Screening (Visit 1), Day 5 (Visit 6) for Cohort 1 or Day 3 (Visit 4) for Cohort 2, 
Day 8 (Visit 7), Day 15 (Visit 8), Day 29 (Visit 9), and Day 57 (Visit 10) ( Table 1 and 
Table 2 ).  Serial vital signs may be obtained to confirm accurate readings. 
[IP_ADDRESS].5 P HYSICAL EXAMINATIONS  
A complete PE will be performed at Screening (Visit 1) and Day 57 (Visit 10) ( Table 1 and 
Table 2 ). 
A complete PE will include weight and an assessment of head, eyes, ears, nose, and throat 
(HEENT), integumentary, gastroint estinal, cardiovascular, respir atory, musculoskeletal, and 
neurological systems. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 42  
CONFIDENTIAL 
 Height will be measured only during the screening physical examination. 
Documentation of the PE will be included in the source documentation at the site.  Only 
changes from screening PE findings that meet the definition of an AE will be recorded on the 
Adverse Events CRF/eCRF. 
[IP_ADDRESS].6 E LECTROCARDIOGRAMS  
A 12-lead ECG will be completed at Screen ing (Visit 1), Day 8 (Visit 7), and Day 57 
(Visit 10) ( Table 1 and Table 2 ), at a convenient time during th e visit.  ECGs will also be 
performed in Cohort 2 subjects at 4 hours postdos e on Day 1 (Visit 2) and Day 3 (Visit 4).  
Subjects must be in the recumbent position for  a period of 5 minutes prior to the ECG.  The 
ECG data recorded on the CRF/eCRF must include  rate, rhythm, intervals, and QTc/QTcF. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015]. 
[IP_ADDRESS].7 P REGNANCY TESTING  
Serum pregnancy tests will be obtained in females of childbearing potential at Screening 
(Visit 1), Day 8 (Visit 7), and Day 57 (Visit 10) ( Table 1 and Table 2 ). 
A urine pregnancy test will be performed on females of childbearing potential before study 
medication application on Day 1 (Visit 2).  Visit [ADDRESS_717185] be reviewed 
before dosing. 
[IP_ADDRESS].8 O THER ASSESSMENTS  
Concomitant Medications 
Concomitant medications will be assessed at all clinic visits ( Table 1 and Table 2 ).  Any 
medication (including nonprescription medicatio ns) or therapy administered to the subject 
during the course of the study (starting at the date of informed consent) will be recorded on the Concomitant Medication CRF/eCRF.  The Investigator will record any AE on the Adverse Events CRF/eCRF for which the concomitant medication/therapy was administered. 
Use of sunblock or any topi[INVESTIGATOR_547947]/eCRF. 
Local Skin Reactions 
At every post-Screening clinic visit through Day 57 (Visit 10), the Investigator or trained 
designee will assess any LSR on the treatment area for signs: 
x Before study medication application (on dosing days) 
x After the assessment of adverse events 
The LSR assessment is the Investigator‚Äôs (or trained designee‚Äôs ) assessment of the following 
signs on the treatment area:  erythema, flaking/scaling, crusting, swelling, 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 43  
CONFIDENTIAL 
 vesiculation/pustulation, and erosion/ulceration.  Th ese signs will be assessed using a grading 
scale ranging from 0 (not present) to 4 (worst) (Table 6) . 
Table 6 Local Skin Reaction Grading Criteria 
 Grading Criteria 
Local Skin 
Response 0 1 2 3 4 
Erythema Not present Slightly pi[INVESTIGATOR_8745] 
<50% Pi[INVESTIGATOR_22764] 
>50% Red, restricted to 
treatment area Red extending 
outside treatment 
area 
Flaking / 
Scaling  Not present Isolated scale, 
specific to lesion Scale <50%  Scale >50%  Scaling 
extending 
outside treatment 
area 
Crusting  Not present Isolated crusting Crusting <50% Crusting >50% Crusting 
extending 
outside treatment 
area 
Swelling Not present Slight, lesion 
specific edema Palpable edema 
extending beyond 
individual lesions Confluent and/or 
visible edema Marked swelling 
extending 
outside treatment 
area 
Vesiculation 
/ Pustulation Not present Vesicles only Transudate or 
pustules, with or 
without vesicles 
<50% Transudate or 
pustules, with or 
without vesicles 
!50% Transudate or 
pustules, with or 
without vesicles 
extending 
outside treatment 
area 
Erosion / 
Ulceration Not present Lesion specific 
erosion Erosion extending 
beyond individual 
lesions Erosion >50% Black eschar or 
ulceration  
 
Examples of LSR signs are shown in photographs in  Appendix 1.15 
Application site reactions not classified as LSRs (eg, pruritus, pain, infection) will be 
reported as adverse events. 
All application site reactions and LSRs will be followed to resolution, or if resolution is 
unlikely, to stabilization. 
Treatment for any LSR or interruption/discontinua tion of study treatment for an LSR will be 
recorded on the CRF/eCRF. 
LSRs will be reported separately from adverse events. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 44  
CONFIDENTIAL 
 Pi[INVESTIGATOR_547963]- and hyper- pi[INVESTIGATOR_547964] e treatment area will be assessed by [CONTACT_3786] (or a trained designee) as being present or absent.   
Pi[INVESTIGATOR_547965]-Screening clinic visit through 
Day 57 (Visit 10) ( Table 1 and Table 2 ).  Pi[INVESTIGATOR_2517]-related changes or scarring should be 
followed until resolution or deemed stabilized by [CONTACT_737]. 
Standardized Photography 
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 
(Visit 7), Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717186]-Day 57).  Before study medication application on Day 1, the Investigator or a qualified staff member must obtain standardized photograph y of each subject‚Äôs treatment area before 
application of study medication. 
Care must be taken to ensure the same ligh ting, background, subject positioning relative to 
the camera and camera settings are used for  each photograph.  Equipment, supplies and 
detailed instructions for obtaining and managin g the photographs will be provided to the 
investigational center prior to the initiation of subject enrollment. 
The photographs are to document the appearance of the subjects‚Äô treatment area and to assist 
with the identification and confirmation of the location of the treatment area throughout the 
study ( Section 9.1.1 ). 
Equipment, supplies and detailed instructions for obtaining and managing the photographs 
will be provided to the investigational center  prior to the initiation of subject enrollment.  
9.5.[ADDRESS_717187], will be collected (ie, Day 57 plus 30 days).  During the Recurrence Follow-up 
Period, all AEs, including SAEs in the treatment area will be collected until the last subject 
Clinical Study Protocol Amendment [ADDRESS_717188] information for reporting of SA Es will be provided in the Investigator 
File. 
It is very important that the SAE report form be  filled out as completely as possible at the 
time of the initial report. This includes the Investigator ‚Äôs assessment of causality.  All 
supporting documents should be sent de-identified and should contain the assigned subject 
number.  Only supporting documents directly related to the event should be sent. 
Any follow-up information received on SAEs should be forwarded as soon as possible.  If the 
follow-up information changes the Investigator ‚Äôs assessment of causality, this should also be 
noted on the follow-up SAE form. 
Preliminary SAE reports should be followed as  soon as possible by [CONTACT_3582][INVESTIGATOR_3103], autopsy reports, and other documents requested by [CONTACT_1034]. 
 Reporting of Pregnancy 
Any pregnancy, whether occurring in a subject or in the female partner of a male subject, for 
which the estimated date of conception was either before the last visit or within [ADDRESS_717189] be reported. 
If an adverse outcome of a pregnancy is suspected to be related to study drug exposure, this 
should be reported regardless of the length of ti me that has passed since the exposure to study 
treatment. 
A congenital anomaly, death during perinatal period, an induced abortion, or a spontaneous 
abortion are considered to be an SAE and shoul d be reported in the same timeframe and in 
the same format as all other SAEs (see Section [IP_ADDRESS] ). 
Pregnancies must be reported by [CONTACT_548019] 
[ADDRESS_717190] 
[IP_ADDRESS].1 R EPORTING OF ADVERSE EVENTS ASSOCIATED WITH STUDY DRUG OVERDOSE , 
MISUSE , ABUSE , OR MEDICATION ERROR  
Study drug overdose is defined as the accidental or intentional use of the drug in an amount 
higher than the dose being studied. 
Any study drug overdose should be noted on the Study Medication CRF/eCRF. All AEs associated with overdose, or medicati on error should be captured on the Adverse 
Event CRF/eCRF and also reported using the procedures detailed in Section [IP_ADDRESS] even if 
the AEs do not meet serious criteria.  If th e AE associated with an overdose or medication 
error does not meet serious criteria, it must still be reported using the SAE form and in an 
expedited manner, but should be noted as nons erious on the SAE form and the Adverse 
Event CRF/eCRF. 
 Expedited Reporting 
The Sponsor (or its designee) must inform In vestigators and regulatory authorities of 
reportable events, in compliance with appli cable regulatory requirements, on an expedited 
basis (ie, within specific timeframes).  For th is reason, it is imperative that sites provide 
complete SAE information in the manner described above. 
In determining what SAEs meet criteria for ex pedited reporting, the current version of the 
Investigator ‚Äôs Brochure will be used  for reference safety information. 
 Breaking the Blind 
Not applicable 
 Regulatory Reporting of Adverse Events 
Adverse events will be reported by [CONTACT_548020] a third party acting on behalf of the 
Sponsor to regulatory authorities in compliance with local law and established guidance.  The format of these reports will be dictated by [CONTACT_119663]. 
9.5.4 Completion/Discontinuation of Subjects 
A subject may elect to discontinue from the study at any time for any reason.  See 
Section 9.3.[ADDRESS_717191] document the actual reason(s ) why they decided to discontinue subjects, 
or why subjects withdrew consent, as appli cable.  Study disposition information will be 
collected on the Disposition CRF/eCRF. 
Subjects who withdraw from study treatment (w ith the exception of death or withdrawal of 
consent) will be encouraged to complete th e Early Termination assessments at the time of 
withdrawal as indicated in  Table [ADDRESS_717192] who has ceased to return for visits 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 47  
CONFIDENTIAL 
 will be followed up by [CONTACT_2319], phone, or other mean s to gather information such as the reason 
for failure to return, the status of treatment comp liance, the presence or absence of AEs, and 
clinical courses of signs and symptoms.  This i nformation will be recorded in the CRF/eCRF.  
9.5.[ADDRESS_717193] 
whether he/she has received medical care by  [CONTACT_3212].  When the subj ect is going to receive medical care by [CONTACT_3213], the Investigator, with the consent of the subject, will inform the other physician 
that the subject is participating in the clinical study. 
9.6 Data Quality Assurance 
This study will be organized, performed, a nd reported in compliance with the protocol, 
SOPs, working practice documents, and applicable  regulations and guidelines.  Site audits 
may be made periodically by [CONTACT_1034]‚Äôs or the CRO‚Äôs qualif ied compliance auditing 
team, which is an independent function from the study team responsible for conduct of the study. 
9.6.[ADDRESS_717194] source documentation, 
collected on the CRF/eCRFs and entered into a validated data management system that is 
compliant with all regulatory requirements.  A CRF/eCRF or a select CRF/eCRF page may be used as a source document.  CRF/eCRFs used as source documents will be listed in the Data Management Plan.  As defined by [CONTACT_12212] E6 guidelines (Section 1.11), the CRF is a 
printed, optical, or electronic document design ed to record all of the protocol-required 
information to be reported to the Sponsor on each study subject.  In this study, the CRF may 
refer to either a paper (CRF) or electronic data collection form (eCRF), or both. 
Data collected on the CRF/eCRF must be comple ted following the instructions described in 
the CRF/eCRF Completion Guidelines, which will be based on the Data Management Plan.  The Investigator has ultimate responsibility for  the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRF/eCRF.  The PI [INVESTIGATOR_547966]/eCRF to 
attest to its accuracy, authenticity, and completeness. 
Completed, original CRFs/eCRFs are the sole property of the Sponsor and should not be 
made available in any form to third parties without written permission from the Sponsor, 
except for authorized representatives of the Sponsor or appropriate regulatory authorities. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 48  
CONFIDENTIAL 
 Responsible site personnel will enter the information required by [CONTACT_548021]/eCRFs in accordance with the CRF/eCRF Completion Guidelines that are provided.  A 
CRA will visit each site as documented in the monitoring plan to re view the CRF/eCRFs for 
completeness and accuracy against the source documents. They will identify any discrepancies and ensure that appropriate site personnel address the discrepancies. 
The original CRFs/eCRFs will be maintained at the site in a central document repository. If 
used, a copy of the CRF will be forwarded to the Sponsor. 
At the end of the study an electronic copy of the database along with appropriate system 
version will be archived. 
Uniform procedures will be discussed at the Investigator meetings or at site initiation and/or 
will be documented in the CRF/eCRF Completion Guidelines. 
9.6.2 Clinical Data Management 
All data, both CRF/eCRF and external data, will be  loaded into a clinical system as specified 
in the Data Management Plan. 
Quality control and data validation procedures w ill be applied to ensure the validity and 
accuracy of the clinical data. 
All software applications used in the collec tion of data will be properly validated following 
standard computer system validation that is compliant with all regulatory requirements. 
9.[ADDRESS_717195] deviation (SD), median, 
minimum, and maximum.  Categorical variable s will be summarized by [CONTACT_548022].  All raw data obtained from the CRF/eCRF, as well as any derived data  will be included in data listings. 
For all analyses, study Day [ADDRESS_717196] dose of study drug. 
9.7.1 Statistical and Analytical Plans 
 Study Endpoints 
[IP_ADDRESS].1 P RIMARY ENDPOINTS  
The primary endpoint is activity. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 49  
CONFIDENTIAL 
 Activity will be evaluated by [CONTACT_547995].  Complete response rate will be 
defined as the proportion of subjects achieving 100% complete clearance of all treated AK 
lesions on the face or scalp at Day 57.  
[IP_ADDRESS].2 S ECONDARY ENDPOINTS  
Activity 
Reduction in lesion counts at each visit during Days 1-57 will be assessed as the secondary 
endpoint for activity. 
Safety 
Safety will be evaluated primarily by [CONTACT_548023].  The 
results of other safety assessments (vital si gns, PEs, ECGs) will also be evaluated. 
Pharmacokinetic  
Secondary endpoints include the following PK  parameters derived by [CONTACT_548024]-time data of KX2-391:  C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
[IP_ADDRESS].3 E XPLORATORY ENDPOINTS  
Exploratory endpoints include recurren ce and sustained response rates. 
Recurrence rate will be defined as the proportion of subjects who achieved 100% complete 
clearance at Day 57 (Visit 10) with any identifi ed AK lesions on the treatment area at 3, 6, 9, 
and [ADDRESS_717197]-Day 57. 
Sustained response rate will be defined as the proportion of subjects who achieved 100% 
complete clearance at Day 57 (Visit 10) without any identified AK lesions on the treatment 
area at [ADDRESS_717198]-Day 57. 
 Definitions of Analysis Sets 
The Per-Protocol Set is the group of protocol-eligible subjects who receive 5 days (Cohort 1) 
or 3 days (Cohort 2) of study treatment and comp lete at least one scheduled post-treatment 
evaluation.  
The Evaluable Set is the group of subjects who receive 5 days (Cohort 1) or 3 days 
(Cohort 2) of treatment and complete most evaluati ons including the Day 57 Follow-up Visit. 
The Safety Analysis/Full Analysis Set is the group of subjects who receive at least one dose 
of study treatment. 
The PK Analysis Set is the group of subjects who receive study treatment and complete at 
least one scheduled post-treatment PK evaluation. 
Clinical Study Protocol Amendment [ADDRESS_717199] Disposition 
All subjects will be tabulated by [CONTACT_548025] 9.3.3 . 
 Demographic and Other Baseline Characteristics 
Demographic and baseline charac teristics will be summarized  by [CONTACT_9084].  For continuous 
demographic variables, results will be summariz ed by [CONTACT_548026], and presented as N, 
mean, SD, median, and minimum and maximum valu es.  For categorical (nominal or ordinal) 
variables, the number and percentage of subjects will be used in each cohort.  No statistical 
testing will be performed. 
 Prior and Concomitant Therapy 
All Investigator terms for medications recorded in the CRF/eCRF will be coded to an 11-digit code using the World Health Orga nization Drug Dictionary drug codes. 
Prior medications will be defined as medicati ons that stopped before the first dose of study 
drug. 
Concomitant medications will be defined as med ications that (1) started before the first dose 
of study drug and were continuing at the time of  the first dose of study drug, or (2) started on 
or after the date of the first dose of study drug.  Prior and concomitant medications will be 
further coded to the appropriate Anatomical-T herapeutic-Chemical (A TC) code indicating 
therapeutic classification.  A listing of prior and concomitant medications by [CONTACT_548027]. 
All medications will be presented by [CONTACT_548028]. 
 Activity Analyses 
AK lesion counts will be summarized by [CONTACT_548029] 1 (pretreatment) and at each 
subsequent timepoint for subjects in the Full  Analysis Set and the Per-Protocol Set. 
A 95% confidence interval (CI) for the complete  clearance (response rate) at Day 57 will be 
estimated by [CONTACT_547997]. 
Recurrence rates for all subjects who achieved  complete clearance at Day 57 will be 
estimated by [CONTACT_547998]. 
A 95% CI for the sustained response rate at [ADDRESS_717200] of listings, graphs, and descriptive statistics. 
Clinical Study Protocol Amendment 2 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 51  
CONFIDENTIAL 
 
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker 
Analyses 
[IP_ADDRESS].1 P HARMACOKINETIC ANALYSES  
PK analyses will be performed on the PK Analysis Set. 
Plasma concentrations of KX2-391 will be analyzed to determine C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Individual timepoints will be tabulated and displa yed graphically and listed for all subjects.  
Summary PK parameters will be analyzed as applicable. 
[IP_ADDRESS].2 P HARMACODYNAMIC , PHARMACOGENOMIC , AND OTHER BIOMARKER ANALYSES  
Not applicable 
 Safety Analyses 
All subjects in the Safety Analysis Set will be included in the safety analyses. 
Safety data will be summarized by [CONTACT_548030] (eg, n, mean, SD, 
median, minimum, maximum for continuous variables; n [%] for categorical variables).  Safety variables include AEs, clinical laborat ory parameters, weight, vital signs, 12-lead 
ECG results, and physical examination findings. 
Similar to the activity analyses, any cont rast between the 2 cohorts will mainly be 
noninferential in the safety analyses. 
[IP_ADDRESS].[ADDRESS_717201] will be summarized by [CONTACT_9084]. 
[IP_ADDRESS].2 A DVERSE EVENTS  
For AEs, verbatim terms on the CRFs/eCRFs wi ll be mapped to preferred terms (PTs) and 
system organ classes (SOCs) using the Medi cal Dictionary for Re gulatory Activities 
(MedDRA; version 16.0 or higher).  Subject incidence of AEs will be displayed by [CONTACT_2946].  The incidence of AEs will be summarized by [CONTACT_9084].
  Adverse events will also be 
summarized by [CONTACT_926], relationship to study drug, and cohort.  Subject incidence of SAEs 
will also be displayed by [CONTACT_9084]. 
Only those AEs that were treatment-emergent  will be included in summary tables.  
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after dosing or  
x those pre-existing AEs that worsen after dosing 
Clinical Study Protocol Amendment [ADDRESS_717202] data listings. 
The number (percentage) of subjects with TEAEs  leading to death will be summarized by 
[CONTACT_12130], PT, and cohort.  A subject data listing of all AEs leading to death will be provided. 
The number (percentage) of subjects with TEAEs leading to discontinuation from study drug 
will be summarized by [CONTACT_12130], PT, and cohort.  A subject data listing of all AEs 
leading to discontinuation from study drug will be provided. 
[IP_ADDRESS].3 L ABORATORY VALUES  
Laboratory parameters will be summarized using descriptive statistics at baseline and at each 
subsequent timepoint by [CONTACT_9084].  Changes from baseline will also be  summarized by [CONTACT_9084]. 
In addition, shift tables (ie, low-normal-high at baseline versus low-normal-high at follow-up 
in a 3-by-3 contingency table) will be provided to assess changes in laboratory values from 
baseline to follow-up in each cohort. 
[IP_ADDRESS].[ADDRESS_717203].  Abnormal 
vital sign values will be identified as thos e outside (above or below) the reference range. 
[IP_ADDRESS].[ADDRESS_717204]. 
[IP_ADDRESS].[ADDRESS_717205]. 
[IP_ADDRESS].7 P REGNANCY TESTS  
Results of pregnancy tests will be listed by [CONTACT_548031], as applicable. 
[IP_ADDRESS].[ADDRESS_717206] a 100% complete 
clearance rate at Day 57 greater than 20% with 80% power, based on a two-sided (alpha=0.05) binomial test, assuming a res ponse rate of 35%, and less than a 25% dropout 
rate.  This corresponds to a two-sided 95% CI with a half-width of less than 15% (ie, lower boundary of the CI above 20%). 
The sample size of Cohort 2 may be adjusted, depending on the results of Cohort 1. 
9.7.3 Interim Analysis 
A formal interim analysis is not planned. Since this is an open-label study, after each group 
of approximately 20 subjects, ongoing analyses wi ll be performed with tabulation of activity, 
LSRs, and adverse events.  The decision to open Cohort 2 will be documented. 
9.7.4 Other Statistical/Analytical Issues 
Not applicable 
9.7.[ADDRESS_717207] 
1. ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance,  
US Department of Health and Human Se rvices, Food and Drug Administration,  April 
1996. 
2. Marks R, Rennie G, Selwood TS.  Malign ant transformation of solar keratoses to 
squamous cell carcinoma.  Lancet 1988;1(8589):795-7. 
3. Criscione VD, Weinstock MA, Naylor MF, et  al. Actinic keratoses: natural history 
and risk of malignant transformation in the Veterans Affairs Topi[INVESTIGATOR_201562]. Cancer 2009;115(11):2523-30. 
4. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 
2000;42(1 Pt 2):23-4. 
5. Salasche SJ. Epi[INVESTIGATOR_231743]. J Am 
Acad Dermatol 2000;42(1 Pt 2):4-7. 
6. Guidelines for the Management of Acti nic Keratoses.  2004/2005 European 
Dermatology Forum.  Available from: http://www.euroderm.org  [Accessed 02 July 
2012]. 
7. Drake LA, Ceilley RI, Cornelison RL, et al. Gu idelines of care for actinic keratoses. 
Committee on Guidelines of Care. J Am Acad Dermatol 1995;32(1):95-8. 
8. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in 
hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37(3 Pt 1):392-4. 
9. Ehrig T, Cockerell C, Pi[INVESTIGATOR_229748] D, et al. Actinic keratoses and the incidence of 
occult squamous cell carcinoma: a clinical- histopathologic correlation. Dermatol Surg 
2006;32(10):1261-5. 
10. Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; 
[LOCATION_007] Academy of Family Physicians. Acti nic keratoses: sequelae and treatments. 
Recommendations from a consensus pa nel.  J Fam Pract 2006;55([ADDRESS_717208]):1-8. 
11. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Ac tinic keratosis: how to differentiate the 
good from the bad ones? Eur J Dermatol 2006;16(4):335-9. 
12. Marks R, Foley P, Goodman G, et al.  S pontaneous remission of solar keratoses:  the 
case for conservative management. Br J Dermatol 1986;115(6):649-55. 
13. Food and Drug Administration Draft Guidance on Ingenol Mebutate; Recommended 
Jan 2016. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 55  
CONFIDENTIAL 
 14. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through IV. 
Arch Dermatol 1998;124(6):869-71. 
15. Rosen R, Marmur E, Anderson L, et al . A new, objective, quantitative scale for 
measuring local skin responses following topi[INVESTIGATOR_547967]. Dermatol Ther (Heidelb) 2014;4:207-19. 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 56  
CONFIDENTIAL 
 11 APPENDICES 
 
Clinical Study Protocol Amendment 2 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v3.0_26 Sep 2016  Page 57  
CONFIDENTIAL 
 Appendix 1 Photographs of Local Skin Reactions 
 
 
Source:  Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin 
responses following topi[INVESTIGATOR_547967]. Dermatol Ther (Heidelb) 
2014;4:207-19.  

Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  i 
CONFIDENTIAL 
 REVISION HISTORY 
Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change Rationale Affected Protocol Sections 
Added a second cohort with a 3-day 
dosing regimen.  If the 5-day treatment regimen 
(Cohort 1) has sufficient activity and safety, a 3
-day regimen 
(Cohort  2) will be evaluated. x Throughout protocol 
x Table 1 
x (new) Table [ADDRESS_717209] of In-Text Tables 
Added a secondary objective. To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Objectives 
x Section 8.2 
Made sustained response an 
exploratory objective; removed it as 
a primary endpoint and revised 
exploratory endpoints and analyses 
to align with  it as an exploratory 
objective ; revised wording to 
describe analysis of recurrence 
rates.  Sustained response is more 
appropriate as exploratory 
because it is assessed post -
Day 57; clarification x Synopsis  
- Objectives 
- Statistical Methods / Study 
Endpoints - Activity Analyses 
x
 Section 8.3 
x Section [IP_ADDRESS].1 
x Section [IP_ADDRESS].3 
x Section [IP_ADDRESS] 
Revised the number of subjects in 
the study.  To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Number of subjects 
x Section 9.1 
x Section 9.1.1 
Revised PK sampling timepoints. To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Pharmacokinetic 
Assessments 
x Table 4 
Removed reference to a Safety 
Management Plan; revised text regarding 
reporting of SAEs , deaths, 
and life -threatening events, and 
corresponding follow-up 
information . Clarification. x Section [IP_ADDRESS] 
Revised statistical-related text to 
reflect increased number of subjects based on the addition of Cohort 2; revised text regarding
 interim 
analysis.  To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis 
 - Analysis Sets 
 - Activity Analyses 
 - Safety Analyses 
 - Interim Analysis 
 - Sample Size Rationale 
x Sections [IP_ADDRESS] - [IP_ADDRESS] 
x Section [IP_ADDRESS] (entirety) 
x Section 9.7.[ADDRESS_717210] the 
intended effects of the study drug. x Synopsis / Exclusion Criteria 
x Section 9.3.2 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  ii 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change Rationale Affected Protocol Sections 
Increased the duration of the study 
period  overall and enrollment 
period . To accommodate addition of a 
3-day regimen (Cohort 2). x Synopsis / Study Period and 
Phase of Development 
x Synopsis / Duration of 
Participation and Treatment 
Increased the number of sites 
conducting the study.  
 
  With addition of additional sites, 
specified that enrollment among 
sites would be monitored to avoid imbalance.
 To accommodate increased 
number of subjects du e to 
addition of Cohort 2; to facilitate 
enrollment.  
 
Clarification.  x Synopsis / Sites 
x Section 6 
   
x
 Synopsis / Study Design 
x Section 9.1 
x Section 9.4.3 
Revised description of study 
treatment.  Clarification. x Table 3 
Specified ‚Äúduring the Treatment 
Period ‚Äù with regard to withdrawal 
of subjects who become pregnant. Clarification of timeframe. x Section [IP_ADDRESS] 
Revised text regarding collection 
and following of adverse events. 
 
Removed reference to Screening Disposition CRF/eCRF.
 Clarification of timeframe; only 
study drug -related AEs will be 
followed.  
There is no Screening Disposition 
CRF/eCRF in the study.  x Section [IP_ADDRESS].1 
Removed Appendix 1 and 
renumbered remaining appendix; 
added appropriate literature citation 
for reference.  Investigators are familiar with the 
method for skin typi[INVESTIGATOR_007]; 
questionnaire and scoring system 
in Appendix [ADDRESS_717211] of Appendices 
x Section [IP_ADDRESS].2 
x Section [IP_ADDRESS].8 
x Section 10 
x (original) Appendix 1 (deleted) 
Revised text regarding removal of 
subjects from the therapy or assessment; modified some of the 
reasons for discontinuation.
 Clarification. x Section 9.3.3 
Modified text regarding restrictions 
on the use of concomitant 
medication/therapi[INVESTIGATOR_014] /topi[INVESTIGATOR_547917]; referred 
the reader to an  FDA draft guidance. Per recommendation of the 
Investigator s and subject matter 
experts ; to provide further 
guidance to the investigators.  x Synopsis / Concomitant 
Drug/Therapy 
x Section [IP_ADDRESS] 
Revised description of the Final 
Visit; specified when the Final Visit 
is for those w ho do not have 
complete response at Day 57.  
 Clarification. x Table 1 / Footnote c 
x Section 9.1.3 
x Section 9.1.4 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  iii 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change Rationale Affected Protocol Sections 
Specified that use of sunblock in the 
treatment area will be recorded in the Concomitant Medication CRF. 
 
Removed text regarding subjects not changing their use of concomitant medications.
 To be able to evaluate the activity 
of study drug in the presence and absence of sunblock.
 
 
Subjects will be able to change concomitant medications per the Investigator‚Äôs instructions.
 x Section [IP_ADDRESS] 
x Section [IP_ADDRESS].8 
Removed use of body charts for 
identifying the location and shape of the treatment area.
 Not needed; this will be done 
with the acetate sheets.  x Section 9.1.1 
x Section 9.1.2 
Specified minimum timeframe 
during which subjects cannot touch 
or wet the treatment area after study treatment application; removed information regarding shower times; revised text about instructions to the subjects for care of the treatment 
area
. Clarification. x Section [IP_ADDRESS] 
Revised description of sun 
exposure.  Clarification. x Synopsis / Inclusion Criteria 
x List of Abbreviations and 
Definition of Terms 
x Section 9.3.1 
Revised description of Medical 
History.  Clarification. x Section [IP_ADDRESS].1 
Revised description of the Final 
Visit ; specified when the Final V isit 
is for those who do not have 
complete response at Day 57.  Clarification. x Table 1 / Footnote c 
x Section 9.1.3 
x Section 9.1.4 
Removed exclusionary use of 
moisturizers or emollients on the face or scalp within 12 hours prior 
to Visit
 1. Not necessary to exclude before 
Visit 1.  x Synopsis / Exclusion Criteria 
x Section 9.3.2 
Revised Medical Monitor signatory. Administrative. x Protocol Signature [CONTACT_548046], in addition 
to pi[INVESTIGATOR_371], will be assessed at 
the visits cited.  Clarification. x Section [IP_ADDRESS].8 / 
Pi[INVESTIGATOR_547918].
 Clarification to align with 
streamlined procedures.  x Section 9.1.1 
Revised text to ensure the signing of 
ICF prior to study procedures.  Clarification. x Section 5.3 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  iv 
CONFIDENTIAL 
 Revisions to KX01-AK-002 protocol v1.0_23 Jan 2016 (original protocol) 
Current Version and Date:  v2.0_26 Apr 2016 (Amendment 1) 
Change Rationale Affected Protocol Sections 
Revised the definition of the 
Evaluable Set . Clarification. x Synopsis / Number of Subjects 
Revised definition of ICH. Clarification to align with recent 
ICH organizational changes.  x Investigator Signature [CONTACT_3490] 
x Title Page 
x List of Abbreviations and 
Definition of Terms 
x Section 5.1 
Corrected 
typographical/punctuation/grammar errors.
 Administrative. x Throughout protocol 
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003] [COMPANY_003][COMPANY_003]
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  vi 
CONFIDENTIAL 
 INVESTIGATOR SIGNATURE [CONTACT_36619]: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face 
or Scalp  
Investigational Product 
Name: [CONTACT_548047]2-391 Ointment 1% 
UTN Number: U1111-1173-[ADDRESS_717212] this study in accordance with all stipulations of 
the protocol and in accordance with Interna tional Council for Harmonisation of Technical 
Requirements for Registration of Pharmaceutic als for Human Use (ICH) and all applicable 
local Good Clinical Practice (GCP) guidelines , including the Declaration of Helsinki. 
  
 
<Name, degree(s)>      
Investigator  Signature  [CONTACT_1782] 
<Name [CONTACT_548048]>      
Study Site      
  
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 1  
CONFIDENTIAL 
 1 TITLE PAGE 
 
CLINICAL STUDY PROTOCOL  
Study Protocol 
Number: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face or 
Scalp  
Sponsor : [LOCATION_002]: 
Kinex Pharmaceuticals, Inc.  
[ADDRESS_717213], New Jersey 0 7016, US 
Tel:  [PHONE_3096] -272-[ADDRESS_717214] Name: [CONTACT_548047]2-391 Ointment 1% 
Indication: Actinic keratosis on the face or scalp 
Phase: 2a 
Approval Date:   v1.0 
v2.0 23 Jan 2016 (original protocol) 
26 Apr 2016 (Amendment 1) 
UTN Number: U1111-1173-5677 
GCP Statement: This study is to be performed in full compliance with International Council 
for Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.  All required study documentation 
will be archived as required by [CONTACT_12721].
 
Confidentiality 
Statement:  This document is confidential.  It contains proprietary information of Kinex 
Pharmaceuticals, Inc. (the Sponsor).  Any viewing or disclosure of such 
information that is not authorized in  writing by [CONTACT_55360].  Such information may be used solely for the purpose of 
reviewing or performing this study.  

Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 2
CONFIDENTIAL2 CLINICAL PROTOCOL SYNOPSIS 
Compound No. KX2-391
Name [CONTACT_3261]: N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) acetamide
Study Protocol Title
A Phase 2a, Open -Label, Multicenter, Activity and Safety Study of KX2- 391 Ointment 1% in Subjects 
with Actinic Keratosis on the Face or Scalp
Investigators
, MD, Lead Principal Investigator
[INVESTIGATOR_547968] [ADDRESS_717215] out, approximately 24 months
Phase 2a
Objectives
Primary Objective :
‚Ä¢To evaluate the activity of KX2- 391 Ointment 1% administered topi[INVESTIGATOR_547920] (AK) by [CONTACT_547992], defined as 100% 
clearance at Day 57
Secondary Objectives: 
‚Ä¢To assess the activity of KX2-391 Ointment 1% during Days 1-57
‚Ä¢To assess the safety and tolerability of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp
‚Ä¢To assess the pharmacokinetics (PK) of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp
‚Ä¢To assess dose regimens by [CONTACT_456105] 5-day treatment with 3- day treatment in terms of the activity 
and safety of KX2-391 Ointment 1% in subjects with AK on the face or scalp
Exploratory Objective s:
‚Ä¢To determine recurrence rates up to [ADDRESS_717216]-Day 57 for subjects who show response at 
Day 57
‚Ä¢To determine sustained response rates at [ADDRESS_717217]- Day 57 for subjects who show response at 
Day 57
Study Design
This study will be an open -label, multicenter, activity, safety, tolerability, and PK study of KX2 -391
Ointmen t 1% administered topi[INVESTIGATOR_547969] 2 sequential 
cohorts :  a 5-day dosing regimen (Cohort 1) and a 3-day dosing regimen (Cohort 2).
The study consists of Screening, Treatment, and Follow-up Periods.
In Cohort 1, eligible subjects will receive 5 consecut ive days of topi[INVESTIGATOR_35786], to be applied at the [COMPANY_003]
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 3  
CONFIDENTIAL 
 study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be 
collected on Day  1 and Day 5.  Subjects will return for Follow-up visits until Day 57.  Thereafter, only 
Day 57 complete responders will continue Recurrence Follow -up Visits every 3 months for an additional 
12 months after Day 57.  Activity (lesion counts) and safety evaluations will be performed. 
The Sponsor will review accumulating data.  If the 5-day regimen (Cohort 1) has sufficient activity and 
safety to warrant evaluating a 3-day regimen, enrollment of Cohort 2 will start after there are 60 evaluable 
subjects  or up to 80 subjects are enrolled (w hichever comes first) in Cohort 1.  For the most part, protocol 
procedures for Cohort [ADDRESS_717218]/be:  
1. Males and females ‚â•18 years old  
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
x is a continuous area measuring [ADDRESS_717219] be postmenopausal (>[ADDRESS_717220] 18 months of amenorrhea), 
surgically sterile (by [CONTACT_547993], bilateral oophorectomy or tubal ligation) or otherwise incapable 
of pregnancy for at least 1 year; or, if of childbearing potential, must be using highly effective 
contraception for at least 90 da ys prior to treatment with KX2- 391 Ointment 1% and must agree to 
continue to use highly effective contraception fo r at least [ADDRESS_717221] dose of 
KX2-391 Ointment 1%.  Highly effective contraception includes oral hormonal contraceptives, 
hormonal contraceptive implant or patch, or intrau terine device.  Abstinence and double barrier 
methods do not qualify as highly ef fective methods of contraception. 
5. Males who have not had a vasectomy must agree to use barrier contraception from Screening through 
[ADDRESS_717222] dose of KX2-391 Ointment 1%. 
6. All subjects must agree not to donate sperm or eggs or attempt conception from Screening through 
[ADDRESS_717223] dose of KX2-391 Ointment 1%. 
7. Females of childbearing potential must have a negative serum pregnancy test at Screening and a 
negative urine pregnancy test on Day 1 prior to administration of study treatment. 
8. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x no physical examination (PE) findings that the Principal Investigator (PI) determines would 
interfere with interpretation of study results 
x screening electrocardiogram (ECG) without clinically significant abnormalities  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 4
CONFIDENTIALxclinical chemistry, hematology, and urinalysis resu lts that are within the reference ranges; clinical 
laboratory values outside the reference ranges th at are considered by [CONTACT_978] [INVESTIGATOR_547923]  
9.Willing to avoid direct sun or ultraviolet (UV) light exposure to the face or scalp  
10.Able to comprehend and are willing to sign an informed consent form (ICF)  
Exclusion Criteria
Eligible subjects must not have/be:
1.Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924]
2.Malignancy within 5 years prior to Screening except basal or squamous cell carcinoma not on the 
treatment area that were treated with curative intent and are without recurrence
3.Used any of the following systemic therapi[INVESTIGATOR_547925] 1:
xretinoids; 90 days
xglucocorticosteroids; 28 days (intra-artic ular and inhaled steroids are allowed)
xmethotrexate or other anti-metabolites; 28 days
ximmunosuppressants or immunomodulators; 28 days
4.Used any of the following topi[INVESTIGATOR_547970] 1:
xretinoids; 90 days
xglucocorticosteroids; 14 days
xanalgesic and/or anti-inflammatory medication on the face or scalp; 72 hours
5.Had any of the following on the treatment area within 90 days (or until the site has healed, whic hever 
is longer) before Visit 1:
xingenol mebutate (eg, Pi[INVESTIGATOR_142724])
x5-fluorouracil (eg, 5-FU; Efudex)
ximiquimod (eg, Aldara; Zyclara)
xdiclofenac with or without hyaluronic acid (eg, Solaraze)
6.Surgical or destructive modalities on the treatment area within 30 da ys (or until the site has healed 
following treatment, whichever is longer) before Visit 1:
xcryotherapy
xelectrodesiccation
xlaser, light (eg, photodynamic therapy, intense pulsed light) or any other energy-based therapy
xchemical peels (eg, tricholoracetic acid)
xdermabrasion
xsurgical removal (eg, curettage, excision)
7. Currently, or has experienced any of the following on the treatment area within the specified period 
before Visit 1:
xcutaneous malignancy; 180 days
xsunburn; 28 days
xbody art (eg, tattoo, pi[INVESTIGATOR_77219]); currently
8.A history of sensitivity and/or allergy to an y of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psoriasis, ec zema) or condition (eg, scarring, open wounds) that, 
in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which 
Clinical Study Protocol_Amendment [ADDRESS_717224] , whichever is longer, before 
Screening
Study Treatment
50mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_231704] 5 consecutive days (Cohort 1) or 
3 consecutive days (Cohort 2) to the 25 cm2treatment area (2 mg/cm2; 0.5 mg KX2-391 total).
Duration of Participation and Treatment
‚Ä¢Planned enrollment period for each cohort:  approximately 3 months (90 days)
‚Ä¢Planned subject participation is approximately 64 weeks: 
oScreening Period:  up to 28 days
oTreatment Period:  For Cohort 1, 5 consecutive treatment days (Days 1-5); for Cohort 2, 
3 consecutive treatment days (Days 1-3)
oFollow-up Period:  Visits at Days 8, 15, 29, and 57
oRecurrence Follow- up Period:  only for complete responders at Day 57, visits every 3 months for 
12 months after Day 57 (ie, at 3, 6, 9, and [ADDRESS_717225]-Day 57).
Length of stay:  On Day 1 (Visit 2 , Cohorts 1 and 2) and Day 5 (Visit 6, Cohort 1) or Day 3 (Visit 4, 
Cohort 2) , subjects may stay for approximately [ADDRESS_717226] PK 
blood s ample is collected.
Concomitant Drug/Therapy
Use of any non -study drug treatment for AK lesions on the treatment area is prohibited until Day 57 .  Any 
lesion in the treatment area that is treated during the Recurrence Follow-up Period will be considered as a 
recurrence.
Assessments
Activity Assessments
The Investigator will perform a count of AK lesions for all subjects at Visits 1 and 2, Visits 7 through 10, and 
for Day 57 complete responders, also at Visits 11 through 14.
Safety Assessments
Safety will be assessed by [CONTACT_547994] (AEs), serious adverse events (SAEs), laboratory 
evaluation of hematology, biochemistry, and urinalysis values, measurement of weight and vital signs, 
evaluation of ECGs, and the performance of physical examinati ons.
Subjects will be queried for spontaneously reported AE s at each study visit, before assessment of local 
skin reactions (LSRs).  AEs will be reported separately from LSRs.
Subject -reported LSRs will not be reported as adverse events. 
Other Assessments
The LSR assessment is the Investigator‚Äôs (or trained designee ‚Äôs) assessment of the following signs on the 
treatment area:  erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration.  
These signs will be assessed using a grading scale ranging from 0 (not present) 
to 4 (worst). In addition to LSRs, hypo- and hyper- pi[INVESTIGATOR_547971]_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 6  
CONFIDENTIAL 
 be assessed as being present or absent.  Application site reactions not classified as LSRs (eg, pruritus, 
pain, infection) will be reported as adverse events.   All application site reactions and LSRs will be 
followed to resolution, or if resolu tion is unlikely, to stabilization.   LSRs will be reported separately from 
AEs.  
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 (Visit 7), 
Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717227]- Day 57).  Before 
study medication application on Day 1, the Investigator or a qualified staff member must obtain 
standardized photography of each subject‚Äôs treatment area before application of study medication.  
Pharmacokinetic Assessments  
PK samples will be collected at the following timepoints  for Cohort 1: 
‚Ä¢ Day 1:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
‚Ä¢ Day 5:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose 
PK samples will be collected at the following timepoints for Cohort 2:  
‚Ä¢ Day 1:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
‚Ä¢ Day 3:  predose, 0.5 (¬±5 minutes),  1 and 4 hours (¬±10 minutes) postdose  
Pharmacodynamic, Pharmacogenomic, and Other Biomarker Assessments  
Not applicable  
Bioanalytical Methods 
Plasma concentrations of study drug will be measured using a validated liquid chromatography/tandem 
mass spectrometry (LC -MS/MS) assay. 
Statistical Methods 
Study Endpoints  
Primary Endpoint  
x Activity will be evaluated by [CONTACT_547995].  Complete response rate will be defined as 
the proportion of subjects achieving 100% complete clearance o f all treated AK lesions on the face 
or scalp at Day 57.   
Secondary Endpoints  
‚Ä¢ Activity:   Reduction in lesion counts during Days 1-57 
‚Ä¢ Safety:  Evaluation of AEs and clinical laboratory data ; the results of other safety assessments (vital 
signs, physical examinations, EC Gs) will also be evaluated. 
‚Ä¢ Pharmacokinetic:  Determination of C max and where applicable, AUC t, C min, and accumulation  
ratio R 
Exploratory Endpoint s 
‚Ä¢ Recurrence rate will be defined as the proportion of subjects who achieved 100% complete cle arance 
at Day 57 (Visit 10) with any identified AK lesions on the treatment area at 3, 6, 9, and [ADDRESS_717228]-Day 57. 
‚Ä¢ Sustained response rate will be defined as the proportion of subjects who achieved 100% complete 
clearance at Day 57 (Visit 10) without any identified AK lesions on the treatment area at [ADDRESS_717229]-Day 57.  
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 7  
CONFIDENTIAL 
 Analysis Sets 
‚Ä¢ Per-Protocol Set:  the group of protocol-eligible subjects who receive 5 days (Cohort 1) or 3 days 
(Cohort 2) of study treatment and complete at least one scheduled post-treatment evaluation. 
‚Ä¢ Evaluable Set:  the group of subjects who receive 5 days (Cohort 1) or 3 days (Cohort 2) of treatment 
and complete most evaluations including the Day 57 Follow-up Visit. 
‚Ä¢ Safety Analysis/Full Analysis Set:  the group of subjects who receive at least one dose of study 
treatment. 
‚Ä¢ PK Analysis Set: the group of subjects who receive study treatment and complete at least one 
scheduled post-treatment PK evaluation. 
Activity Analyses  
AK lesion counts will be summarized  by [CONTACT_547996] 1 (pre treatment) and at each subsequent timepoint 
for subjects in the Full Analysis Set  and the Per-Protocol Set. 
A 95% confidence interval (CI) for the complete clearance (response rate) at Day 57 will be estimated by 
[CONTACT_547997]. 
Recurrence rat es for all subjects who achieved complete clearance at Day 57 will be estimated by 
[CONTACT_547998]. 
A 95% CI for the sustained response rate at [ADDRESS_717230] one dose of KX2-391 Ointment 1% will be included in the safety 
analyses.  Treatment -emergent AEs (TEAEs) are defined as either those AEs with an onset after dosing or 
those pre -existing AEs that worsen after dosing.  For AEs, verbatim terms on the case report 
form/electronic case report form ( CRF/eCRF) will be mapped to preferred terms (PTs) and system organ 
classes (SOCs) using the Medical Dictionary for Regulatory Activities (MedDRA; v 16. 0 or higher).  
Subject incidence of AEs will  be displayed by [CONTACT_2946].  The incidence of AEs will be summarized by 
[CONTACT_9084].  Adverse events will also be summarized by [CONTACT_926], relationship to study drug , and cohort.  
Subject incidence of SAEs will also be displayed  by [CONTACT_9084].  Laboratory parameters will be summarized 
using descriptive statistics at baseline and at each subsequent timepoint  by [CONTACT_9084] .  Changes from baseline 
will also be summarized  by [CONTACT_9084].  In addition, shift tables (ie, low-normal- high at baseline versus low-
normal -high at follow-up in a 3-by- 3 contingency table) will be provided to assess changes in laboratory 
values from baseline to follow -up in each cohort. 
Local skin reactions, pi[INVESTIGATOR_371], and scarring as reported by [CONTACT_737], will be displayed and 
summarized by [CONTACT_547999]. 
Similar to the activity analyses, any contrast between the [ADDRESS_717231]  deviation (SD), median, minimum, and maximum.  
Categorical variables will be summarized by [CONTACT_374560].  All raw data obtained from the CRF/eCRF, as well as any derived data will be included in 
data lis tings.  
Sample Size Rationale 
For either cohort, a  sample size of [ADDRESS_717232] a 100% complete clearance rate at 
Day 57 greater than 20% with 80% power, based on a two -sided (alpha=0.05) binomial test, assuming a 
response rate of 35% , and less than a 25% dropout rate.  This corresponds to a two- sided 95% CI with a 
half-width of less than 15% (ie, lower boundary of the CI above 20%).  The sample size of Cohort 2 may 
be adjusted, depending on the results of Cohort 1.  
FINAL  v2.0_26 Apr 2016  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 9
CONFIDENTIALTable 1 Schedule of Procedures/Assessments in Study KX01-AK-002 (Cohort 1)
Period Screening Treatment Follow-up Recurrence Follow-upa
Visit 1 2 3 4 5 6 7 8 910b/
Early 
Term11, 12, 13, [ADDRESS_717233] -Day 57c
Visit time window (days) None None None None None None ¬±2 ¬±2 ¬±2 ¬±2 ¬±14
Informed consent X
Inclusion & exclusion criteria X Xd
Demographics X
Medical/surgical history X
AK history/AK treatment history X
Fitzpatrick skin-type scale X
Vital signseX X X X X X
Prior and concomitant 
medications/therapi[INVESTIGATOR_547972] X X X X X X XX
Physical examination, including weightfX X
Treatment area identification X Xd
AK lesion count X XdX X X X X
ECGgX X X
Clinical chemistry, hematology, and 
urinalysish X X X
Pregnancy test X Xd,iX X
PK blood samples XjXj
Study medication application X X X X X
AEskX X X X X X X X X X Xl
LSRs XdXdXdXdXdX X X X
Pi[INVESTIGATOR_547973] X X X X
Standardized photography X XdX X X
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 10  
CONFIDENTIAL 
 Table 1 Schedule of Procedures/Assessmen ts in Study KX01-AK-002 (Cohort 1) 
AE = adverse event; AK = actinic keratosi s; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local sk in reaction; PK = pharmacokinetic; 
Term  = Termination. 
a For Day [ADDRESS_717234] be fasted for laboratory assessments. 
i For females of childbearing potential; urine pregnancy test on Day 1 before study medication application.  All other pregnancy tests are performed with serum. 
j PK assessments on Day 1 and Day 5 at 0 hour (just before study medication application) and at 0.5 (¬±5 min), 1 and 4 hours (¬±10 min) after study drug application.  
k Before LSR assessment, subjects will be queried for spontaneously reported AEs. 
l Only AEs in the selected treatment area will be recorded. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 11
CONFIDENTIALTable 2 Schedule of Procedures/Assessments in Study KX01-AK-002 (Cohort 2)
Period Screening Treatment Follow-up Recurrence Follow-upa
Visit 1 2 3 4 5b6b7 8 910c/
Early 
Term11, 12, 13, [ADDRESS_717235]- Day 57d
Visit time window (days) None None None None ¬±2 ¬±2 ¬±2 ¬±2 ¬±14
Informed consent X
Inclusion & exclusion criteria X Xe
Demographics X
Medical/surgical history X
AK history/AK treatment history X
Fitzpatrick skin-type scale X
Vital signsfX X X X X X
Prior and concomitant 
medications/therapi[INVESTIGATOR_547974] X X X X XX
Physical examination, including weightgX X
Treatment area identification X Xe
AK lesion count X XeX X X X X
ECGhX X X
Clinical chemistry, hematology, and 
urinalysisi X X X
Pregnancy test X Xe,jX X
PK blood samples XkXk
Study medication application X X X
AEslX X X X X X X X Xm
LSRs XeXeXeX X X X
Pi[INVESTIGATOR_547975] X X X X
Standardized photography X XeX X X
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 12  
CONFIDENTIAL 
 Table 2 Schedule of Procedures/Assessments in Study KX01-AK-002 (Cohort 2) 
AE = adverse event; AK = actinic keratosi s; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local sk in reaction; PK = pharmacokinetic; 
Term  = Termination. 
a For Day [ADDRESS_717236] be fasted for laboratory assessments. 
j For females of childbearing potential; urine pregnancy test on Day 1 before study medication application.  All other pregnancy tests are performed with serum. 
k PK assessments on Day 1 and Day 3 at 0 hour (just before study medication application) and at 0.5 (¬±5 min), 1 and 4 hours (¬±10  min) after study drug application.  
l Before LSR assessment, subjects will be queried for spontaneously reported AEs. 
m Only AEs in the selected treatment area will be recorded. 
Clinical Study Protocol_Amendment [ADDRESS_717237] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..................................17  
5 ETHICS......................................................................................................................... ...18 
5.1 Institutional Review Boards/Independent Ethics Committees ..............................[ADDRESS_717238] Information and Informed Consent ...........................................................19  
6 INVESTIGATORS AND STUDY PERSONNEL ..........................................................19  
7 INTRODUCTION ...........................................................................................................19  
7.1 Indication ...............................................................................................................19  
7.1.1  Mechanism of Action ...................................................................................20  
7.1.2  Clinical Experience with KX2-391 ..............................................................20  
7.2 Study Rationale ......................................................................................................21  
8 STUDY OBJECTIVES ....................................................................................................21  
8.1 Primary Objective ..................................................................................................21  
8.2 Secondary Objectives.............................................................................................21  
8.3 Exploratory Objectives ..........................................................................................22  
9 INVESTIGATIONAL PLAN ..........................................................................................22  
9.1 Overall Study Design and Plan ..............................................................................22  
9.1.1  Screening Period ..........................................................................................23  
9.1.2  Treatment Period ..........................................................................................24  
9.1.3  Follow-up Period .........................................................................................24  
9.1.4  Recurrence Follow-up Period ......................................................................25  
9.2 Discussion of Study Design, Including Choice of Control Groups .......................25  
9.3 Selection of Study Population ................................................................................25  
9.3.1  Inclusion Criteria .........................................................................................25  
9.3.2  Exclusion Criteria ........................................................................................26  
9.3.3  Removal of Subjects from Therapy or Assessment .....................................27  
9.4 Treatments..............................................................................................................28  
9.4.1  Treatment Administered ..............................................................................28  
9.4.2  Identity of Investigational Products .............................................................29  
 Chemical Name [CONTACT_548049]2-391 .........................29  
 Labeling for Study Drug ......................................................................29  
 Storage Conditions...............................................................................30  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 14
CONFIDENTIAL Administration of Investigational Products .........................................[ADDRESS_717239] ..........................................31  
9.4.6  Blinding........................................................................................................31  
9.4.7  Prior and Concomitant Therapy ...................................................................31  
 Prior Therapy .......................................................................................31  
 Concomitant Medication/Therapy .......................................................31  
 Prohibited Medication/Therapy ...........................................................32  
9.4.8  Prohibitions and Restrictions during Study Period ......................................33  
9.4.9  Treatment Compliance .................................................................................33  
9.4.10  Drug Supplies and Accountability ...............................................................33  
9.5 Study Assessments .................................................................................................34  
9.5.1  Assessments .................................................................................................34  
 Demography .........................................................................................34  
 Baseline Assessments ..........................................................................34  
[IP_ADDRESS].1  Medical/Surgical and Actinic Keratosis History ...........................34  
[IP_ADDRESS].2  Fitzpatrick Skin-Type Classification .............................................34  
[IP_ADDRESS].3  Prior Medications ...........................................................................34  
 Activity Assessments ...........................................................................35  
[IP_ADDRESS].1  Actinic Keratosis Lesion Count .....................................................35  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Assessments.............................................................35  
[IP_ADDRESS].1  Pharmacokinetic Assessments .......................................................35  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Assessments ...................................................................................36  
 Safety Assessments ..............................................................................36  
[IP_ADDRESS].[ADDRESS_717240] ................................36  
[IP_ADDRESS].[ADDRESS_717241] ...................39  
[IP_ADDRESS].3  Laboratory Measurements .............................................................40  
[IP_ADDRESS].4  Vital Signs ......................................................................................41  
[IP_ADDRESS].5  Physical Examinations ...................................................................41  
[IP_ADDRESS].6  Electrocardiograms ........................................................................41  
[IP_ADDRESS].7  Pregnancy Testing ..........................................................................41  
[IP_ADDRESS].[ADDRESS_717242]..........................................................................................................44  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 15
CONFIDENTIAL Reporting of Serious Adverse Events ..................................................44  
 Reporting of Pregnancy and Exposure to Study Drug through
Breastfeeding .......................................................................................44  
 Reporting of Other Events of Interest ..................................................45  
[IP_ADDRESS].1  Reporting of Adverse Events Associated With Study Drug 
Overdose, Misuse, Abuse, or Medication Error ............................45  
 Expedited Reporting ............................................................................45  
 Breaking the Blind ...............................................................................45  
 Regulatory Reporting of Adverse Events ............................................46  
9.5.4  Completion/Discontinuation of Subjects .....................................................46  
9.5.5  Abuse or Diversion of Study Drug ..............................................................46  
9.5.6  Confirmation of Medical Care by [CONTACT_548000] ..................................46  
9.6 Data Quality Assurance .........................................................................................46  
9.6.1  Data Collection ............................................................................................46  
9.6.2  Clinical Data Management ..........................................................................47  
9.7 Statistical Methods .................................................................................................47  
9.7.1  Statistical and Analytical Plans ....................................................................48  
 Study Endpoints ...................................................................................48  
[IP_ADDRESS].1  Primary Endpoints .........................................................................48  
[IP_ADDRESS].2  Secondary Endpoints .....................................................................48  
[IP_ADDRESS].3  Exploratory Endpoints ...................................................................48  
 Definitions of Analysis Sets.................................................................49  
 Subject Disposition ..............................................................................49  
 Demographic and Other Baseline Characteristics ...............................49  
 Prior and Concomitant Therapy ...........................................................49  
 Activity Analyses.................................................................................50  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Analyses ...................................................................50  
[IP_ADDRESS].1  Pharmacokinetic Analyses .............................................................50  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Analyses .........................................................................................50  
 Safety Analyses ....................................................................................50  
[IP_ADDRESS].1  Extent of Exposure .........................................................................51  
[IP_ADDRESS].2  Adverse Events ..............................................................................51  
[IP_ADDRESS].3  Laboratory Values ..........................................................................51  
[IP_ADDRESS].4  Vital Signs ......................................................................................51  
[IP_ADDRESS].5  Electrocardiograms ........................................................................51  
[IP_ADDRESS].6  Physical Examinations ...................................................................52  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 16
CONFIDENTIAL9.[IP_ADDRESS]  Pregnancy Tests .............................................................................52  
[IP_ADDRESS].8  Other Analyses ...............................................................................52  
9.7.2  Determination of Sample Size .....................................................................52  
9.7.3  Interim Analysis ...........................................................................................52  
9.7.4  Other Statistical/Analytical Issues ...............................................................[ADDRESS_717243] OF IN-TEXT TABLES
Table 1  Schedule of Procedures/Assessm ents in Study KX01-AK-002 
(Cohort 1) .....................................................................................................9  
Table 2  Schedule of Procedures/Assessm ents in Study KX01-AK-002 
(Cohort 2) ...................................................................................................[ADDRESS_717244] OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Terms 
AE adverse event 
AK actinic keratosis 
AUC area under the plasma concentration-time curve  
CFR Code of Federal Regulations 
CI confidence interval 
Cmax maximum plasma concentration 
Cmin minimum (trough) plasma concentration 
CRA clinical research associate 
CRF case report form 
CRO contract research organization 
ECG electrocardiogram 
eCRF electronic case report form 
GCP Good Clinical Practice 
ICF informed consent form 
ICH International Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
LC-MS/MS liquid chromatography/tandem mass spectrometry 
LSR local skin reaction 
MedDRA Medical Dictionary for Regulatory Activities 
PE physical examination 
PI [INVESTIGATOR_547930] 
R accumulation ratio 
SAE serious adverse event 
SCC squamous cell carcinoma 
SD standard deviation 
SOC system organ class 
SOP standard operating procedure 
TEAE treatment-emergent adverse event 
US [LOCATION_002] 
UV ultraviolet (light) 
 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 18
CONFIDENTIAL5 ETHICS 
5.1 Institutional Review Boards/Independent Ethics Committees 
The protocol, any protocol amendments, i nformed consent form (ICF), and appropriate 
related documents must be reviewed and approve d before subjects are screened for entry by 
[CONTACT_3551] (IRB) or Indepe ndent Ethics Committee (IEC) constituted and 
functioning in accordance with International Council for Harmonisation (ICH) E6 (Good 
Clinical Practice [GCP]1), Section 3, and any local regulations (eg, Federal Regulations, Title
21 Code of Federal Regulations [CFR] Part 56 ).  Documentation of IRB/IEC compliance 
with the ICH E6 and any local regulations rega rding constitution and review conduct will be 
provided to the Sponsor. 
A signed letter of study approval from the IRB/IEC chairman must be sent to the Principal 
Investigator (PI) with a copy to the Sponsor be fore study start and the release of any study 
drug to the site by [CONTACT_4885] (ICH E6, Section 4.4).  If the IRB/IEC decides 
to suspend or terminate the study, the Investig ator will immediately send the notice of study 
suspension or termination by [CONTACT_1201]/IEC to the Sponsor. 
Study progress is to be reported to IRB/IECs annually (or as required) by [CONTACT_425826], depending on local regulatory obligations.  If the Investigator is required to report 
to the IRB/IEC, he/she will forward a copy to the Sponsor at the time of each periodic report.  
The Investigator(s) or the Sponsor will subm it, depending on local regulations, periodic 
reports and inform the IRB/IEC of any reportable adverse events (AEs) per ICH guidelines and local IRB/IEC standards of practice.  Upon co mpletion of the study, the Investigator will 
provide the IRB/IEC with a brief report of the outcome of the study, if required. 
5.[ADDRESS_717245] operating procedures (SOPs) of the 
Sponsor (or designee), which are designed to en sure adherence to GCP guidelines as required 
by [CONTACT_716]: 
‚Ä¢Principles of the World Medical Associati on Declaration of Helsinki (2013) 
‚Ä¢ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance, US
Department of Health and Human Services, Food and Drug Administration, April 1996.
‚Ä¢Title 21 of the [LOCATION_002] CFR (US 21 CFR) regarding clinical studies, including Part 
[ADDRESS_717246] the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits involved, any potential discomfort, potential alternative procedure(s) or course( s) of treatment available to the subject, and the extent of 
maintaining confidentiality of the subject‚Äôs reco rds.  Each subject must be informed that 
participation in the study is voluntary, that he/s he may withdraw from the study at any time, 
and that withdrawal of consent will not affe ct his/her subsequent medical treatment or 
relationship with the treating physician. 
This informed consent should be given by [CONTACT_15276] a standard written statement, written in 
nontechnical language.  The subject should understand the statement before signing and 
dating it, and will be given a copy of the signed  document.  If a subject is unable to read, an 
impartial witness should be present during the entire informed consent discussion.  After the 
ICF and any other written information to be provided to subjects is read and explained to the 
subject, and after the subject provides verbal consent to the subject‚Äôs participation in the 
study and has signed and personally dated th e ICF, the witness should sign and personally 
date the consent form.  The subject will be asked to sign an ICF and all authorizations required by [CONTACT_1769] (eg, Protected Health Information in North America) before any study-specific procedures are performed.  No subject can en ter the study before his/her informed consent 
has been obtained. 
An unsigned copy of an IRB/IEC-approved ICF must be prepared in accordance with 
ICH E6, Section 4, and all applicable local regulations.  The original, signed ICF for each subject will be verified by [CONTACT_548001]. 
6 INVESTIGATORS AND STUDY PERSONNEL 
This study will be conducted by [CONTACT_548002], Inc. at approximately 8 to 16 i nvestigational sites in the [LOCATION_002] (US). 
The name [CONTACT_548050] [CONTACT_548003] o rganizations (CROs) will be listed in the 
Regulatory Binder provided to the site. 
7 INTRODUCTION 
7.1 Indication 
In this study, the activity, safety, and pharm acokinetics (PK) of KX2-391 Ointment 1% will 
be evaluated in adult subjects with a clinical diagnosis of stable, clinically typi[INVESTIGATOR_547931] (AK) on the face or scalp. 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 20  
CONFIDENTIAL 
 7.1.1 Mechanism of Action 
KX2-391 (also referred to as KX01) is a synt hetic and highly selective inhibitor of Src 
tyrosine kinase signaling and tubulin polymer ization. KX2-[ADDRESS_717247] overall response in  these early studies has been ‚Äòstable disease‚Äô  
in 25-30% of patients. 
KX2-391 promotes the induction of p53, G2/M arrest of proliferating cell populations and 
subsequent apoptosis via the stimulation of Ca spase-[ADDRESS_717248] clinical activity in dermatology indications 
such as actinic keratosis.  Potent inhibition of the growth of primary human keratinocytes and 
several melanoma cell lines in vitro (50% growth inhibition [GI
50 values] ‚â§50 nM), suggests 
that KX2-391 has the potential to inhibit the proliferative expansion and promote apoptosis 
of abnormally proliferating cells in the epi[INVESTIGATOR_547932]. 
KX2-391 has also been observed to inhibit T cell migration and endothelial tubule formation 
in vitro, suggesting additional potential therapeutic benefits for conditions where pathology is supported by [CONTACT_548004], inflammation, and/or angiogenesis. 
Information regarding KX2-391 noncli nical studies is provided in the Investigator‚Äôs 
Brochure. 
7.1.2 Clinical Experience with 
KX2-391  
KX2-391 Ointment 1% has been administered  to humans in ongoing study KX01-AK-01-
US.  Based on preliminary PK data from this study in AK lesions on the forearm, the systemic exposure to KX2-[ADDRESS_717249] ication site reactions and systemic toxicity. 
KX2-391 has been administered orally to a pproximately 120 patients with malignancy. 
The Kinex studies of oral KX2-391 are as follows: 
KX2-391 was evaluated in a Phase I clinical trial, Study No. KX01-01- 07, entitled ‚ÄúA 
Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase I Study to Evaluate Safety, Tolerability, and Pharmacoki netics of KX2-391 in Patients with Advanced 
Malignancies That Are Refractory to Conventional Therapi[INVESTIGATOR_014]‚Äù.  
KX2-391 has been evaluated in Study No. KX01-002-09, ent itled ‚ÄúA Phase II, Open -Label, 
Single-Arm Study Evaluating the Safety, Ef ficacy and Pharmacokinetics of KX2-[ADDRESS_717250] Not Received 
Prior Chemotherapy.‚Äù 
KX2-391 was evaluated in Study No, KX01-03- 11, ‚ÄúA Phase 1b Rising Multiple -Dose 
Clinical Study to Evaluate Safety, Tolerability  and Activity of Oral Monotherapy with KX2-
391 in Elderly Subjects with Acute Myeloi d Leukemia (AML) Who Are Refractory to or 
Have Declined Standard Induction Therapy‚Äù.
7.2 Study Rationale 
Actinic keratoses represent the initial intra- epi[INVESTIGATOR_547976] (SCC).  Squamous 
cell carcinoma is the second leading cause of skin cancer deaths in the US, with up to 65% of 
SCC arising from pre-existing actinic keratoses.2,3 The risk of progression has been 
determined to be between 0.025% and 16% per year,2,4and the calculated lifetime risk of 
malignant transformation for a patient with AK s followed up for 10 years is between 6.1% 
and 10.2%.5The rationale behind treating every AK is  based on the difficulty in predicting 
which single AK will progress to squamous cell carcinoma.6,7 Suchniak et al8reported 36% 
of lesions previously diagnosed clinically as AKs being in fact SCC, with 14% being in situ 
SCC.  Ehrig et al9showed that 4% of AKs clinically diagnosed by [CONTACT_17685]-certified 
dermatologists were in fact SCC and 5% were  considered occult early stage of cutaneous 
malignancy.  Spontaneous regression has been  reported in up to 25.9% of AKs over a 
12-month period, although 15% later reappeared.10,11,12The goals of treatment are to 
completely eliminate AKs, minimizing their risk of progression to invasive SCC, reducing 
the potential to metastasize and cause death, while obtaining the best cosmetically acceptable 
outcomes.  Current approved/marketed trea tment has shown up to approximately 60% 
efficacy, with a recurrence rate of approximately 35%. 
8 STUDY OBJECTIVES 
8.1 Primary Objective 
The primary objective of the study is: 
‚Ä¢To evaluate the activity of KX2-391 Ointment 1% administered topi[INVESTIGATOR_547934], defined as 100% 
clearance at Day 57 
8.2 Secondary Objectives 
The secondary objectives of the study are: 
xTo assess the activity of KX2-391 Ointment 1% during Days 1-57 
xTo assess the safety and tolerability of KX2-391 Ointment 1% in subjects with AK on 
the face or scalp 
xTo assess the PK of KX2-391 Ointment 1% in subjects with AK on the face or scalp 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 22  
CONFIDENTIAL 
 x To assess dose regimens by [CONTACT_456105] 5-da y treatment with 3-da y treatment in terms 
of the activity and safety of KX2-391 Ointment  1% in subjects with AK on the face 
or scalp 
8.3 Exploratory Objectives 
The exploratory objectives of the study are: 
x To determine recurrence rates up to [ADDRESS_717251]-Day 57 for subjects who 
show response at Day 57 
9 INVESTIGATIONAL PLAN 
9.1 Overall Study Design and Plan 
This study will be an open-label, multicenter, activity, safety, tolerability, and PK study of 
KX2-391 Ointment 1% administered topi[INVESTIGATOR_547935] 2 sequential c ohorts:  a 5-day dosing regimen (Cohort 1) and a 3-day dosing 
regimen (Cohort 2). 
The study consists of Screening, Treatment, and Follow-up Periods. 
Cohort 1:  
Eligible subjects will receive 5 consecutive days  of topi[INVESTIGATOR_35786], to be applied at the 
study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 and Day 5.  Subjects will return for Follow-up visits until Day 57.  
Thereafter, only Day 57 complete responders w ill continue Recurrence Follow-up Visits 
every 3 months for an additional 12 months afte r Day 57.  Activity (lesion counts) and safety 
evaluations will be performed. 
Cohort 2: 
Eligible subjects will receive 3 consecutive days  of topi[INVESTIGATOR_35786], to be applied at the 
study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 and Day 3.  Subjects will return for Follow-up visits until Day 57.  
Thereafter, only Day 57 complete responders w ill continue Recurrence Follow-up Visits 
every 3 months for an additional 12 months afte r Day 57.  Activity (lesion counts) and safety 
evaluations will be performed. 
For both cohorts, subjects may stay for approx imately [ADDRESS_717252] PK blood sample is coll ected on Days 1 and 5 (Cohort 1) or Days 1 and 3 
(Cohort 2). 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 23
CONFIDENTIALThe Sponsor will review accumulating data.  If the 5-day regimen (Cohort 1) has sufficient 
activity and safety to warrant evaluating a 3- day regimen, enrollment of Cohort 2 will start 
after there are 60 evaluable subjects or up to 80 s ubjects are enrolled (whichever comes first) 
in Cohort 1.  For the most part, protocol proc edures for Cohort [ADDRESS_717253] dose of study drug.  All screening assessments/evaluations, as 
presented in Table [ADDRESS_717254] provides informed 
consent and eligibility criteria are met. 
Treatment Area Identification 
At Screening (Visit 1), the Investigator will se lect a continuous treatment area affected with 
AK on the face or scalp for each subject that: 
xmeasures 25 cm
2 
xcontains 4 to 8 AK lesions that are clinically typi[INVESTIGATOR_547936].
At Visit 1, the Investigator and an investigational center staff member will identify the 
treatment area by:  
[CONTACT_548032] a dot of removable marker. 
xUsing an [ADDRESS_717255] 2 anatomical landmarks on the acetate sheet.  Example of landmarks 
could be bony prominences, scars, moles, seborrheic keratosis, and veins. 
xIndicating the location of AK lesions with  permanent marker dots on the acetate 
transparency sheet. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 24
CONFIDENTIALxOutlining the treatment area on the transparency sheet with the permanent marker. 
xRemoving marker dots on the face/scalp with  alcohol swabs or water (after taking the 
screening photo). 
9.1.2 Treatment Period 
The inclusion/exclusion criteria will be review ed again prior to treatment on Day 1, to 
re-confirm subjects‚Äô eligibility to participate in the study . 
Subjects in Cohort 1 will be treated for 5 cons ecutive days (Days 1-5 [Visits 2-6]) during the 
Treatment Period. Visits 2 through 6 should be  scheduled to occur at approximately the 
same time each day. 
Subjects in Cohort 2 will be treated for 3 cons ecutive days (Days 1-3 [Visits 2-4]) during the 
Treatment Period.  Subjects will not return on Day 4 (Visit 5) or Day 5 (Visit 6).  Visits 2 
through 4 should be scheduled to occur at approximately the same time each day.  
At Visit 2 (Day 1), prior to study drug application, the Investigator and any appropriate 
investigational staff member(s) (Investigator-tra ined designee) will confirm the location of 
the treatment area using the Visit 1 acetate sheet.  The Investigator should re-mark the 
treatment area borders as needed so the study evaluations may be effectively completed. 
Once the treatment area has been re-ident ified at Visit 2, photographs will be taken 
(Section [IP_ADDRESS].8 ).  50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_231704] 
5 consecutive days (Cohort 1) or 3 cons ecutive days (Cohort 2) to the 25 cm2treatment area 
(2 mg/cm2; 0.5 mg KX2-391 total).  See Section [IP_ADDRESS] for a detailed description of study 
medication application. 
Pharmacokinetic blood sampling, activity, safety assessments, and local skin reaction (LSR) 
assessments (see Section 9.5 for details) will be performed ( Table 1 and Table 2 ).  
Pi[INVESTIGATOR_547937] (or a 
trained designee).
Standardized photography will be performed at  designated visits throughout the study 
(Table 1 andTable 2 ). 
9.1.[ADDRESS_717256]-Day 57 (ie, at 3, 6, 9, and [ADDRESS_717257]-Day 57) to assess recurrence of AK lesions . These subjects will continue to undergo 
scheduled activity and safety assessments ( Table 1 andTable 2 ).
For subjects who have complete response at Day [ADDRESS_717258] their Final Visit at the visit when the AK recurrence is identified.
9.2 Discussion of Study Design, Including Choice of Control Groups 
This is a nonrandomized, open-label study.   No control group has been included. 
9.3 Selection of Study Population
Eligible subjects will be adults (‚â•18 years of age) with a clinical diagnosis of stable, 
clinically typi[INVESTIGATOR_547938]. 
9.3.1 Inclusion Criteria 
Inclusion criteria will be rev iewed at Screening (Visit 1). 
Subjects must meet all of the following criteria to be included in this study: 
1.Males and females ‚â•18 years old
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
xis a continuous area measuring [ADDRESS_717259] be postmenopausal (>[ADDRESS_717260] 18 months of 
amenorrhea), surgically sterile (by [CONTACT_548005], bilateral oophorectomy or tubal 
ligation) or otherwise incapable of pregnancy fo r at least 1 year; or, if of childbearing 
potential, must be using highly effective c ontraception for at least 90 days prior to 
treatment with KX2-391 Ointment 1% and must agree to continue to use highly 
effective contraception for at least [ADDRESS_717261] dose of KX2-391 
Ointment 1%.  Highly effective contrace ption includes oral hormonal contraceptives, 
hormonal contraceptive implant or patch, or intrauterine device.  Abstinence and double 
barrier methods do not qualify as highly effective methods of contraception.
5. Males who have not had a vasectomy must agree to use barrier contraception from 
Screening through [ADDRESS_717262] dose of KX2-391 Ointment 1%. 
6. All subjects must agree not to donate sp erm or eggs or attempt conception from 
Screening through [ADDRESS_717263] dose of KX2-391 Ointment 1%. 
Clinical Study Protocol_Amendment [ADDRESS_717264] on Day 1 prior to administration of study 
treatment. 
8. Subjects who in the judgment of the Investigator, are in good general health based on: 
xmedical history 
xno physical examination (PE) findings that th e Principal Investigator (PI) determines 
would interfere with interpretation of study results 
xscreening electrocardiogram (ECG) without clinically significant abnormalities  
xclinical chemistry, hematology, and urinalysis results that are within the reference 
ranges; clinical laboratory values outside the reference ranges that are considered by 
[CONTACT_978] [INVESTIGATOR_547939]  
9. Willing to avoid direct sun or ultraviole t (UV) light exposure to the face or scalp  
10. Able to comprehend and are willing to sign an informed consent form  
9.3.2 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from this study: 
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924] 
2. Malignancy within 5 years prior to Screen ing except basal or squamous cell carcinoma 
not on the treatment area that were treated  with curative intent and are without 
recurrence 
3. Used any of the following systemic therapi[INVESTIGATOR_547940] 1: 
xretinoids; 90 days 
xglucocorticosteroids; 28 days (intra-articu lar and inhaled steroids are allowed) 
xmethotrexate or other anti-metabolites; 28 days 
ximmunosuppressants or immunomodulators; 28 days 
4. Used any of the following topi[INVESTIGATOR_547977] s on the treatment area within the specified 
period before Visit 1: 
xretinoids; 90 days 
xglucocorticosteroids; 14 days 
xanalgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
5. Had any of the following on the treatment area within 90 days (or until the site has 
healed, whichever is longer) before Visit 1: 
xingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
x5-fluorouracil (eg, 5-FU; Efudex) 
ximiquimod (eg, Aldara; Zyclara) 
xdiclofenac with or without hyaluronic acid (eg, Solaraze) 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 27
CONFIDENTIAL6. Surgical or destructive modalities on the treatm ent area within 30 days (or until the site 
has healed following treatment, wh ichever is longer) before Visit 1: 
xcryotherapy 
xelectrodesiccation 
xlaser, light (eg, photodynamic therapy, intens e pulsed light) or any other energy-based 
therapy 
xchemical peels (eg, tricholoracetic acid) 
xdermabrasion 
xsurgical removal (eg, curettage, excision) 
7. Currently, or has experienced any of the following on the treatment area within the 
specified period before Visit 1: 
xcutaneous malignancy; 180 days 
xsunburn; 28 days 
xbody art (eg, tattoo, pi[INVESTIGATOR_77219]); currently 
8. A history of sensitivity and/or allergy to any of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psori asis, eczema) or condition (eg, scarring, open 
wounds) that, in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which exposes the subj ect to an unacceptable risk by [CONTACT_160823] 
10. Other significant uncontrolled or unstable med ical diseases or conditions that, in the 
opi[INVESTIGATOR_689], would expose the subject to unacceptable risk by [CONTACT_160823] 
11. Females who are pregnant or nursing 12. Participated in an investigational drug tr ial during which an investigational study 
medication was administered within [ADDRESS_717265] from the study for any of 
the reasons listed below:  
xOccurrence of AEs 
xOccurrence of pregnancy  
xUse of a prohibited concomitant medication or treatment (see Section [IP_ADDRESS] ) 
xConditions that, in the opi[INVESTIGATOR_689] , would make the subject‚Äôs 
continued participation in the study in advisable (actual condition must be 
documented) 
xNoncompliance (Investigator must describe) 
xWithdrawal of consent (subject asked, but not required to give a reason) 
xOther (Investigato r must describe) 
If the study is terminated by [CONTACT_1034], the Inve stigator will promptly explain to the subject
involved that the study will be discontinued and provide appropriate medical treatment and 
other necessary measures for the subject. 
9.[ADDRESS_717266] in the study is KX2-391 Ointment 1%.
9.4.[ADDRESS_717267] StrengthSize of 
Treatment 
AreaQuantity study 
medication/
KX2-391Number 
Appli cations 
and FrequencyStudy Days 
Administered
KX2 -391 Ointment 1% 1% 25 cm250 mg of study 
drug = 0.5 mg
of KX2- 3911 application 
daily for 
5consecutive 
days (Cohort 1) 
or 3 consecutive 
days (Cohort 2)Days 1 -5(Cohort 1)
Days 1 -3 (Cohort 2)
Clinical Study Protocol_Amendment 1 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 29  
CONFIDENTIAL 
 9.4.2 Identity of Investigational Products 
 Chemical Name [CONTACT_548049]2-391 
x Study drug code:  KX2-391 Ointment 1% 
x Drug Product:  KX2-391 free base ointment formulated with glyceryl 
monostearate and propylene glycol 
x Chemical name:  N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) 
acetamide   
x Molecular formula:  C 26H29N3O3 
x Molecular weight:  431.53 g/mole 
x Structural formula:   
 
 Labeling for Study Drug 
Investigational product will be packaged and labeled in a manner consistent with the study 
and will be designed by:  
[CONTACT_548006], Inc. 
[ADDRESS_717268] will be  in accordance with US regulations and will 
include (but will not be limited to) the following information: 
‚Ä¢  For clinical study use only 
‚Ä¢ Name [CONTACT_49256] 
‚Ä¢ Chemical name/drug identifier 
‚Ä¢ Lot number/batch number 
‚Ä¢ Storage conditions, expi[INVESTIGATOR_547978]_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 30
CONFIDENTIAL
Storage Conditions
Study drug will be stored in accordance w ith labeled storage conditions. Temperature 
monitoring is required at the storage location to ensure that the study drug is maintained within an established temperature range.  The Investigator is responsible for ensuring that the temperature is monitored throughout the tota l duration of the trial and that records are 
maintained; the temperature should be monitored continuously by [CONTACT_548007], a mechanical recording device, such as a calibrated chart 
recorder, or by [CONTACT_3177], such that minimu m and maximum thermometric values over a 
specific time period can be recorded and retrieved as required. 
Administration of Investigational Products
The study medication is for external topi[INVESTIGATOR_453609] e on the treatment area.  An investigational 
center staff member will perform the study medic ation applications.  Th e staff member must 
wash her/his hands before and after each study medication application. 
50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_547943] a 25 cm2 treatment area.  This 
amount contains a total of 0.5 mg KX2-391 free  base.  KX2-391 Ointment 1% will be 
applied once daily for 5 consecutive days (Cohort 1) or 3 consecutive days (Cohort 2) (see 
Table 3 ).
The staff member will weigh the appropriate amount of study medication into a weighing 
boat (or equivalent) using a calibrated scale.  The amount of study medication applied will be 
calculated by [CONTACT_548008]. The am ount of study medication weighed will be as 
close to the intended dose as possible. 
A study staff member will perform and document a scale accuracy check at least every day 
before weighing study medication. 
The stud y medication will be applied to the subj ect‚Äôs treatment area using a fingertip 
protected with a powder-free finger cot or exam ination glove. The study medication will be 
gently and evenly rubbed over the treatment area until no visible accumulation is evident. The time when the study medication applicat ion is completed (Application Completion 
Time) will be recorded. 
The study medication should remain on the treat ment area. Subjects must avoid touching or 
wetting the treatment area for at least [ADDRESS_717269] application and are not 
allowed to apply any topi[INVESTIGATOR_547944] (see Section [IP_ADDRESS] ).  Instructions 
will be sent home with the subject clarifying on how to care for the treatment area. 
9.4.3 Method of Assigning S ubjects to Treatment Groups 
This is an open-label study with 2 sequential cohorts.  Each site will enroll subjects for 
Cohort 1 (5-day regimen) first, and will not assign any subjects to Cohort 2 (3-day regimen) 
until being notified.  The Sponsor will review accumulating data on Cohort 1 to decide if, 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 31
CONFIDENTIALwhen, and where to start Cohort 2.  In addi tion, the Sponsor study team will monitor the 
enrollment status closely and ensure that any individual site does not enroll too many 
subjects. 
9.4.4 Selection of Doses in the Study 
The dose of 50 mg of KX2-391 applied to a 25 cm2 area on the face or scalp for 5 or 
3 consecutive days is based on a previous study using the same dose regimen for the treatment of AK on the forearm (study KX01-A K-01-US). Preliminary data show that this 
regimen had an acceptable LSR and safety profile, with efficacy outcomes considered to warrant further investigation.
9.4.[ADDRESS_717270] 
Section [IP_ADDRESS] provides detailed instructions for admini stering KX2-391 Ointment 1% in 
this study.  Study medication should be applied at about the same time each day. 
9.4.6 Blinding 
The study will not be blinded. 
9.4.7 Prior and Concomitant Therapy 
Prior Therapy
All medications (prescription and nonprescr iption including vitamins and dietary 
supplements), treatments, and therapi[INVESTIGATOR_547945] [ADDRESS_717271] be recorde d in the case report form/electronic case report 
form (CRF/eCRF).  A complete AK treatment hist ory will be recorded on the AK Treatment 
History CRF/eCRF (see Section [IP_ADDRESS].1 ).
Concomitant Medication/Therapy
Concomitant medication/therapi[INVESTIGATOR_547946]. 
Any medication (including nonprescription medications) or therapy administered to the 
subject during the course of the study (startin g at the date of informed consent) will be 
recorded on the Concomitant Medication CRF/eCRF. 
Use of sunblock or any topi[INVESTIGATOR_547947]/eCRF. 
The Investigator will record any AE on the Adverse Events CRF/eCRF for which the 
concomitant medication/therapy was administered. 
Subjects will refrain from receipt of any ther apy in accordance with the inclusion/exclusion 
criteria 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 32
CONFIDENTIAL
Prohibited Medication/Therapy
Use of any non-study drug treatment for AK lesions on the treatment area is prohibited until 
Day 57.  AK lesions located outside the treatm ent area may be treated by [CONTACT_240765]-directed 
treatment only, eg, cryotherapy or biopsy, as determined by [CONTACT_737].  A list of prohibited medications follows. 
Prohibited drug products and treatments that migh t influence or mask the effects of treatment 
until Day 57 include:  immunomodulators or im munosuppressive therapi[INVESTIGATOR_014], cytotoxic drugs, 
interferon/interferon inducers, topi[INVESTIGATOR_547948], 5-FU, ingenol mebutate, 
imiquimod, diclofenac, topi[INVESTIGATOR_547949], topi[INVESTIGATOR_547950] c acid, bichloroacetic 
acid, trichloroacetic acid, acid-containing therapeutic products, benzoyl peroxide, 
chemodestruction, medicated/therap eutic topi[INVESTIGATOR_547951], photodynamic 
therapy, psoralen plus UVA or UVB therapy, artificial tanner, excessive or prolonged 
exposure to UV light source.
13
During the Recurrence Follow-up Period, lesion-di rected treatment such as cryotherapy or 
biopsy, and topi[INVESTIGATOR_547952].  Any lesion in the treatment area th at is treated during the Recurrence Follow-up 
Period will be considered as a recurrence. 
Subjects are prohibited from applying any t opi[INVESTIGATOR_49186], including but not limited to, 
lotions, creams, and ointments to the treatmen t area up until the end of Visit 10 (Day 57), 
except when those medications are prescribed by [CONTACT_548009].  All other routinely used  topi[INVESTIGATOR_547953] [ADDRESS_717272] er a prohibited medication/treatment is done with the safety of the 
study subject as the primary consideration. 
Clinical Study Protocol_Amendment [ADDRESS_717273] be fasted for laboratory 
assessments (see Section [IP_ADDRESS].3 ); otherwise there are no food, water, beverage, or physical 
activity restrictions during the study. 
9.4.[ADDRESS_717274] will be kept during the study.  The 
clinical research associates (CRAs) will rev iew treatment administ ration throughout the 
course of the study. 
9.4.10 Drug Supplies and Accountability 
The Investigator and study staff will be responsible for the accountability of all clinical 
supplies (dispensing, inventory, and record keepi[INVESTIGATOR_007]) fol lowing the Sponsor‚Äôs instructions.  In 
this matter, the Investigator and study staff must adhere to GCP guidelines, as well as national requirements. 
Under no circumstances will the Investigator allo w the study drugs to be used other than as 
directed by [CONTACT_3181].  Clinical supplies will be dispensed only by [CONTACT_548033]. 
An accurate and timely record of the receipt of all clinical supplies and dispensing of study 
drug to the subject must be maintained.  This includes, but is not limited to: 
xdocumentation of receipt of clinical supplies 
xstudy drugs dispensing/return reconciliation log, including amount and date of 
dispensing 
xstudy drugs accountability log 
xall shippi[INVESTIGATOR_547979] (or its designee).  Any comparable forms that the 
investigational site wishes to use must be approved by [CONTACT_1034].  A copy of the drug accountability record must be provided to the Sponsor at the end of the study. 
The supplies and inventory records must be made available, on request, for inspection by [CONTACT_429] (or its designee) or a representative of a h ealth authority.  If applicable, all unused 
study drugs and empty containers, are to be re turned to the Investigator by [CONTACT_548011].  On completion 
of drug accountability and reconciliation procedure s by [CONTACT_548012], st udy drug that is to be returned to the 
Clinical Study Protocol_Amendment [ADDRESS_717275] be boxed and sealed  and shipped back to the Sponsor following 
all local regulatory requirements. 
The CRA(s) will review drug accountability duri ng monitoring site visits and at the 
completion of the study. 
9.5 Study Assessments 
9.5.1 Assessments 
All assessments and timing of the assessmen ts should be performed according to the 
Schedule of Procedures and Assessments ( Table 1 andTable 2 ).
Demography
Subject demographic information will be coll ected at the Screening Visit.  Demographic
information includes date of birth (or age), sex, race/ethnicity. 
Baseline Assessments
[IP_ADDRESS].1 M EDICAL /SURGICAL AND ACTINIC KERATOSIS HISTORY
Medical and surgical history and current medi cal conditions will be recorded at Screening 
(Visit 1).  All pertinent medical history must be noted in the CRF/eCRF.  A complete AKmedical history will also be recorded. 
Medical history will include:  
xSignificant medical and surgical history;  childhood diseases and common colds are 
not required unless it is ongoing at Screening 
xA complete AK history from the time of initial diagnosis 
xA complete AK treatment history including  all commercial and investigational 
products, including medical therapi[INVESTIGATOR_547957], and other prescribed 
and nonprescription therapi[INVESTIGATOR_547958]. 
[IP_ADDRESS].2 F ITZPATRICK SKIN-TYPE CLASSIFICATION
The Fitzpatrick Skin-Type is a skin classification system 13which measures 2 components 
(genetic disposition and reaction to sun exposure).  Skin-types range from very fair (Type I) 
to very dark (Type VI). 
Subjects‚Äô skin will be typed using this classificat ion system at Screening (Visit 1). 
[IP_ADDRESS].3 P RIOR MEDICATIONS
Prior medications taken within 28 days before Day 1, including nonprescription remedies, 
vitamins, etc, will be recorded at Screening (Visit 1).
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 35
CONFIDENTIAL
Activity Assessments
[IP_ADDRESS].1 A CTINIC KERATOSIS LESION COUNT
The Investigator will perform a count of AK lesions (lesion count) for all subjects at Visits 1
and 2, Visits 7 through 10, and for Day 57 complete responders, also at Visits 11 through 14.
The AK lesion count is the Investigator ‚Äôs assessment of the number of AK lesions  in the 
treatment area.  A subject must have [ADDRESS_717276] with the AK lesion count.  
This is not a comparison with the AK lesion count at any other timepoint. 
Pharmacokinetic, Pharmacodynamic, Ph armacogenomic, and Other Biomarker
Assessments
[IP_ADDRESS].1 P HARMACOKINETIC ASSESSMENTS
Blood samples (3 mL at each timepoint) for PK an alysis of KX2-391 will be collected at the 
following timepoints (Table 4) : 
Table 4 Blood Sample Collection Times for Pharmacokinetic Analyses 
Application Day Time (hours)   
0
predose0.5
postdose1
postdose4
postdose
Window ¬±5 minutes ¬±10 minutes ¬±10 minutes
Both cohorts: Day 1 (Visit 2) XaX X X
Cohort 1:  Day 5 (Visit 6) XaX X X
Cohort 2:  Day 3 (Visit 4) XaX X X
a Prior to application of study treatment.
Approximately 24 mL will be collected for  measurement of plasma concentrations of 
KX2-391. 
The actual times of PK sampling will be recorded. A description of collection, handling, and ship pi[INVESTIGATOR_547959]. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 36
CONFIDENTIALPlasma concentrations of KX2-391 will be analyzed to determine C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Plasma concentrations of study drug will  be measured using a validated liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) assay. 
[IP_ADDRESS].2 P HARMACODYNAMIC ,PHARMACOGENOMIC , AND OTHER BIOMARKER ASSESSMENTS
Not applicable 
Safety Assessments
Safety assessments will include recording all AEs and serious adverse events (SAEs).
Safety assessments also include laboratory evaluation of hematology, biochemistry, and 
urinalyses; periodic measurement of weight, vita l signs, ECGs, and performance of PEs, as 
detailed in the sections below and shown in Table [ADDRESS_717277]-reported LSRs will not be reported as  adverse events. Treatments administered for 
LSRs will be recorded on the Concomitant Medications CRF. 
[IP_ADDRESS].[ADDRESS_717278].  For this study, the study drug is KX2-391 Ointment 1%.
Treatment-emergent AEs are defined as: 
xeither those AEs with an onset after dosing or  
xthose pre-existing conditions that worsen after dosing 
The criteria for identifying AEs are: 
‚Ä¢any unfavorable and unintended sign (incl uding an abnormal laboratory finding), 
symptom, or disease temporally associated wi th the use of an investigational product, 
whether or not considered related to the investigational product 
‚Ä¢any new disease or exacerbation of an existing disease  
‚Ä¢any deterioration in nonprotocol-required mea surements of a laboratory value or other 
clinical test (eg, ECG or x-ray) that results in symptoms, a change in treatment, or 
discontinuation from study drug 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 37
CONFIDENTIAL‚Ä¢recurrence of an intermittent medical conditi on (eg, headache) not present at baseline 
All AEs, regardless of relationship to study drug  or procedure, should be collected beginning 
from the time the subject signs the study IC F through the final contact [CONTACT_548013]-up 
Period on Day 57. For subjects participating in  the Recurrence Follow-up Period, only AEs 
at the treatment area will be collected. 
Subjects with study drug-related AEs will be followed until resolution, resolved with 
sequelae, or under medical care.  All SAEs must be  followed to resolution or, if resolution is 
unlikely, to stabilization. 
All AEs observed during the study will be reported on the CRF/eCRF. 
Laboratory Adverse Events 
A treatment-emergent abnormal laboratory test re sult should be considered as a treatment-
emergent AE (TEAE) if the identified labor atory abnormality leads to any type of 
intervention whether prescribed in the protocol or not. 
An abnormal laboratory result should be considered by [CONTACT_548014]: 
xresults in the withdrawal of study drug 
xresults in withholding of study drug pending some investigational outcome 
xresults in the initiation of an inte rvention, based on medical evaluation (eg, 
potassium supplement for hypokalemia) 
xresults in any out of range laboratory value that in the Investigator ‚Äôs judgment 
fulfills the definitions of an AE with regard to the subject ‚Äôs medical profile
xincreases in severity compared with baseline 
Abnormal laboratory values should not be listed as  separate AEs if they are considered to be 
part of the clinical syndrome that is being report ed as an AE.  It is the responsibility of the 
Investigator to review all laboratory findings in  all subjects and determine if they constitute 
an AE.  Medical and scientific judgment should be  exercised in deciding whether an isolated 
laboratory abnormality should be classified  as an AE.  Any laboratory abnormality 
considered to constitute an AE should be reported on the Adverse Event CRF/eCRF. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015].  An ECG abnormality in a subject with symptoms may meet the criteria for an AE as described in this protocol.  In these instances, the AE 
corresponding to the symptomatic ECG abnormality will be recorded on the Adverse Events 
CRF/eCRF. 
For symptomatic ECG abnormalities meeting criteria as SAEs, the study site must submit an 
SAE report, including the ECG report to the Sponsor, or designee, using the SAE reporting procedures ( Section [IP_ADDRESS] ).
Clinical Study Protocol_Amendment [ADDRESS_717279] be made by [CONTACT_548016].
Adverse events will be graded for severity as follows: 
Mild An event that is easily tolerated by  [CONTACT_102], causing minimal discomfort 
and not interfering with everyday activities 
Moderate An event that is sufficiently discomforting to interfere with everyday 
activities 
Severe An event that prevents normal everyday activities
Investigators will assess severity for all AEs (f or both increasing and decreasing severity).  
The criteria for assessing severity are different from those used for seriousness (see Section [IP_ADDRESS].2 ).
Assessing Relationship to Study Treatment 
Items to be considered when assessing the relationship of an AE to the study treatment are: 
xtemporal relationship of the onset of the event to the initiation of the study treatment 
xthe course of the event, especially the effe ct of discontinuation of study treatment or 
reintroduction of study treatment, as applicable 
xwhether the event is known to be associated  with the study treatment or with other 
similar treatments 
xthe presence of risk factors in the study s ubject known to increase the occurrence of 
the event 
xthe presence of nonstudy treatment-related factors that are known to be associated 
with the occurrence of the event 
Classification of Causality 
The relationship of each AE to the study drug will be recorded on the CRF/eCRF using the 
following criteria: 
Definitely Related: A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administ ration, and which cannot be explained by 
[CONTACT_548017]: A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, unl ikely to be attributed to concurrent or 
underlying disease or other drugs or conditions  
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 39
CONFIDENTIALPossibly Related: A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, but which could also be explained by [CONTACT_548018]: A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which makes  a causal relationship improbable, and in 
which other drugs, conditions or concurrent  or underlying disease provide plausible 
explanations 
[IP_ADDRESS].[ADDRESS_717280] medical occurrence that at any dose: 
‚Ä¢results in death 
‚Ä¢is life-threatening (ie, the s ubject was at immediate risk of death from the AE as it 
occurred; this does not include an event that,  had it occurred in a more severe form or 
was allowed to continue, might have caused death) 
‚Ä¢requires inpatient hospi[INVESTIGATOR_1081] 
‚Ä¢results in persistent or significant disability/incapacity
‚Ä¢is a congenital anomaly/birth defect (in th e child of a subject who was exposed to the 
study drug) 
Other important medical events that may not be  immediately life-threatening or result in 
death or hospi[INVESTIGATOR_313], when based on appropriate medical judgment, may jeopardize 
the subject or may require intervention to pre vent one of the outcomes in the definition of 
SAE listed above should also be considered SAEs.  Medical and scientific judgment should 
be exercised in deciding whether expedited reporting is appropriate in such situations. 
In addition to the above, other events of in terest, which include pregnancy, overdose, and 
significant treatment-emergent laboratory abnormality (See Section [IP_ADDRESS].1 ), are to be 
captured using the SAE procedures but are to be considered as SAEs only if they met one of the above criteria. All events of these types are to be reported on the CRF/eCRF whether or not they meet the criteria for SAEs. 
The following hospi[INVESTIGATOR_547960] ‚ÄúAE‚Äù (ie, 
there is no untoward medical occurrence) associated with the hospi[INVESTIGATOR_059]: 
‚Ä¢hospi[INVESTIGATOR_547961] (where the condition requiring the 
hospi[INVESTIGATOR_81403]) 
All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 40
CONFIDENTIAL9.[IP_ADDRESS] L ABORATORY MEASUREMENTS
Blood will be collected for clinical laboratory te sts at Screening (Visit 1), Day 8 (Visit 7), 
and Day 57 (Visit 10) ( Table 1 and Table 2 ).  Collection of blood and urine (including 
samples for pregnancy testing, where applicable)  will be conducted at the clinic site.  
Approximately [ADDRESS_717281] be documented for all 
laboratory samples. 
Microscopic urinalysis will be conducted only when clinically indicated based on dipstick 
results (laboratory protocol) or as determined by [CONTACT_737].  When conducted, microscopic urinalysis results will be recorded on the CRF/eCRF. 
The clinical laboratory tests to be measured during the study are provided in  Table 5 .
Table 5 Clinical Laboratory Tests
Category Parameters
Hematology red blood cells (RBC), hemoglobin, hematocrit, platelets, and white 
blood cells (WBC) with differential (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), RBC dist
ribution width (RDW)
Chemistry
Electrolytes chloride, potassium, sodium, bicarbonate (HCO 3)
Liver function tests alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), gamma glutamyl transpeptidase (GGT), direct
bilirubin, total bilirubin
Renal function tests blood urea/blood urea nitrogen, creatinine
Other Albumin, calcium, cholesterol, glucose, lactate dehydrogenase (LDH),
phosphorus, total protein, triglycerides, uric acid
Urinalysis (dipstick)ahydrogen ion concentration (pH), specific gravity, protein, glucose, 
ketones, leukocyte esterase, nitr ite, bilirubin, urobilinogen, blood
Pregnancy Testing serum pregnancy test, urine pregnancy test (where applicable)
a Microscopic urinalysis will be conducted only when clinically indicated based on dipstick results 
(laboratory protocol) or as determined by [CONTACT_737].
A laboratory abnormality may meet the criteria to  qualify as an AE as described in this 
protocol (see Section [IP_ADDRESS].1 ).  In these instances, the AE  corresponding to the laboratory 
abnormality will be recorded on the Adverse Event CRF/eCRF. 
For laboratory abnormalities meeting the criteria of SAEs (see Section [IP_ADDRESS].2 ), the site 
must electronically transmit the SAE report including the laboratory report to the Sponsor using the SAE form (see Section [IP_ADDRESS] ).
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 41
CONFIDENTIAL9.[IP_ADDRESS] V ITAL SIGNS
Vital sign (pulse rate, systolic and diastolic blood pressure, respi[INVESTIGATOR_697], and body 
temperature) measurements will be taken after the subject has been seated for at least 
5 minutes at Screening (Visit 1), Day 5 (Visit 6) for Cohort 1 or Day 3 (Visit 4) for Cohort 2, 
Day 8 (Visit 7), Day 15 (Visit 8), Day 29 (Visit 9), and Day 57 (Visit 10) ( Table 1 and
Table 2 ).  Serial vital signs may be obtained to confirm accurate readings.  
[IP_ADDRESS].5 P HYSICAL EXAMINATIONS
A complete PE will be performed at Screening (Visit 1) and Day 57 (Visit 10) ( Table 1 and
Table 2 ).
A complete PE will include weight and an as sessment of head, eyes, ears, nose, and throat 
(HEENT), integumentary, gastrointestinal, ca rdiovascular, respi[INVESTIGATOR_696], muscular-skeleton, 
and neurological systems. 
Documentation of the PE will be included in the source documentation at the site.  Only 
changes from screening PE findings that meet th e definition of an AE will be recorded on the 
Adverse Events CRF/eCRF. 
[IP_ADDRESS].6 E LECTROCARDIOGRAMS
A 12-lead ECG will be completed at Screen ing (Visit 1), Day 8 (Visit 7), and Day 57
(Visit 10) ( Table 1 andTable 2 ). ECGs may be performed at a convenient time during the 
visit.  Subjects must be in the recumbent posit ion for a period of 5 minutes prior to the ECG.  
The ECG data recorded on the CRF/eCRF mu st include rate, rhythm, intervals, and 
QTc/QTcF. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015]. 
[IP_ADDRESS].7 P REGNANCY TESTING
Serum pregnancy tests will be obtained in females of childbearing potential at Screening 
(Visit 1), Day 8 (Visit 7), and Day 57 (Visit 10) ( Table 1 andTable 2 ).
A urine pregnancy test will be performed  on females of childbearing potential before study 
medication application on Day 1 (Visit 2). Visit [ADDRESS_717282] be reviewed 
before dosing. 
[IP_ADDRESS].8 O THER ASSESSMENTS
Concomitant Medications 
Concomitant medications will be assessed at all clinic visits ( Table 1 andTable 2 ).  Any 
medication (including nonprescription medicatio ns) or therapy administered to the subject 
during the course of the study (starting at the date of informed consent) will be recorded on 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 42
CONFIDENTIALthe Concomitant Medication CRF/eCRF.  The Investigator will record any AE on the 
Adverse Events CRF/eCRF for which the concomitant medication/therapy was administered. 
Use of sunblock or any topi[INVESTIGATOR_547947]/eCRF. 
Local Skin Reactions 
At every post-Screening clinic visit through Day 57 (Visit 10), the Investigator or trained 
designee will assess any LSR on the treatment area for signs: 
xBefore study medication application (on dosing days) 
xAfter the assessment of adverse events 
The LSR assessment is the Investigator‚Äôs (or trained designee‚Äôs ) assessment of the following 
signs on the treatment area:  erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and eros ion/ulceration.  These signs will be assessed using a grading 
scale ranging from 0 (not present) to 4 (worst) ( Table 6 ).
Table 6 Local Skin Reaction Grading Criteria
Grading Criteria
Local Skin 
Response01 2 3 4
Erythema Not presentSlightly pi[INVESTIGATOR_8745] 
<50%Pi[INVESTIGATOR_22764] 
>50%Red, restricted to 
treatment areaRed extending 
outside treatment 
area
Flaking / 
ScalingNot presentIsolated scale, 
specific to lesionScale <50% Scale >50%Scaling 
extending 
outside treatment 
area
Crusting Not present Isolated crusting Crusting <50% Crusting >50%Crusting 
extending 
outside treatment 
area
Swelling Not presentSlight, lesion 
specific edemaPalpable edema 
extending beyond 
individual lesionsConfluent and/or 
visible edemaMarked swelling 
extending 
outside treatment 
area
Vesiculation 
/ PustulationNot present Vesicles onlyTransudate or 
pustules, with or 
without vesicles 
<50%Transudate or 
pustules, with or 
without vesicles 
!50%Transudate or 
pustules, with or 
without vesicles 
extending 
outside treatment 
area
Erosion / 
UlcerationNot presentLesion specific 
erosionErosion extending 
beyond individual 
lesionsErosion >50%Black eschar or 
ulceration
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 43
CONFIDENTIALExamples of LSR signs are shown in photographs in Appendix 1 .15
Application site reactions not classified as LSRs (eg, pruritus, pain, infection) will be 
reported as adverse events. 
All application site reactions and LSRs will be followed to resolution, or if resolution is 
unlikely, to stabilization. 
Treatment for any LSR or interruption/discontinua tion of study treatment for an LSR will be 
recorded on the CRF/eCRF.
LSRs will be reported separately from adverse events.
Pi[INVESTIGATOR_547963]- and hyper- pi[INVESTIGATOR_547964] e treatment area will be assessed by [CONTACT_3786] (or a trained designee) as being present or absent.   
Pi[INVESTIGATOR_547965]-Screening clinic visit through 
Day 57 (Visit 10) ( Table 1 andTable 2 ).
Standardized Photography 
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 
(Visit 7), Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717283]-Day 57).  Before study medication application on Day 1, the Investigator or a qualified staff member must obtain standardized photography of ea ch subject‚Äôs treatment area before 
application of study medication. 
Care must be taken to ensure the same lighting, background, subject positioning relative to 
the camera and camera settings are used for  each photograph.  Equipment, supplies and 
detailed instructions for obtaining and managin g the photographs will be provided to the 
investigational center prior to the initiation of subject enrollment. 
The photographs are to document the appearance of the subjects‚Äô treatment area and to assist 
with the identification and confirmation of the location of the treatment area throughout the 
study ( Section 9.1.1 ).
Equipment, supplies and detailed instructions for obtaining and managing the photographs 
will be provided to the investigational center  prior to the initiation of subject enrollment.
9.5.[ADDRESS_717284], will be collected (ie, Day 57 plus 30 days).  During the Recurrence Follow-up 
Period, all AEs, including SAEs in the treatment area will be collected until the last subject 
contact.  These SAEs will be discussed in the clinical study report.  Any SAE event judged by [CONTACT_548034]. 
Deaths and life-threatening events should be reported immediately by [CONTACT_756].  The 
initial report must be submitted within [ADDRESS_717285] information for reporting of SA Es will be provided in the Investigator 
File. 
It is very important that the SAE report form be  filled out as completely as possible at the 
time of the initial report. This includes the Investigator ‚Äôs assessment of causality.  All 
supporting documents should be sent de-identified and should contain the assigned subject number.  Only supporting documents directly related to the event should be sent. 
Any follow-up information received on SAEs should be forwarded as soon as possible.  If the 
follow-up information changes the Investigator ‚Äôs assessment of causality, this should also be 
noted on the follow-up SAE form. 
Preliminary SAE reports should be followed as soon as possible by [CONTACT_3582][INVESTIGATOR_3103], autopsy reports, and other documents requested by [CONTACT_1034]. 
 Reporting of Pregnancy and Exposure to Study Drug through Breastfeeding 
Any pregnancy for which the estimated date of c onception was either before the last visit or 
within [ADDRESS_717286] be reported. 
If an adverse outcome of a pregnancy is suspected to be related to study drug exposure, this 
should be reported regardless of the length of ti me that has passed since the exposure to study 
treatment. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 45
CONFIDENTIALA congenital anomaly, death during perinatal period, an induced abortion, or a spontaneous 
abortion are considered to be an SAE and should  be reported in the same timeframe and in 
the same format as all other SAEs (see Section [IP_ADDRESS] ).
Pregnancies must be reported by [CONTACT_548035] 
[ADDRESS_717287]
[IP_ADDRESS].1 R EPORTING OF ADVERSE EVENTS ASSOCIATED WITH STUDY DRUG OVERDOSE ,
MISUSE ,ABUSE , OR MEDICATION ERROR
Study drug overdose is defined as the accidental or intentional use of the drug in an amount 
higher than the dose being studied. 
Any study drug overdose should be noted on the Study Medication CRF/eCRF. All AEs associated with overdose, or medicati on error should be captured on the Adverse 
Event CRF/eCRF and also reported using the procedures detailed in Section [IP_ADDRESS] even if 
the AEs do not meet serious criteria.  If th e AE associated with an overdose or medication 
error does not meet serious criteria, it must still be reported using the SAE form and in an 
expedited manner but should be noted as nonserious on the SAE form and the Adverse Event CRF/eCRF. 
Expedited Reporting
The Sponsor (or its designee) must inform In vestigators and regulatory authorities of 
reportable events, in compliance with appli cable regulatory requirements, on an expedited 
basis (ie, within specific timeframes).  For th is reason, it is imperative that sites provide 
complete SAE information in the manner described above. 
In determining what SAEs meet criteria for ex pedited reporting, the current version of the 
Investigator ‚Äôs Brochure will b e used for reference safety information. 
Breaking the Blind
Not applicable 
Clinical Study Protocol_Amendment [ADDRESS_717288] party acting on behalf of the 
Sponsor to regulatory authorities in compliance with local law and established guidance.  The format of these reports will be dictated by [CONTACT_119663]. 
9.5.4 Completion/Discontinuation of Subjects 
A subject may elect to discontinue from the study at any time for any reason.  See 
Section 9.3.[ADDRESS_717289] document the actual reason(s ) why they decided to discontinue subjects, 
or why subjects withdrew consent, as appli cable.  Study disposition information will be 
collected on the Disposition CRF/eCRF. 
Subjects who withdraw from study treatment (w ith the exception of death or withdrawal of 
consent) will be encouraged to complete th e Early Termination assessments at the time of 
withdrawal as indicated in Table [ADDRESS_717290] who has ceased to return for visits 
will be followed up by [CONTACT_2319], phone, or other mean s to gather information such as the reason 
for failure to return, the status of treatment comp liance, the presence or absence of AEs, and 
clinical courses of signs and symptoms.  This i nformation will be recorded in the CRF/eCRF.  
9.5.[ADDRESS_717291] 
whether he/she has received medical care by  [CONTACT_3212].  When the subj ect is going to receive medical care by [CONTACT_3213], the Investigator, with the consent of the subject, will inform the other physicianthat the subject is participating in the clinical study. 
9.6 Data Quality Assurance 
This study will be organized, performed, a nd reported in compliance with the protocol, 
SOPs, working practice documents, and applicab le regulations and guidelines.  Site audits 
may be made periodically by [CONTACT_1034]‚Äôs or the CRO‚Äôs qualified compliance auditing team, which is an independent function from the study team responsible for conduct of the 
study. 
9.6.[ADDRESS_717292] source documentation, 
collected on the CRF/eCRFs and entered into a validated data management system that is 
compliant with all regulatory requirements.  A CRF/eCRF or a select CRF/eCRF page may 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 47  
CONFIDENTIAL 
 be used as a source document.  CRF/eCRFs used as source documents will be listed in the 
Data Management Plan.  As defined by [CONTACT_12212] E6 guidelines (Section 1.11), the CRF is a 
printed, optical, or electronic document design ed to record all of the protocol-required 
information to be reported to the Sponsor on each study subject.  In this study, the CRF may refer to either a paper (CRF) or electronic data collection form (eCRF), or both. 
Data collected on the CRF/eCRF must be comple ted following the instructions described in 
the CRF/eCRF Completion Guidelines, which will be based on the Data Management Plan.  The Investigator has ultimate responsibility for  the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRF/eCRF.  The PI [INVESTIGATOR_547966]/eCRF to attest to its accuracy, authenticity, and completeness. 
Completed, original CRFs/eCRFs are the sole property of the Sponsor and should not be 
made available in any form to third parties without written permission from the Sponsor, 
except for authorized representatives of the Sponsor or appropriate regulatory authorities. 
Responsible site personnel will enter the information required by [CONTACT_548021]/eCRFs in accordance with the CRF/eCRF Completion Guidelines that are provided.  A CRA will visit each site as documented in the monitoring plan to re view the CRF/eCRFs for 
completeness and accuracy against the source documents. They will identify any discrepancies and ensure that appropriate site personnel address the discrepancies. 
The original CRFs/eCRFs will be maintained at th e site in a central document repository. If 
used, a copy of the CRF will be forwarded to the Sponsor. 
At the end of the study an electronic copy of the database along with appropriate system 
version will be archived. 
Uniform procedures will be discussed at the Investigator meetings or at site initiation and/or 
will be documented in the CRF/eCRF Completion Guidelines. 
9.6.2 Clinical Data Management 
All data, both CRF/eCRF and external data, will be  loaded into a clinical system as specified 
in the Data Management Plan. 
Quality control and data validation procedures w ill be applied to ensure the validity and 
accuracy of the clinical data. 
All software applications used in the collec tion of data will be properly validated following 
standard computer system validation that is compliant with all regulatory requirements. 
9.[ADDRESS_717293] deviation (SD), median, 
minimum, and maximum.  Categorical variable s will be summarized by [CONTACT_548022].  All raw data obtained from the CRF/eCRF, as well as any derived data  will be included in data listings. 
For all analyses, study Day [ADDRESS_717294] dose of study drug. 
9.7.1 Statistical and Analytical Plans 
 Study Endpoints 
[IP_ADDRESS].1 P RIMARY ENDPOINTS  
The primary endpoint is activity. 
Activity will be evaluated by [CONTACT_547995].  Complete response rate will be 
defined as the proportion of subjects achieving 100% complete clearance of all treated AK 
lesions on the face or scalp at Day 57.  
[IP_ADDRESS].2 S ECONDARY ENDPOINTS  
Activity 
Reduction in lesion counts at each visit during Days 1-57 will be assessed as the secondary 
endpoint for activity. 
Safety 
Safety will be evaluated primarily by [CONTACT_548023].  The 
results of other safety assessments (vital si gns, PEs, ECGs) will also be evaluated. 
Pharmacokinetic  
Secondary endpoints include the following PK  parameters derived by [CONTACT_548024]-time data of KX2-391:  C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
[IP_ADDRESS].3 E XPLORATORY ENDPOINTS  
Exploratory endpoints include recurren ce and sustained response rates. 
Recurrence rate will be defined as the proportion of subjects who achieved 100% complete 
clearance at Day 57 (Visit 10) with any identified AK lesions on the treatment area at 3, 6, 9, and [ADDRESS_717295]-Day 57. 
Sustained response rate will be defined as  the proportion of subjects who achieved 100% 
complete clearance at Day 57 (Visit 10) without any identified AK lesions on the treatment 
area at [ADDRESS_717296]-Day 57. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
Kinex Pharmaceuticals, Inc.
FINAL v2.0_26 Apr 2016Page 49
CONFIDENTIAL
Definitions of Analysis Sets
The Per-Protocol Set is the group of protocol-eligible subjects who receive 5 days (Cohort 1) 
or 3 days (Cohort 2) of study treatment and comp lete at least one scheduled post-treatment 
evaluation.  
The Evaluable Set is the group of subjects who receive 5 days (Cohort 1) or 3 days 
(Cohort 2) of treatment and complete most evaluati ons including the Day 57 Follow-up Visit. 
The Safety Analysis/Full Analysis Set is the group of subjects who receive at least one dose 
of study treatment. 
The PK Analysis Set is the group of subjects who receive study treatment and complete at 
least one scheduled post-treatment PK evaluation. 
Subject Disposition
All subjects will be tabulated by [CONTACT_548025] 9.3.3.
Demographic and Other Baseline Characteristics
Demographic and baseline charac teristics will be summarized  by [CONTACT_9084].  For continuous 
demographic variables, results will be summariz ed by [CONTACT_548026], and presented as N, 
mean, SD, median, and minimum and maximum valu es.  For categorical (nominal or ordinal) 
variables, the number and percentage of subjects will be used in each cohort.  No statistical 
testing will be performed. 
Prior and Concomitant Therapy
All Investigator terms for medications recorde d in the CRF/eCRF will be coded to an 
11-digit code using the World Health Orga nization Drug Dictionary drug codes. 
Prior medications will be defined as medicati ons that stopped before the first dose of study 
drug. 
Concomitant medications will be defined as med ications that (1) started before the first dose 
of study drug and were continuing at the time of  the first dose of study drug, or (2) started on 
or after the date of the first dose of study drug.  Prior and concomitant medications will be 
further coded to the appropriate Anatomical-T herapeutic-Chemical (A TC) code indicating 
therapeutic classification.  A listing of prior and concomitant medications by [CONTACT_548027]. 
All medications will be presented by [CONTACT_548028]. 
Clinical Study Protocol_Amendment 1 KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 50  
CONFIDENTIAL 
 
 Activity Analyses 
AK lesion counts will be summarized by [CONTACT_548029] 1 (pretreatment) and at each 
subsequent timepoint for subjects in the Full  Analysis Set and the Per-Protocol Set. 
A 95% confidence interval (CI) for the complete  clearance (response rate) at Day 57 will be 
estimated by [CONTACT_547997]. 
Recurrence rates for all subjects who achieved  complete clearance at Day 57 will be 
estimated by [CONTACT_543293] c ohort in the Evaluable Set. 
A 95% CI for the sustained response rate at [ADDRESS_717297] of listings, graphs, and descriptive statistics. 
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker 
Analyses 
[IP_ADDRESS].1 P HARMACOKINETIC ANALYSES  
PK analyses will be performed on the PK Analysis Set. 
Plasma concentrations of KX2-391 will be analyzed to determine C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Individual timepoints will be tabulated and displa yed graphically and listed for all subjects.  
Summary PK parameters will be analyzed as applicable. 
[IP_ADDRESS].2 P HARMACODYNAMIC , PHARMACOGENOMIC , AND OTHER BIOMARKER ANALYSES  
Not applicable 
 Safety Analyses 
All subjects in the Safety Analysis Set will be included in the safety analyses. 
Safety data will be summarized by [CONTACT_548030] (eg, n, mean, SD, 
median, minimum, maximum for continuous variables; n [%] for categorical variables).  
Safety variables include AEs, clinical laborat ory parameters, weight, vital signs, 12-lead 
ECG results, and physical examination findings. 
Similar to the activity analyses, any cont rast between the 2 cohorts will mainly be 
noninferential in the safety analyses. 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 51  
CONFIDENTIAL 
 [IP_ADDRESS].[ADDRESS_717298] will be summarized by [CONTACT_9084]. 
[IP_ADDRESS].2 A DVERSE EVENTS  
For AEs, verbatim terms on the CRFs/eCRFs wi ll be mapped to preferred terms (PTs) and 
system organ classes (SOCs) using the Medi cal Dictionary for Re gulatory Activities 
(MedDRA; version 16.0 or higher).  Subject incidence of AEs will be displayed by [CONTACT_2946].  The incidence of AEs will be summarized by [CONTACT_9084].
  Adverse events will also be 
summarized by [CONTACT_926], relationship to study drug, and cohort.  Subject incidence of SAEs 
will also be displayed by [CONTACT_9084]. 
Only those AEs that were treatment-emergent  will be included in summary tables.  
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after dosing or  
x those pre-existing AEs that worsen after dosing 
All AEs, treatment emergent or otherwise, will be presented in subject data listings. 
The number (percentage) of subjects with TEAEs leading to death will be summarized by 
[CONTACT_12130], PT, and cohort.  A subject data listing of all AEs leading to death will be provided. 
The number (percentage) of subjects with TEAEs leading to discontinuation from study drug 
will be summarized by [CONTACT_12130], PT, and cohort.  A subject data listing of all AEs 
leading to discontinuation from study drug will be provided. 
[IP_ADDRESS].3 L ABORATORY VALUES  
Laboratory parameters will be summarized using descriptive statistics at baseline and at each 
subsequent timepoint by [CONTACT_9084].  Changes from baseline will also be  summarized by [CONTACT_9084]. 
In addition, shift tables (ie, low-normal-high at baseline versus low-normal-high at follow-up 
in a 3-by-3 contingency table) will be provided to assess changes in laboratory values from 
baseline to follow-up in each cohort. 
[IP_ADDRESS].[ADDRESS_717299].  Abnormal 
vital sign values will be identified as thos e outside (above or below) the reference range. 
[IP_ADDRESS].[ADDRESS_717300]. 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 52  
CONFIDENTIAL 
 [IP_ADDRESS].[ADDRESS_717301]. 
[IP_ADDRESS].7 P REGNANCY TESTS  
Results of pregnancy tests will be listed by [CONTACT_548031], as applicable. 
[IP_ADDRESS].[ADDRESS_717302] a 100% complete 
clearance rate at Day 57 greater than 20% with 80% power, based on a two-sided (alpha=0.05) binomial test, assuming a res ponse rate of 35%, and less than a 25% dropout 
rate.  This corresponds to a two-sided 95% CI with a half-width of less than 15% (ie, lower boundary of the CI above 20%). 
The sample size of Cohort 2 may be adjusted, depending on the results of Cohort 1. 
9.7.3 Interim Analysis 
 A formal interim analysis is not planned. Since this is an open-label study, after each group 
of approximately 20 subjects, ongoing analyses wi ll be performed with tabulation of activity, 
LSRs, and adverse events.  The decision to open Cohort 2 will be documented. 
9.7.4 Other Statistical/Analytical Issues 
Not applicable 
9.7.[ADDRESS_717303] 
1. ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance,
US Department of Health and Human Service s, Food and Drug Administration, April 
1996.
2. Marks R, Rennie G, Selwood TS.  Malign ant transformation of solar keratoses to 
squamous cell carcinoma.  Lancet 1988;1(8589):795-7.
3. Criscione VD, Weinstock MA, Naylor MF, et  al. Actinic keratoses: natural history 
and risk of malignant transformation in the Veterans Affairs Topi[INVESTIGATOR_201562]. Cancer 2009;115(11):2523-30.
4. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 
2000;42(1 Pt 2):23-4.
5. Salasche SJ. Epi[INVESTIGATOR_231743]. J Am 
Acad Dermatol 2000;42(1 Pt 2):4-7.
6. Guidelines for the Management of Ac tinic Keratoses.  2004/2005 European 
Dermatology Forum.  Available from: http://www.euroderm.org [Accessed 02 July 
2012]. 
7. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. 
Committee on Guidelines of Care. J Am Acad Dermatol 1995;32(1):95-8. 
8. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in 
hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37(3 Pt 1):392-4.
9. Ehrig T, Cockerell C, Pi[INVESTIGATOR_229748] D, et al. Actinic keratoses and the incidence of 
occult squamous cell carcinoma: a clinical- histopathologic correlation. Dermatol Surg
2006;32(10):1261-5.
10. Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; 
[LOCATION_007] Academy of Family Physicians. Acti nic keratoses: sequelae and treatments. 
Recommendations from a consensus pa nel.  J Fam Pract 2006;55([ADDRESS_717304]):1-8.
11. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the 
good from the bad ones? Eur J Dermatol 2006;16(4):335-9.
12. Marks R, Foley P, Goodman G, et al.  S pontaneous remission of solar keratoses:  the 
case for conservative management. Br J Dermatol 1986;115(6):649-55.
13. Food and Drug Administration Draft Guidance on Ingenol Mebutate; Recommended 
Jan 2016. 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 54  
CONFIDENTIAL 
 14. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through IV. 
Arch Dermatol 1998;124(6):869-71. 
15. Rosen R, Marmur E, Anderson L, et al . A new, objective, quantitative scale for 
measuring local skin responses following topi[INVESTIGATOR_547967]. Dermatol Ther (Heidelb) 2014;4:207-19. 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 55  
CONFIDENTIAL 
 11 APPENDICES 
 
Clinical Study Protocol_Amendment 1 KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v2.0_26 Apr 2016  Page 56  
CONFIDENTIAL 
 Appendix 1 Photographs of Local Skin Reactions 
 
 
Source:  Rosen R, Marmur E, Anderson L, et al. A new, objective, quantitative scale for measuring local skin 
responses following topi[INVESTIGATOR_547967]. Dermatol Ther (Heidelb) 
2014;4:207-19.  

[COMPANY_003][COMPANY_003]
[COMPANY_003]
PP
D[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  ii 
CONFIDENTIAL 
 INVESTIGATOR SIGNATURE [CONTACT_36619]: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face 
or Scalp  
Investigational Product 
Name: [CONTACT_548047]2-391 Ointment 1% 
UTN Number: U1111-1173-[ADDRESS_717305] this study in accordance with all stipulations of 
the protocol and in accordance with Internati onal Conference on Harm onisation of Technical 
Requirements for Registration of Pharmaceutic als for Human Use (ICH) and all applicable 
local Good Clinical Practice (GCP) guidelines, including the Declaration of Helsinki. 
  
 
<Name, degree(s)>      
Investigator  Signature  [CONTACT_1782] 
<Name [CONTACT_548048]>      
Study Site      
  
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 1  
CONFIDENTIAL 
 1 TITLE PAGE 
 
CLINICAL STUDY PROTOCOL  
Study Protocol 
Number: KX01-AK-002 
Study Protocol Title: A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of 
KX2 -391 Ointment 1% in Subjects with Actinic Keratosis on the Face or 
Scalp  
Sponsor : [LOCATION_002]: 
Kinex Pharmaceuticals, Inc.  
[ADDRESS_717306], New  Jersey [ZIP_CODE], US 
Tel:  [PHONE_3096] -272-[ADDRESS_717307] Name: [CONTACT_548047]2-391 Ointment 1% 
Indication: Actinic keratosis on the face or scalp 
Phase: 2a 
Approval Date:   v1.0 23 Jan 2016 (original protocol) 
UTN Number: U1111-1173-5677 
GCP Statement: This study is to be performed in full compliance with International 
Conference on Harmonisation of Techni cal Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) and all applicable local Good 
Clinical Practice (GCP) and regulations.  All required study documentation 
will be archived as required by [CONTACT_12721].  
Confidentiality 
Statement:  This document is confidential.  It contains proprietary information of Kinex 
Pharmaceuticals, Inc. (the Sponsor).  Any viewing or disclosure of such 
information that is not authorized in  writing by [CONTACT_55360].  Such information may be used solely for the purpose of 
reviewing or performing this study.  

Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 2  
CONFIDENTIAL 
 2 CLINICAL PROTOCOL SYNOPSIS 
Compound No.  KX2-391 
Name [CONTACT_3261]: N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) acetamide 
Study Protocol Title 
A Phase 2a, Open -Label, Multicenter, Activity and Safety Study of KX2- 391 Ointment 1% in Subjects 
with Actinic Keratosis on the Face or Scalp  
Investigators 
, MD, Lead Principal Investigator  
[INVESTIGATOR_547919] [ADDRESS_717308] out, approximately  18 months 
Phase 2a  
Objectives 
Primary Objective: 
‚Ä¢ To evaluate the activity of KX2- 391 Ointment 1% administered topi[INVESTIGATOR_547920] (AK) by [CONTACT_547992], defined as 100% 
clearance at Day 57 
Secondary Objectives:  
‚Ä¢ To assess the activity of KX2-391 Ointment 1% during Days 1-57 
‚Ä¢ To assess the safety and tolerability of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp 
‚Ä¢ To assess the pharmacokinetics (PK) of KX2- 391 Ointment 1% in subjects with AK on the face or 
scalp 
Exploratory Objective:  
‚Ä¢ To determine recurrence rates to [ADDRESS_717309]-Day 57 for subjects who show response at Day 57 
Study Design 
This study will be an open -label, multicenter, activity, safety, tolerability, and PK study of KX2 -391 
Ointment 1% administ ered topi[INVESTIGATOR_547980]. 
The study consists of Screening, Treatment, and Follow-up Periods. 
Eligible subjects will receive 5 consecutive days of topi[INVESTIGATOR_35786], to be applied at the study site, with 
50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 
and Day  5.  Subjects will return for Follow-up visits until Day 57.  Thereafter, only Day 57 complete 
responders will continue Recurrence Follow -up Visits every 3 months for an additional 12 months after 
Day 57.  Activity (lesion counts) and safety evaluations will be performed.  
Number of Subjects 
Approximately [ADDRESS_717310]/be:  
1. Males and females ‚â•18 years old  
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
x is a continuous area measuring [ADDRESS_717311] be postmenopausal (>[ADDRESS_717312] 18 months of amenorrhea), 
surgically sterile (by [CONTACT_548036], bilateral oophorectomy or tubal ligation) or otherwise incapable 
of pregnancy for at least 1 year; or, if of childbearing potential, must be using highly effective 
contraception for at least 90 da ys prior to treatment with KX2- 391 Ointment 1% and must agree to 
continue to use highly effective contraception for at least [ADDRESS_717313] dose of 
KX2- 391 Ointment 1%.  Highly effective contraception includes oral hormonal contraceptives, 
hormonal contraceptive implant or patch, or intrau terine device).  Abstinence and double barrier 
methods do not qualify as highly ef fective methods of contraception. 
5. Males who have not had a vasectomy must agree to use barrier contraception from Screening through 
[ADDRESS_717314] dose of KX2-391 Ointment 1%. 
6. All subjects must agree not to donate sperm or eggs or attempt conception from Screening through 
[ADDRESS_717315] dose of KX2-391 Ointment 1%. 
7. Females of childbearing potential must have a negative serum pregnancy test at Screening and a 
negative urine pregnancy test on Day 1 prior to administration of study treatment. 
8. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x no physical examination (PE) findings that Principa l Investigator (PI) determines would interfere 
with interpretation of study results 
x screening electrocardiogram (ECG) without clinically significant abnormalities  
x clinical chemistry, hematology, and urinalysis resu lts that are within the reference ranges; clinical 
laboratory values outside the reference ranges that are considered by [CONTACT_978] [INVESTIGATOR_547923]  
9. Willing to avoid excessive sun exposure  
10. Able to comprehend and are willing to sign an informed consent form (ICF)  
Exclusion Criteria 
Eligible subjects must not have/be:  
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924] 
2. Malignancy within 5 years prior to Screening except basal or squamous cell carcinoma not on the 
treatment area that were treated with curative intent and are without recurrence 
3. Used any of the following systemic therapi[INVESTIGATOR_547925] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 28 days (intra-artic ular and inhaled steroids are allowed) 
x methotrexate or other anti-metabolites; 28 days 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 4  
CONFIDENTIAL 
 4. Used any of the following topi[INVESTIGATOR_547926] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 14 days 
x analgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
x moisturizers or emollients on the face or scalp; 12 hours 
5. Had any of the following on the treatment area within 90 days (or until the site has healed, whichever 
is longer) before Visit 1: 
x ingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
x 5-fluorouracil (eg, 5-FU; Efudex) 
x imiquimod (eg, Aldara; Zyclara) 
x diclofenac with or without hyaluronic acid (eg, Solaraze) 
6. Surgical or destructive modalities on the treatment area within 30 days (or until the site has healed 
following treatment, whichever is longer) before Visit 1: 
x cryotherapy 
x electrodesiccation 
x laser, light (eg, photodynamic therapy, intense pulsed light) or any other energy-based therapy  
x chemical peels (eg, tricholoracetic acid) 
x dermabrasion 
x surgical removal (eg, curettage, excision) 
7. Currently, or has experienced any of the following on the treatment area within the specified period 
before Visit 1: 
x cutaneous malignancy; 180 days 
x sunburn; 28 days 
x body art (eg, tattoo, pi[INVESTIGATOR_77219]); currently 
8. A history of sensitivity and/or allergy to an y of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psoriasis, eczema) or condition (eg, scarring, open wounds) that, 
in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which 
exposes the subject to an unacceptable risk by [CONTACT_28224] 
10. Other significant uncontrolled or unstable medical diseases or conditions that, in the opi[INVESTIGATOR_684], would expose the subject to unacceptable risk by [CONTACT_28224] 
11. Females who are pregnant or nursing 
12. Participated in an investigational drug trial during which an investigational study medication was 
administered within [ADDRESS_717316], whichever is longer, before 
Screening 
Study Treatment 
50 mg of KX2 -391 Ointment 1% will be applied topi[INVESTIGATOR_547981] 25 cm2 treatment area 
(2 mg/cm2; 0.5 mg KX2-391 total). 
KX2 -391 Ointment 1% will be applied once daily for 5 consecutive days. 
Duration of Participation and Treatment 
‚Ä¢ Planned enrollment period:  approximately 3 months (90 days) 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 5  
CONFIDENTIAL 
 ‚Ä¢ Planned subject participation is approximately 64 weeks:  
o Screening Period:  up to 28 days 
o Treatment Period:  5 consecutive treatment days (Days 1-5) 
o Follow-up Period:  Visits at Days 8, 15, 29, and 57 
o Recurrence Follow-up Period:  only for complete responders at Day 57, visits every 3 months for 
12 months after Day 57 (ie, at 3, 6, 9, and [ADDRESS_717317]-Day 57). 
Length of stay:  On Day 1 (Visit 2) and Day 5 (Visit 6), subjects will stay for approximately [ADDRESS_717318] PK blood sample is colle cted. 
Concomitant Drug/Therapy 
Use of any non -study drug treatment for AK lesions on the face or scalp is prohibited during the study.  
During the Recurrence Follow -up Period, isolated lesion treatment such as cryotherapy or biopsy is 
allowed for treatment of AK lesions emerging in the selected treatment area.  Any treated lesion will be 
considered as a recurrence.  
Assessments 
Activity Assessments  
The Investigator will perform a count of AK lesions for all subjects at Visits 1 and 2, Visits 7 through 10, and 
for Day 57 complete responders, also at Visits 11 through 14. 
Safety Assessments  
Safety will be assessed by [CONTACT_547994] (AEs), serious adverse events (SAEs), laboratory 
evaluation of hematology, biochemistry, and urinalysis  values, measurement of weight and vital signs, 
evaluation of ECGs, and the performance of physical examinations.  
Subjects will be queried for spontaneously reported AE s at each study visit, before assessment of local 
skin reactions (LSRs).  AEs will be re ported separately from LSRs. 
Subject -reported LSRs will not be reported as adverse events.  
Other Assessments  
The LSR assessment is the Investigator‚Äôs (or trained designee ‚Äôs) assessment of the following signs on the 
treatment area:  erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration.  These signs will be assessed using a grading scale ranging from 0 (not present)  
to 4 (worst).
  In addition to LSRs, hypo- and hyper- pi [INVESTIGATOR_547982].  Application site reactions not classified as LSRs (eg, pruritus, 
pain, infection) will be reported as adverse events.   All application site reactions and LSRs will be 
followed to resolution, or if resolution i s unlikely, to stabilization.  LSRs will be reported separately from 
AEs.  
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 (Visit 7), 
Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717319]- Day 57).  Before 
study medication application on Day 1, the Investigator or a qualified staff member must obtain 
standardized photography of each subject‚Äôs treatment area before application of study medication.  
Pharmacokinetic Assessments  
PK samples will be collected at the following timepoints: 
‚Ä¢ Day 1:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose  
‚Ä¢ Day 5:  predose, 0.5 (¬±5 minutes), 1 and 4 hours (¬±10 minutes) postdose 
 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 6  
CONFIDENTIAL 
 Pharmacodynamic, Pharmacogenomic, and Other Biomarker Assessments 
Not applicable  
Bioanalytical Methods 
Plasma concentrations of study drug will be measured using a validated liquid chromatography/tandem 
mass spectrometry (LC -MS/MS) assay. 
Statistical Methods 
Study Endpoints  
Primary Endpoint  
x Activity will be evaluated by [CONTACT_547995].  Complete response rate will be defined as 
the proportion of subjects achieving 100% complete clearance of all treated AK lesions on the face 
or scalp at Day 57.  Sustained response will be defined a s the proportion of subjects achieving 100% 
(complete) clearance at Day [ADDRESS_717320]-Day 57. 
Secondary Endpoints  
‚Ä¢ Activity:   Reduction in lesion counts during Days 1-57 
‚Ä¢ Safety:  Evaluation of AEs and clinical laboratory data ; the results of other safety assessments (vital 
signs, physical examinations, ECGs) will also be evaluated. 
‚Ä¢ Pharmacokinetic:  Determination of C max,  and where applicable, AUC t, C min, and accumulation  
ratio R 
Exploratory Endpoint 
‚Ä¢ Recurrence rate will be defined as the proportion of subjects who achieved 100% complete clearance 
at Day 57 (Visit 10) with any identified AK lesions on the face or scalp at 3, 6, 9, and [ADDRESS_717321]-Day 57. 
Analysis Sets  
‚Ä¢ Per-Protocol Set:  the group of protocol- eligible subjects who receive [ADDRESS_717322]-treatment evaluation. 
‚Ä¢ Evaluable Set:  the group of subjects who receive [ADDRESS_717323] evaluations 
including the Day 57 Follow-up Visit. 
‚Ä¢ Safety Analysis/Full Analysis Set:  the group of subjects who receive at least one dose of study 
treatment. 
‚Ä¢ PK Analysis Set: the group of subjects who receive study treatment and complete at least one 
scheduled post-treatment PK evaluation. 
Activity Analyses  
AK lesion counts will be summarized at Day 1 (pre treatment) and at each subsequent timepoint for 
subjects in the Full Analysis Set  and the Per-Protocol Set. 
A 95% confidence interval (CI) for th e complete clearance (response rate) at  Day [ADDRESS_717324] one dose of KX2-391 Ointment 1% will be included in the safety 
analyses.  Treatment -emergent AEs (TEAEs) are defined as either those AEs with an onset after dosing or 
those pre -existing AEs that worsen after dosing.  For AEs, verbatim terms on the case report 
form/electronic case report form ( CRF/eCRF) will be mapped to preferred terms (PTs) and system organ 
classes (SOCs) using the Medical Dictionary for Regulatory Activities (MedDRA; v 16. 0 or higher).  
Subject incidence of AEs will be displayed by [CONTACT_2946].  Adverse events will also be summarized by [CONTACT_548037].  Subject incidence of SAEs will also be displayed.  Laboratory parameters will be summarized using descriptive statistics at ba seline and at each subsequent timepoint.  Changes 
from baseline will also be summarized.  In addition, shift tables (ie, low
-normal- high at baseline versus 
low-normal-high at follow-up in a 3-by- 3 contingency table) will be provided to assess changes in 
labora tory values from baseline to follow-up. 
Local skin reactions, pi[INVESTIGATOR_371], and scarring as reported by [CONTACT_737], will be displayed and 
summarized by [CONTACT_548038].  
Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker Ana lyses 
Pharmacokinetic Analyses  
Plasma concentrations for KX2 -[ADDRESS_717325] de viation (SD), median, minimum, and maximum.  
Categorical variables will be summarized by [CONTACT_374560].  All raw data obtained from the CRF/eCRF, as well as any derived data will be included in data listings.
 
Sample Size Rationale 
A sample size of [ADDRESS_717326] a 100% complete clearance rate at Day 57 greater than 
20% with 80% power, based on a two -sided (alpha=0.05) binomial test, assuming a response rate of 35%, 
and less than a 25% dropout rate.  This corresponds to a two -sided 95% CI with a half-width of less th an 
15% (ie, lower boundary of the CI above 20%).  
FINAL   v1.0_23 Jan 2016  
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 8  
CONFIDENTIAL 
 Table 1 Schedule of Procedures/Assessments in Study KX01-AK-002 
Period Screening Treatment Follow-up Recurrence Follow-up a 
Visit 1 2 3 4 5 6 7 8 9 10 b/ 
Early 
Term  11, 12, 13, [ADDRESS_717327] -Day 57c 
Visit time window (days) None None None None None None ¬±2 ¬±2 ¬±2 ¬±2 ¬±14 
Informed consent X           
Inclusion & exclusion criteria X Xd          
Demographics X           
Medical/surgical history X           
AK history/AK treatment history X           
Fitzpatrick skin-type scale X           
Vital signse X     X X X X X  
Prior and concomitant 
medications/therapi[INVESTIGATOR_014]  X Xd X X X X X X X X X 
Physical examination, including weightf X         X  
Treatment area identification X Xd           
AK lesion count X Xd     X X X X X 
ECGg X      X   X  
Clinical chemistry, hematology, and 
urinalysish X      X   X  
Pregnancy test  X Xd,i     X   X  
PK blood samples  Xj    Xj      
Study medication application  X X X X X      
AEsk X X X X X X X X X X Xl 
LSRs  Xd Xd Xd Xd Xd X X X X  
Pi[INVESTIGATOR_547928] X X X X  
Standardized photography X Xd     X   X X 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 9  
CONFIDENTIAL 
 Table 1 Schedule of Procedures/Assessments in Study KX01-AK-002 
AE = adverse event; AK = actinic kerato sis; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local skin reaction; PK = pharmacokinetic; Term = 
Termination.  
a For Day [ADDRESS_717328] be fasted for laboratory assessments. 
i For females of childbearing potential; urine pregnancy test on Day 1 before study medication application.  All other pregnancy tests are performed with serum. 
j PK assessments on Day 1 and Day 5 at 0 hour (just before study medication application) and at 0.5 (¬±5 min), 1, and 4 hours (¬±10  min) after study drug application.  
k Before LSR assessment, subjects will be queried for spontaneously reported AEs. 
l Only AEs in the selected treatment area will be recorded. 
Clinical Study Protocol KX01-AK-[ADDRESS_717329] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..................................14  
5 ETHICS......................................................................................................................... ...15 
5.1 Institutional Review Boards/Independent Ethics Committees ..............................[ADDRESS_717330] Information and Informed Consent ...........................................................16  
6 INVESTIGATORS AND STUDY PERSONNEL ..........................................................16  
7 INTRODUCTION ...........................................................................................................16  
7.1 Indication ...............................................................................................................16  
7.1.1  Mechanism of Action ...................................................................................17  
7.1.2  Clinical Experience with KX2-391 ..............................................................17  
7.2 Study Rationale ......................................................................................................18  
8 STUDY OBJECTIVES ....................................................................................................18  
8.1 Primary Objective ..................................................................................................18  
8.2 Secondary Objectives.............................................................................................18  
8.3 Exploratory Objective ............................................................................................19  
9 INVESTIGATIONAL PLAN ..........................................................................................19  
9.1 Overall Study Design and Plan ..............................................................................19  
9.1.1  Screening Period ..........................................................................................19  
9.1.2  Treatment Period ..........................................................................................20  
9.1.3  Follow-up Period .........................................................................................21  
9.1.4  Recurrence Follow-up Period ......................................................................21  
9.2 Discussion of Study Design, Including Choice of Control Groups .......................21  
9.3 Selection of Study Population ................................................................................21  
9.3.1  Inclusion Criteria .........................................................................................21  
9.3.2  Exclusion Criteria ........................................................................................22  
9.3.3  Removal of Subjects from Therapy or Assessment .....................................23  
9.4 Treatments..............................................................................................................24  
9.4.1  Treatment Administered ..............................................................................24  
9.4.2  Identity of Investigational Products .............................................................24  
 Chemical Name [CONTACT_548049]2-391 .........................24  
 Labeling for Study Drug ......................................................................25  
 Storage Conditions ...............................................................................25  
 Administration of Investigational Products .........................................[ADDRESS_717331] ..........................................27  
9.4.6  Blinding........................................................................................................27  
9.4.7  Prior and Concomitant Therapy ...................................................................27  
 Prior Therapy .......................................................................................27  
 Concomitant Medication/Therapy .......................................................27  
 Prohibited Medication/Therapy ...........................................................27  
9.4.8  Prohibitions and Restrictions during Study Period ......................................29  
9.4.9  Treatment Compliance .................................................................................29  
9.4.10  Drug Supplies and Accountability ...............................................................29  
9.5 Study Assessments .................................................................................................30  
9.5.1  Assessments .................................................................................................30  
 Demography .........................................................................................30  
 Baseline Assessments ..........................................................................30  
[IP_ADDRESS].1  Medical/Surgical and Actinic Keratosis History ...........................30  
[IP_ADDRESS].2  Fitzpatrick Skin-Type Classification .............................................30  
[IP_ADDRESS].3  Prior Medications ...........................................................................31  
 Activity Assessments ...........................................................................31  
[IP_ADDRESS].1  Actinic Keratosis Lesion Count .....................................................31  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Assessments .............................................................31  
[IP_ADDRESS].1  Pharmacokinetic Assessments .......................................................31  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Assessments ...................................................................................32  
 Safety Assessments ..............................................................................32  
[IP_ADDRESS].[ADDRESS_717332] ................................32  
[IP_ADDRESS].[ADDRESS_717333] ...................35  
[IP_ADDRESS].3  Laboratory Measurements .............................................................36  
[IP_ADDRESS].4  Vital Signs ......................................................................................37  
[IP_ADDRESS].5  Physical Examinations ...................................................................37  
[IP_ADDRESS].6  Electrocardiograms ........................................................................37  
[IP_ADDRESS].7  Pregnancy Testing ..........................................................................37  
[IP_ADDRESS].[ADDRESS_717334]..........................................................................................................39  
 Reporting of Serious Adverse Events ..................................................39  
Clinical Study Protocol KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016 Page 12 
CONFIDENTIAL  Reporting of Pregnancy and Exposure to Study Drug through 
Breastfeeding .......................................................................................40  
 Reporting of Other Events of Interest ..................................................41  
[IP_ADDRESS].1  Reporting of Adverse Events Associated With Study Drug 
Overdose, Misuse, Abuse, or Medication Error ............................41  
 Expedited Reporting ............................................................................41  
 Breaking the Blind ...............................................................................41  
 Regulatory Reporting of Adverse Events ............................................41  
9.5.4  Completion/Discontinuation of Subjects .....................................................41  
9.5.5  Abuse or Diversion of Study Drug ..............................................................42  
9.5.6  Confirmation of Medical Care by [CONTACT_548000] ..................................42  
9.6 Data Quality Assurance .........................................................................................42  
9.6.1  Data Collection ............................................................................................42  
9.6.2  Clinical Data Management ..........................................................................43  
9.7 Statistical Methods .................................................................................................43  
9.7.1  Statistical and Analytical Plans ....................................................................44  
 Study Endpoints ...................................................................................44  
[IP_ADDRESS].1  Primary Endpoints .........................................................................44  
[IP_ADDRESS].2  Secondary Endpoints .....................................................................44  
[IP_ADDRESS].3  Exploratory Endpoints ...................................................................44  
 Definitions of Analysis Sets.................................................................44  
 Subject Disposition ..............................................................................45  
 Demographic and Other Baseline Characteristics ...............................45  
 Prior and Concomitant Therapy ...........................................................45  
 Activity Analyses .................................................................................45  
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and 
Other Biomarker Analyses ...................................................................46  
[IP_ADDRESS].1  Pharmacokinetic Analyses .............................................................46  
[IP_ADDRESS].2  Pharmacodynamic, Pharmacoge nomic, and Other Biomarker 
Analyses .........................................................................................46  
 Safety Analyses ....................................................................................46  
[IP_ADDRESS].1  Extent of Exposure .........................................................................46  
[IP_ADDRESS].2  Adverse Events ..............................................................................46  
[IP_ADDRESS].3  Laboratory Values ..........................................................................47  
[IP_ADDRESS].4  Vital Signs ......................................................................................47  
[IP_ADDRESS].5  Electrocardiograms ........................................................................47  
[IP_ADDRESS].6  Physical Examinations ...................................................................47  
[IP_ADDRESS].7  Pregnancy Tests .............................................................................47  
Clinical Study Protocol KX01-AK-002 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016 Page 13 
CONFIDENTIAL [IP_ADDRESS].8  Other Analyses ...............................................................................47  
9.7.2  Determination of Sample Size .....................................................................47  
9.7.3  Interim Analysis ...........................................................................................48  
9.7.4  Other Statistical/Analytical Issues ...............................................................[ADDRESS_717335] OF IN-TEXT TABLES 
Table 1  Schedule of Procedures/Assessmen ts in Study KX01-AK-002...................[ADDRESS_717336] OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Terms 
AE adverse event 
AK actinic keratosis 
AUC area under the plasma concentration-time curve  
CFR Code of Federal Regulations 
CI confidence interval 
Cmax maximum plasma concentration 
Cmin minimum (trough) plasma concentration 
CRA clinical research associate 
CRF case report form 
CRO contract research organization 
ECG electrocardiogram 
eCRF electronic case report form 
GCP Good Clinical Practice 
ICF informed consent form 
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
LC-MS/MS liquid chromatography/tandem mass spectrometry 
LSR local skin reaction 
MedDRA Medical Dictionary for Regulatory Activities 
PE physical examination 
PI [INVESTIGATOR_547930] 
R accumulation ratio 
SAE serious adverse event 
SCC squamous cell carcinoma 
SD standard deviation 
SOC system organ class 
SOP standard operating procedure 
TEAE treatment-emergent adverse event 
US [LOCATION_002] 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 15  
CONFIDENTIAL 
 5 ETHICS 
5.1 Institutional Review Boards/Independent Ethics Committees 
The protocol, any protocol amendments, i nformed consent form (ICF), and appropriate 
related documents must be reviewed and approve d before subjects are screened for entry by 
[CONTACT_3551] (IRB) or Indepe ndent Ethics Committee (IEC) constituted and 
functioning in accordance with International Conference on Harmonisation (ICH) E6 (Good 
Clinical Practice [GCP]1), Section 3, and any local regulations (eg, Federal Regulations, Title 
21 Code of Federal Regulations [CFR] Part 56).  Documentation of IRB/IEC compliance 
with the ICH E6 and any local regulations rega rding constitution and review conduct will be 
provided to the Sponsor. 
A signed letter of study approval from the IRB/IEC chairman must be sent to the Principal 
Investigator (PI) with a copy to the Sponsor be fore study start and the release of any study 
drug to the site by [CONTACT_4885] (ICH E6, Section 4.4).  If the IRB/IEC decides 
to suspend or terminate the study, the Investig ator will immediately send the notice of study 
suspension or termination by [CONTACT_1201]/IEC to the Sponsor. 
Study progress is to be reported to IRB/IECs annually (or as required) by [CONTACT_425826], depending on local regulatory obligations.  If the Investigator is required to report 
to the IRB/IEC, he/she will forward a copy to the Sponsor at the time of each periodic report.  
The Investigator(s) or the Sponsor will subm it, depending on local regulations, periodic 
reports and inform the IRB/IEC of any reportable adverse events (AEs) per ICH guidelines and local IRB/IEC standards of practice.  Upon co mpletion of the study, the Investigator will 
provide the IRB/IEC with a brief report of the outcome of the study, if required. 
5.[ADDRESS_717337] operating procedures (SOPs) of the 
Sponsor (or designee), which are designed to en sure adherence to GCP guidelines as required 
by [CONTACT_716]: 
‚Ä¢ Principles of the World Medical Associati on Declaration of Helsinki (2013) 
‚Ä¢ ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance, US 
Department of Health and Human Services, Food and Drug Administration, April 1996.  
‚Ä¢ Title 21 of the [LOCATION_002] CFR (US 21 CFR) regarding clinical studies, including Part 
[ADDRESS_717338] the nature of the study, its pu rpose, the procedures i nvolved, the expected 
duration, the potential risks and benefits involved, any potential discomfort, potential alternative procedure(s) or course( s) of treatment available to the subject, and the extent of 
maintaining confidentiality of the subject‚Äôs reco rds.  Each subject must be informed that 
participation in the study is voluntary, that he/s he may withdraw from the study at any time, 
and that withdrawal of consent will not affe ct his/her subsequent medical treatment or 
relationship with the treating physician. 
This informed consent should be given by [CONTACT_15276] a standard written statement, written in 
nontechnical language.  The subject should understand the statement before signing and 
dating it, and will be given a copy of the signed  document.  If a subject is unable to read, an 
impartial witness should be present during the entire informed consent discussion.  After the 
ICF and any other written information to be provide d to subjects is read and explained to the 
subject, and after the subject provides verbal consent to the subject‚Äôs participation in the 
study and has signed and personally dated th e ICF, the witness should sign and personally 
date the consent form.  The subject will be asked to sign an ICF at the Screening visit and all 
authorizations required by [CONTACT_1769] (eg, Protected Health Information in North America) before any study-specific procedures are performed.  No subject can enter the study before his/her informed consent has been obtained. 
An unsigned copy of an IRB/IEC-approved ICF must be prepared in accordance with 
ICH E6, Section 4, and all applicable local regulations.  The original, signed ICF for each subject will be verified by [CONTACT_548001]. 
6 INVESTIGATORS AND STUDY PERSONNEL 
This study will be conducted by [CONTACT_548002], Inc. at approximately 4 to 6 i nvestigational sites in the [LOCATION_002] (US). 
The name [CONTACT_548050] [CONTACT_548003] o rganizations (CROs) will be listed in the 
Regulatory Binder provided to the site. 
7 INTRODUCTION 
7.1 Indication 
In this study, the activity, safety, and pharm acokinetics (PK) of KX2-391 Ointment 1% will 
be evaluated in adult subjects with a clinical diagnosis of stable, clinically typi[INVESTIGATOR_547931] (AK) on the face or scalp. 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 17  
CONFIDENTIAL 
 7.1.1 Mechanism of Action 
KX2-391 (also referred to as KX01) is a synt hetic and highly selective inhibitor of Src 
tyrosine kinase signaling and tubulin polymer ization. KX2-[ADDRESS_717339] overall response in these early studies has been ‚Äòstable disease‚Äô 
in 25-30% of patients.   
KX2-391 promotes the induction of p53, G2/M arrest of proliferating cell populations and 
subsequent apoptosis via the stimulation of Ca spase-[ADDRESS_717340] clinical activity in dermatology indications 
such as actinic keratosis.  Potent inhibition of the growth of primary human keratinocytes and 
several melanoma cell lines in vitro (50% growth inhibition [GI
50 values] ‚â§50 nM), suggests 
that KX2-391 has the potential to inhibit the proliferative expansion and promote apoptosis 
of abnormally proliferating cells in the epi[INVESTIGATOR_547932]. 
KX2-391 has also been observed to inhibit T cell migration and endothelial tubule formation 
in vitro, suggesting additional potential therapeutic benefits for conditions where pathology is supported by [CONTACT_548004], inflammation, and/or angiogenesis. 
Information regarding KX2- 391 nonclinical studies is provided in the Investigator‚Äôs 
Brochure. 
7.1.2 Clinical Experience with 
KX2-391  
KX2-391 Ointment 1% has been administered  to humans in ongoing study KX01-AK-01-
US.  Based on preliminary PK data from this study in AK lesions on the forearm, the systemic exposure to KX2-[ADDRESS_717341] ication site reactions and systemic toxicity. 
KX2-391 has been administered orally to a pproximately 120 patients with malignancy. 
The Kinex studies of oral KX2-391 are as follows: 
KX2-391 was evaluated in a Phase I clinical trial, Study No. KX01-01- 07, entitled ‚ÄúA 
Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase I Study to Evaluate Safety, Tolerability, and Pharmacoki netics of KX2-391 in Patients with Advanced 
Malig nancies That Are Refractory to Conventional Therapi[INVESTIGATOR_014]‚Äù.  
KX2-391 has been evaluated in Study No. KX01-002- 09, entitled ‚ÄúA Phase II, Open -Label, 
Single-Arm Study Evaluating the Safety, Ef ficacy and Pharmacokinetics of KX2-[ADDRESS_717342] Not Received 
Prior Chemotherapy.‚Äù  
KX2-391 was evaluated in Study No, KX01-03- 11, ‚ÄúA Phase 1b Rising Multiple -Dose 
Clinical Study to Evaluate Safety, Tolerability  and Activity of Oral Monotherapy with KX2-
391 in Elderly Subjects with Acute Myeloi d Leukemia (AML) Who Are Refractory to or 
Have Declined Standard Induction Therapy‚Äù.  
7.2 Study Rationale 
Actinic keratoses represent the initial intra- epi[INVESTIGATOR_547976] (SCC).  Squamous 
cell carcinoma is the second leading cause of skin cancer deaths in the US, with up to 65% of 
SCC arising from pre-existing actinic keratoses.2,3  The risk of progression has been 
determined to be between  0.025% and 16% per year,2,4 and the calculated lifetime risk of 
malignant transformation for a patient with AK s followed up for 10 years is between 6.1% 
and 10.2%.5  The rationale behind treating every AK is  based on the difficulty in predicting 
which single AK will progress to squamous cell carcinoma.6,7  Suchniak et al8 reported 36% 
of lesions previously diagnosed clinically as AKs being in fact SCC, with 14% being in situ SCC.  Ehrig et al
9 showed that 4% of AKs clinically diagnosed by [CONTACT_17685]-certified 
dermatologists were in fact SCC and 5% were  considered occult early stage of cutaneous 
malignancy.  Spontaneous regression has been  reported in up to 25.9% of AKs over a 
12-month period, although 15% later reappeared.10,11,[ADDRESS_717343] cosmetically acceptable 
outcomes.  Current approved/marketed trea tment has shown up to approximately 60% 
efficacy, with a recurrence rate of approximately 35%. 
8 STUDY OBJECTIVES 
8.1 Primary Objective 
The primary objective of the study is: 
‚Ä¢ To evaluate the activity of KX2-391 Ointment 1% administered topi[INVESTIGATOR_547934], defined as 100% 
clearance at Day 57 
8.2 Secondary Objectives 
The secondary objectives of the study are: 
x To assess the activity of KX2-391 Ointment 1% during Days 1-57 
x To assess the safety and tolerability of KX2-391 Ointment 1% in subjects with AK on 
the face or scalp 
x To assess the PK of KX2-391 Ointment 1% in subjects with AK on the face or scalp 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 19  
CONFIDENTIAL 
 8.3 Exploratory Objective 
The exploratory objective of the study is: 
x To determine recurrence rates to [ADDRESS_717344]-Day 57 for subjects who show 
response at Day 57 
9 INVESTIGATIONAL PLAN 
9.1 Overall Study Design and Plan 
This study will be an open-label, multicenter, activity, safety, tolerability, and PK study of 
KX2-391 Ointment 1% administered topi[INVESTIGATOR_547983]. 
The study consists of Screening, Treatment, and Follow-up Periods. 
Eligible subjects will receive 5 consecutive days  of topi[INVESTIGATOR_35786], to be applied at the 
study site, with 50 mg of KX2-391 Ointment 1% each day.  Blood samples for PK analysis will be collected on Day 1 and Day 5.  Subjects will return for Follow-up visits until Day 57.  
Thereafter, only Day 57 complete responders w ill continue Recurrence Follow-up Visits 
every 3 months for an additional 12 months afte r Day 57.  Activity (lesion counts) and safety 
evaluations will be performed. 
On Day 1 (Visit 2) and Day 5 (Visit 6), subject s will stay for approximately [ADDRESS_717345] dose of study drug.  All screening assessments/evaluations, as 
presented in Table [ADDRESS_717346] provides informed consent and 
eligibility criteria are met. 
Approximately 80 subjects will  be enrolled to provide approx imately 60 subjects in the 
Evaluable Set, defined as subjects who comple te 5 days of treatment and the Day 57 Follow-
up visit. 
Treatment Area Identification 
At Screening (Visit 1), the Investigator will se lect a continuous treatment area affected with 
AK on the face or scalp for each subject that: 
x measures 25 cm
2 
x contains 4 to 8 AK lesions that are clinically typi[INVESTIGATOR_547984]01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 20  
CONFIDENTIAL 
 The location and approximate shape of the treatm ent area will be recorded on the appropriate 
body chart. 
At Visit 1, the Investigator and an investigational center staff member will identify the 
treatment area by:  
x Examining the face or scalp and locating each AK with a dot of removable surgical 
skin marker. 
x Using an [ADDRESS_717347] 2 anatomical landmarks on the acetate sheet.  Example of landmarks 
could be bony prominences, scars, moles, seborrheic keratosis, and veins. 
x Indicating location of AK lesions with permanent marker dots on transparency acetate 
sheet. 
x Removing surgical skin mar ker dots with alcohol swabs. 
x Outlining the treatment area on the face or scalp with a fine-tipped indelible marker. 
9.1.2 Treatment Period 
The inclusion/exclusion criteria will be review ed again prior to treatment on Day 1, to 
re-confirm subjects‚Äô eligibility to participate in the study . 
Subjects will be treated for 5 consecutive da ys (Days 1-5 [Visits 2-6]) during the Treatment 
Period.  Visits 2 through 6 should be scheduled to occur at approximately the same time each 
day. 
At Visit 2 (Day 1), prior to study drug application, the Investigator and any appropriate 
investigational staff member(s) (Investigator-tra ined designee) will confirm the location of 
the treatment area using the Visit 1 acetate sh eet and the body charts.  The Investigator 
should re-mark the treatment area borders as needed so the study evaluations may be 
effectively completed. 
Once the treatment area has been re-ident ified at Visit 2, photographs will be taken 
(Section [IP_ADDRESS].8 ).  50 mg of KX2-391 Ointment 1% will  be applied topi[INVESTIGATOR_547985] 25 cm2 treatment area (2 mg/cm2; 0.5 mg KX2-391 total).  KX2-391 Ointment 1% will be 
applied for 5 consecutive days (see Section [IP_ADDRESS] for a detailed description of study 
medication application). 
Pharmacokinetic blood sampling, activity, safety assessments, and local skin reaction (LSR) 
assessments (see Section 9.5 for details) will be performed ( Table 1 ).  Pi[INVESTIGATOR_547986] (or a trained designee). 
Standardized photography will be performed at  designated visits throughout the study 
(Table 1 ). 
Clinical Study Protocol KX01-AK-[ADDRESS_717348]-Day 57 (ie, at 3, 6, 9, and [ADDRESS_717349]-Day 57) to 
assess recurrence of AK lesions.  These subjects will continue to undergo scheduled activity 
and safety assessments ( Table 1 ). 
9.2 Discussion of Study Design, Including Choice of Control Groups 
This is a nonrandomized, open-label study.   No control group has been included. 
9.3 Selection of Study Population 
Eligible subjects will be adults (‚â•18 years of age) with a clinical diagnosis of stable, 
clinically typi[INVESTIGATOR_547938]. 
9.3.1 Inclusion Criteria 
Inclusion criteria will be rev iewed at Screening (Visit 1). 
Subjects must meet all of the following criteria to be included in this study: 
1. Males and females ‚â•18 years old  
2. Clinical diagnosis of stable, clinically typi[INVESTIGATOR_547922] 
3. A treatment area on the face or scalp that: 
x is a continuous area measuring [ADDRESS_717350] be postmenopausal (>[ADDRESS_717351] 18 months of 
amenorrhea), surgically sterile (by [CONTACT_548005], bilateral oophorectomy or tubal 
ligation) or otherwise incapable of pregnancy fo r at least 1 year; or, if of childbearing 
potential, must be using highly effective c ontraception for at least 90 days prior to 
treatment with KX2-391 Ointment 1% and must agree to continue to use highly 
effective contraception for at least [ADDRESS_717352] dose of KX2-391 
Ointment 1%.  Highly effective contrace ption includes oral hormonal contraceptives, 
hormonal contraceptive implant or patch, or intrauterine device).  Abstinence and 
double barrier methods do not qualify as highly effective methods of contraception. 
5. Males who have not had a vasectomy must agree to use barrier contraception from 
Screening through [ADDRESS_717353] dose of KX2-391 Ointment 1%. 
Clinical Study Protocol KX01-AK-[ADDRESS_717354] dose of KX2-391 Ointment 1%. 
7. Females of childbearing potential must have a negative serum pregnancy test at 
Screening and a negative urine pregnancy test on Day 1 prior to administration of study treatment. 
8. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x no physical examination (PE) findings that Principal Investigator (PI) determines 
would interfere with interpretation of study results 
x screening electrocardiogram (ECG) without clinically significant abnormalities  
x clinical chemistry, hematology, and urinalysis results that are within the reference 
ranges; clinical laboratory values outside the reference ranges that are considered by 
[CONTACT_978] [INVESTIGATOR_547939]  
9. Willing to avoid excessive sun exposure  
10. Able to comprehend and are willing to sign an informed consent form  
9.3.2 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from this study: 
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924] 
2. Malignancy within 5 years prior to Screenin g except basal or squamous cell carcinoma 
not on the treatment area that were treated  with curative intent and are without 
recurrence 
3. Used any of the following systemic therapi[INVESTIGATOR_547925] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 28 days (intra-articu lar and inhaled steroids are allowed) 
x methotrexate or other anti-metabolites; 28 days 
4. Used any of the following topi[INVESTIGATOR_547941] 1: 
x retinoids; 90 days 
x glucocorticosteroids; 14 days 
x analgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
x moisturizers or emollients on the face or scalp; 12 hours 
5. Had any of the following on the treatment ar ea within 90 days (or until the site has 
healed, whichever is longer) before Visit 1: 
x ingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
x 5-fluorouracil (eg, 5-FU; Efudex) 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 23  
CONFIDENTIAL 
 x imiquimod (eg, Aldara; Zyclara) 
x diclofenac with or without hyaluronic acid (eg, Solaraze) 
6. Surgical or destructive modalities on the treatm ent area within 30 days (or until the site 
has healed following treatment, wh ichever is longer) before Visit 1: 
x cryotherapy 
x electrodesiccation 
x laser, light (eg, photodynamic therapy, intens e pulsed light) or any other energy-based 
therapy 
x chemical peels (eg, tricholoracetic acid) 
x dermabrasion 
x surgical removal (eg, curettage, excision) 
7. Currently, or has experienced any of the following on the treatment area within the 
specified period before Visit 1: 
x cutaneous malignancy; 180 days 
x sunburn; 28 days 
x body art (eg, tattoo, pi[INVESTIGATOR_77219]); currently 
8. A history of sensitivity and/or allergy to any of the ingredients in the study medication  
9. A skin disease (eg, atopic dermatitis, psorias is, eczema) or condition (eg, scarring, open 
wounds) that, in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or which exposes the subj ect to an unacceptable risk by [CONTACT_160823] 
10. Other significant uncontrolled or unstable medic al diseases or conditions that, in the 
opi[INVESTIGATOR_689], would expose the subject to unacceptable risk by [CONTACT_160823] 
11. Females who are pregnant or nursing 
12. Participated in an investigational drug tria l during which an investigational study 
medication was administered within [ADDRESS_717355] may 
decide to discontinue study treatment or withdra w from the study at any time for any reason. 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 24  
CONFIDENTIAL 
 Subjects will be removed from the study if any of the following occurs:  
x Death 
x Occurrence of serious or clinically significant AEs 
x Occurrence of pregnancy  
x Use of a prohibited concomitant medication or treatment (see Section [IP_ADDRESS] ) 
x Conditions that, in the opi[INVESTIGATOR_689] , would make the subject‚Äôs 
continued participation in the study inadvisable 
x Noncompliance 
x Withdrawal of consent (subject asked, but not required to give a reason) 
x Other (Investigato r must describe) 
If the study is terminated by [CONTACT_1034], the Inve stigator will promptly explain to the subject 
involved that the study will be discontinued and provide appropriate medical treatment and 
other necessary measures for the subject. 
9.[ADDRESS_717356] in the study is KX2-391 Ointment 1%. 
9.4.[ADDRESS_717357]  Strength Size of 
Treatment 
Area  Quantity 
study 
medication/
KX2- 391 Number 
Applications and 
Frequency Study Days 
Administered 
KX2 -391 Ointment 1%  1% 25 cm2 50 mg/ 
0.5 mg 1 application daily 
for 5 consecutive 
days Days 1-5  
 
9.4.2 Identity of Investigational Products 
 Chemical Name [CONTACT_548049]2-391 
x Study drug code:  KX2-391 Ointment 1% 
x Drug Product:  KX2-391 free base ointment formulated with glyceryl 
monostearate and propylene glycol 
x Chemical name:  N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) 
acetamide   
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 25  
CONFIDENTIAL 
 x Molecular formula:  C 26H29N3O3 
x Molecular weight:  431.53 g/mole 
x Structural formula:   
 
 Labeling for Study Drug 
Investigational product will be packaged and labeled in a manner consistent with the study 
and will be designed by:  
[CONTACT_548006], Inc. 
[ADDRESS_717358] will be in accordance with US regulations and will 
include (but will not be limited to) the following information: 
‚Ä¢  For clinical study use only 
‚Ä¢ Name [CONTACT_49256] 
‚Ä¢ Chemical name/drug identifier 
‚Ä¢ Lot number/batch number 
‚Ä¢ Storage conditions, expi[INVESTIGATOR_547942] w ith labeled storage conditions. Temperature 
monitoring is required at the storage location to ensure that the study drug is maintained within an established temperature range.  The Investigator is responsible for ensuring that the 
temperature is monitored throughout the tota l duration of the trial and that records are 
maintained; the temperature should be monitored continuously by [CONTACT_548007], a mechanical recording device, such as a calibrated chart 
recorder, or by [CONTACT_3177], such that minimu m and maximum thermometric values over a 
specific time period can be recorded and retrieved as required. 

Clinical Study Protocol KX01-AK-[ADDRESS_717359] 
wash her/his hands before and after each study medication application. 
50 mg of KX2-391 Ointment 1% will be applied topi[INVESTIGATOR_547943] a 25 cm2 treatment area.  This 
amount contains a total of 0.5 mg KX2-391 free  base.  KX2-391 Ointment 1% will be 
applied once daily for 5 consecutive days (see  Table 2 ). 
The staff member will weigh the appropriate amount of study medication into a weighing 
boat (or equivalent) using a calibrated scale.  The amount of study medication applied will be 
calculated by [CONTACT_548008].  The amount of study medication weighed will be as 
close to the intended dose as possible. 
A study staff member will perform and document a scale accuracy check at least every day 
before weighing study medication. 
The study medication will be applied to the subject‚Äôs treatment area using a fingertip 
protected with a powder-free finger cot or exam ination glove.  The study medication will be 
gently and evenly rubbed over the treatment ar ea until no visible accumulation is evident. 
The time when the study medication applicat ion is completed (Application Completion 
Time) will be recorded. 
The study medication should remain on the treat ment area. Subjects must avoid touching or 
wetting the treatment area and are not allowed to apply any topi[INVESTIGATOR_547987] (see Section [IP_ADDRESS] ) up until the end of Visit 7 (Day 8).  Showers may be taken in the 
morning on Days [ADDRESS_717360] clarifying on how to 
care for the treatment area on Days 1 through 8. 
9.4.3 Method of Assigning S ubjects to Treatment Groups 
This is a study with one treatment group.  All subjects will be assigned the same treatment. 
9.4.4 Selection of Doses in the Study 
The dose of 50 mg of KX2-391 applied to a 25 cm2 area on the face or scalp for 
5 consecutive days is based on a previous study using the same dose regimen for the 
treatment of AK on the forearm (study KX01-A K-01-US).  Preliminary data show that this 
regimen had an acceptable LSR and safety profile, with efficacy outcomes considered to warrant further investigation. 
Clinical Study Protocol KX01-AK-[ADDRESS_717361] 
Section [IP_ADDRESS] provides detailed instructions for admini stering KX2-391 Ointment 1% in 
this study.  Study medication should be applied at about the same time each day. 
9.4.6 Blinding 
The study will not be blinded. 
9.4.7 Prior and Concomitant Therapy 
 Prior Therapy 
All medications (prescription and nonprescription including vitamins and dietary 
supplements), treatments, and therapi[INVESTIGATOR_547945] [ADDRESS_717362] be recorde d in the case report form/electronic case report 
form (CRF/eCRF).  A complete AK treatment hist ory will be recorded on the AK Treatment 
History CRF/eCRF (see Section [IP_ADDRESS].1 ). 
 Concomitant Medication/Therapy 
Concomitant medication/therapi[INVESTIGATOR_547946]. 
Any medication (including nonprescription medications) or therapy administered to the 
subject during the course of the study (startin g at the date of informed consent) will be 
recorded on the Concomitant Medication CRF/eCRF.  The Investigator will record any AE 
on the Adverse Events CRF/eCRF for which the concomitant medication/therapy was 
administered.  
Subjects will refrain from receipt of any th erapy in accordance with the inclusion/exclusion 
criteria.  Subjects should refrain from changing the use of any concomitant therapi[INVESTIGATOR_226]. 
 Prohibited Medication/Therapy 
Use of any non-study drug treatment for AK le sions on the face or scalp is prohibited during 
the study.  During the Recurrence Follow-u p Period, isolated lesion treatment such as 
cryotherapy or biopsy is allowed for treatmen t of AK lesions emerging in the selected 
treatment area.  Any treated lesion will be considered as a recurrence. 
Subjects are prohibited from applying any t opi[INVESTIGATOR_49186], including but not limited to, 
lotions, creams, and ointments (Note: routine clea nsers are allowed) to the treatment area up 
until the end of Visit 7 (Day 8), except when  those medications are prescribed by [CONTACT_548039]. 
Clinical Study Protocol KX01-AK-[ADDRESS_717363] unrestricted use of skin products on areas outside of the treatment area during 
the study.  Lesions located outside the stud y treatment area may be treated topi[INVESTIGATOR_547988]. 
Subjects are excluded from participation in this study if they:  
x Have used any of the following systemic th erapi[INVESTIGATOR_547989] 1: 
‚óã retinoids; 90 days 
‚óã glucocorticosteroids; 28 days (intra-articu lar and inhaled steroids are allowed) 
‚óã methotrexate or other anti-metabolites; [ADDRESS_717364] used any of the following topi[INVESTIGATOR_547990] 1: 
‚óã retinoids; 90 days 
‚óã glucocorticosteroids; 14 days 
‚óã analgesic and/or anti-inflammatory medication on the face or scalp; 72 hours 
‚óã moisturizers or emollients on the face or scalp; 12 hours 
x Had any of the following on the treatment area within 90 days (or until the site has 
healed, whichever is longer) before Visit 1:  
‚óã ingenol mebutate (eg, Pi[INVESTIGATOR_142724]) 
‚óã 5-fluorouracil (eg, 5-FU; Efudex) 
‚óã  imiquimod (eg, Aldara; Zyclara) 
‚óã diclofenac with or without hyaluronic acid (eg, Solaraze) 
x Surgical or destructive modalities on the trea tment area within 30 days (or until the 
site has healed following treatment, whichever is longer) before Visit 1: 
‚óã cryotherapy 
‚óã electrodesiccation 
‚óã laser, light (eg, photodynamic therapy, intense pulsed light) or any other 
energy-based therapy 
‚óã chemical peels (eg, tricholoracetic acid) 
‚óã dermabrasion 
‚óã surgical removal (eg, curettage, excision) 
Subjects should not start such medications/treatments while enrolled in this protocol. 
Any subjects who start systemic therapi[INVESTIGATOR_256957] e treatment of AK will be withdrawn from 
the study. 
Clinical Study Protocol KX01-AK-[ADDRESS_717365] er a prohibited medication/treatment is done with the safety of the 
study subject as the primary consideration. 
9.4.[ADDRESS_717366] be fasted for laboratory 
assessments (see Section [IP_ADDRESS].3 ); otherwise there are no food, water, beverage, or physical 
activity restrictions during the study. 
9.4.[ADDRESS_717367] will be kept during the study.  The 
clinical research associates (CRAs) will rev iew treatment administ ration throughout the 
course of the study. 
9.4.10 Drug Supplies and Accountability 
The Investigator and study staff will be responsible for the accountability of all clinical 
supplies (dispensing, inventory, and record keepin g) following the Sponsor‚Äôs instructions.  In 
this matter, the Investigator and study staff must adhere to GCP guidelines, as well as national requirements. 
Under no circumstances will the Investigator allo w the study drugs to be used other than as 
directed by [CONTACT_3181].  Clinical supplies will be dispensed only by [CONTACT_548033]. 
An accurate and timely record of the receipt of all clinical supplies and dispensing of study 
drug to the subject must be maintained.  This includes, but is not limited to: 
x documentation of receipt of clinical supplies 
x study drugs dispensing/return reconciliation log, including amount and date of 
dispensing 
x study drugs accountability log 
x all shippi[INVESTIGATOR_3087]  
x documentation of study drug returned to the Sponsor 
All forms will be provided by [CONTACT_1034] (or its designee).  Any comparable forms that the 
investigational site wishes to use must be approved by [CONTACT_1034].  A copy of the drug accountability record must be provided to the Sponsor at the end of the study. 
The supplies and inventory records must be made available, on request, for inspection by [CONTACT_429] (or its designee) or a representative of a health authority.  If applicable, all unused 
study drugs and empty containers, are to be re turned to the Investigator by [CONTACT_548040]01-AK-[ADDRESS_717368] be boxed and sealed  and shipped back to the Sponsor following 
all local regulatory requirements. 
The CRA(s) will review drug accountability duri ng monitoring site visits and at the 
completion of the study. 
9.5 Study Assessments 
9.5.1 Assessments 
All assessments and timing of the assessmen ts should be performed according to the 
Schedule of Procedures and Assessments ( Table 1 ). 
 Demography 
Subject demographic information will be coll ected at the Screening Visit.  Demographic 
information includes date of birth (or age), sex, race/ethnicity. 
 Baseline Assessments 
[IP_ADDRESS].1 M EDICAL /SURGICAL AND ACTINIC KERATOSIS HISTORY  
Medical and surgical history and current medi cal conditions will be recorded at Screening 
(Visit 1).  All pertinent medical history must be noted in the CRF/eCRF.  A complete AK 
medical history will also be recorded. 
Medical history will include:  
x A complete medical and surgical history;  childhood diseases and common colds are 
not required unless it is ongoing at Screening 
x A complete AK history from the time of initial diagnosis 
x A complete AK treatment history including  all commercial and investigational 
products, including medical therapi[INVESTIGATOR_547957], and other prescribed 
and nonprescription therapi[INVESTIGATOR_547958].  
[IP_ADDRESS].2 F ITZPATRICK SKIN-TYPE CLASSIFICATION  
The Fitzpatrick Skin-Type is a skin classification system ( Appendix 1 ) which measures 
2 components (genetic disposition and reaction to  sun exposure).  Skin-types range from very 
fair (Type I) to very dark (Type VI). 
Subjects‚Äô skin will be typed using this classificat ion system at Screening (Visit 1). 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 31  
CONFIDENTIAL 
 [IP_ADDRESS].3 P RIOR MEDICATIONS  
Prior medications taken within 28 days before Day 1, including nonprescription remedies, 
vitamins, etc, will be recorded at Screening (Visit 1). 
 Activity Assessments 
[IP_ADDRESS].1 A CTINIC KERATOSIS LESION COUNT  
The Investigator will perform a count of AK lesions (lesion count) for all subjects at Visits 1 
and 2, Visits 7 through 10, and for Day 57 complete responders, also at Visits 11 through 14. 
The AK lesion count is the Investigator ‚Äôs assessment of the number of AK lesions in the 
treatment area.  A subject must have [ADDRESS_717369] with the AK lesion count.  
This is not a comparison with the AK lesion count at any other timepoint. 
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker 
Assessments 
[IP_ADDRESS].1 P HARMACOKINETIC ASSESSMENTS  
Blood samples (3 mL at each timepoint) for PK an alysis of KX2-391 will be collected at the 
following timepoints ( Table 3 ): 
Table 3 Blood Sample Collection Times for Pharmacokinetic Analyses  
Application Day  Time (hours)   
 0 
predose 0.5 
postdose 1 
postdose 4 
postdose  
Window  ¬±5 minutes ¬±10 minutes ¬±10 minutes 
Day 1 (Visit 2) X X X X 
Day 5 (Visit 6) Xa X X X 
a Prior to application of study treatment. 
Approximately 24 mL will be collected for  measurement of plasma concentrations of 
KX2-391. 
The actual times of PK sampling will be recorded. 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 32  
CONFIDENTIAL 
 A description of collection, handling, and ship pi[INVESTIGATOR_547959]. 
Plasma concentrations of KX2-391 will be analyzed to determine C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Plasma concentrations of study drug will  be measured using a validated liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) assay. 
[IP_ADDRESS].2 P HARMACODYNAMIC , PHARMACOGENOMIC , AND OTHER BIOMARKER ASSESSMENTS  
Not applicable 
 Safety Assessments 
Safety assessments will include recording all AEs and serious adverse events (SAEs). 
Safety assessments also include laboratory evaluation of hematology, biochemistry, and 
urinalyses; periodic measurement of weight, vita l signs, ECGs, and performance of PEs, as 
detailed in the sections below and shown in  Table [ADDRESS_717370]-reported LSRs will not be reported as adverse events.  Treatments administered for 
LSRs will be recorded on the Concomitant Medications CRF. 
[IP_ADDRESS].[ADDRESS_717371].  For this study, the study drug is KX2-391 Ointment 1%. 
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after dosing or  
x those pre-existing conditions that worsen after dosing 
The criteria for identifying AEs are: 
‚Ä¢ any unfavorable and unintended sign (incl uding an abnormal laboratory finding), 
symptom, or disease temporally associated wi th the use of an investigational product, 
whether or not considered related to the investigational product 
‚Ä¢ any new disease or exacerbation of an existing disease  
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 33  
CONFIDENTIAL 
 ‚Ä¢ any deterioration in nonprotocol-required mea surements of a laboratory value or other 
clinical test (eg, ECG or x-ray) that result s in symptoms, a change in treatment, or 
discontinuation from study drug 
‚Ä¢ recurrence of an intermittent medical conditi on (eg, headache) not present at baseline 
All AEs, regardless of relationship to study drug  or procedure, should be collected beginning 
from the time the subject signs the study IC F through the final contact [CONTACT_548013]-up 
Period.   For subjects participating in the Recurren ce Follow-up Period, only AEs at the 
treatment area will be collecte d.  Subjects who fail screening primarily due to AE(s) must 
have the AE(s) leading to screen failure reported on the Screening Disposition CRF/eCRF. 
Subjects with onset of an AE  or deterioration of a pre-exist ing condition will be followed 
until resolution, resolved with sequelae, or under  medical care.  All SAEs must be followed 
to resolution or, if resolution is unlikely, to stabilization. 
All AEs observed during the study will be reported on the CRF/eCRF. 
Laboratory Adverse Events 
A treatment-emergent abnormal laboratory test re sult should be considered as a treatment-
emergent AE (TEAE) if the identified labor atory abnormality leads to any type of 
intervention whether prescribed in the protocol or not. 
An abnormal laboratory result should be considered by [CONTACT_548014]: 
x results in the withdrawal of study drug 
x results in withholding of study drug pending some investigational outcome 
x results in the initiation of an inte rvention, based on medical evaluation (eg, 
potassium supplement for hypokalemia) 
x results in any out of range laboratory value that in the Investigator ‚Äôs judgment 
fulfills the definitions of an AE with regard to the subject ‚Äôs medical profile  
x increases in severity compared with baseline 
Abnormal laboratory values should not be listed as  separate AEs if they are considered to be 
part of the clinical syndrome that is being reported  as an AE.  It is the responsibility of the 
Investigator to review all laboratory findings in  all subjects and determine if they constitute 
an AE.  Medical and scientific judgment should be  exercised in deciding whether an isolated 
laboratory abnormality should be classified  as an AE.  Any laboratory abnormality 
considered to constitute an AE should be reported on the Adverse Event CRF/eCRF. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015].  An ECG abnormality in a subject with symptoms may meet the criteria for an AE as described in this protocol.  In these instances, the AE 
corresponding to the symptomatic ECG abnormality will be recorded on the Adverse Events 
CRF/eCRF. 
Clinical Study Protocol KX01-AK-[ADDRESS_717372] submit an 
SAE report, including the ECG report to the Sponsor, or designee, using the SAE reporting 
procedures ( Section [IP_ADDRESS] ). 
Assessing Severity of Adverse Events 
Every effort must be made by [CONTACT_548016].  
Adverse events will be graded for severity as follows: 
Mild An event that is easily tolerated by  [CONTACT_102], causing minimal discomfort 
and not interfering with everyday activities 
Moderate An event that is sufficiently discomforting to interfere with everyday 
activities 
Severe An event that prevents normal everyday activities  
Investigators will assess severity for all AEs (f or both increasing and decreasing severity).  
The criteria for assessing severity are different from those used for seriousness (see Section [IP_ADDRESS].2 ). 
Assessing Relationship to Study Treatment 
Items to be considered when assessing the re lationship of an AE to the study treatment are: 
x temporal relationship of the onset of the event to the initiation of the study treatment 
x the course of the event, especially the effe ct of discontinuation of study treatment or 
reintroduction of study treatment, as applicable 
x whether the event is known to be associated  with the study treatment or with other 
similar treatments 
x the presence of risk factors in the study s ubject known to increase the occurrence of 
the event 
x the presence of nonstudy treatment-related factors that are known to be associated 
with the occurrence of the event 
Classification of Causality 
The relationship of each AE to the study drug will be recorded on the CRF/eCRF using the 
following criteria: 
Definitely Related:   A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administ ration, and which cannot be explained by 
[CONTACT_548041]01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 35  
CONFIDENTIAL 
 Probably Related:   A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, unl ikely to be attributed to concurrent or 
underlying disease or other drugs or conditions  
Possibly Related:   A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, but which could also be explained by [CONTACT_548018]:   A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which makes  a causal relationship improbable, and in 
which other drugs, conditions or concurrent  or underlying disease provide plausible 
explanations 
[IP_ADDRESS].[ADDRESS_717373] medical occurrence that at any dose: 
‚Ä¢ results in death 
‚Ä¢ is life-threatening (ie, the s ubject was at immediate risk of death from the AE as it 
occurred; this does not include an event that, had it occurred in a more severe form or 
was allowed to continue, might have caused death) 
‚Ä¢ requires inpatient hospi[INVESTIGATOR_1081] 
‚Ä¢ results in persistent or significant disability/incapacity 
‚Ä¢ is a congenital anomaly/birth defect (in th e child of a subject who was exposed to the 
study drug) 
Other important medical events that may not be  immediately life-threatening or result in 
death or hospi[INVESTIGATOR_313], when based on appropriate medical judgment, may jeopardize the subject or may require intervention to pre vent one of the outcomes in the definition of 
SAE listed above should also be considered SAEs.  Medical and scientific judgment should 
be exercised in deciding whether expedited reporting is appropriate in such situations. 
In addition to the above, other events of in terest, which include pregnancy, overdose, and 
significant treatment-emergent laboratory abnormality (See Section [IP_ADDRESS].1 ), are to be 
captured using the SAE procedures but are to be considered as SAEs only if they met one of the above criteria. All events of these types are to be reported on the CRF/eCRF whether or not they meet the criteria for SAEs. 
The following hospi[INVESTIGATOR_547960] ‚ÄúAE‚Äù (ie, 
there is no untoward medical occurrence) associated with the hospi[INVESTIGATOR_059]: 
‚Ä¢ hospi[INVESTIGATOR_547961] (where the condition requiring the 
hospi[INVESTIGATOR_547962] t study drug administration) 
Clinical Study Protocol KX01-AK-[ADDRESS_717374] be followed to resolution or, if resolution is unlikely, to stabilization. 
[IP_ADDRESS].3 L ABORATORY MEASUREMENTS  
Blood will be collected for clinical laboratory te sts at Screening (Visit 1), Day 8 (Visit 7), 
and Day 57 (Visit 10) ( Table 1 ).  Collection of blood and urine (including samples for 
pregnancy testing, where applicable) will be conducted at the clinic site.  Approximately 
[ADDRESS_717375] be documented for all laboratory samples. 
Microscopic urinalysis will be conducted only when clinically indicated based on dipstick 
results (laboratory protocol) or as determin ed by [CONTACT_737].  When conducted, 
microscopic urinalysis results will be recorded on the CRF/eCRF. 
The clinical laboratory tests to be measured during the study are provided in  Table 4.  
Table 4 Clinical Laboratory Tests 
Category Parameters 
Hematology  red blood cells (RBC), hemoglobin, hematocrit, platelets, and white 
blood cells (WBC) with differential (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils),  mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), RBC distribution width (RDW)
 
Chemistry  
 Electrolytes chloride, potassium, sodium, bicarbonate (HCO 3) 
 Liver function tests alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), gamma glutamyl transpeptidase (GGT), direct bilirubin, total bilirubin
 
 Renal function tests blood urea/blood urea nitrogen, creatinine 
 Other Albumin, calcium, cholest erol, glucose, lactate dehydrogenase (LDH) , 
phosphorus, total protein, triglycerides, uric acid  
Urinalysis  (dipstick)a hydrogen ion concentration (pH), specific gravity, protein, glucose, 
ketones, leukocyte esterase, nitr ite, bilirubin, urobilinogen, blood 
Pregnancy Testing  serum pregnancy test, urine pregnancy test (where applicable)  
a Microscopic urinalysis will be conducted only when clinically indicated based on dipstick results 
(laboratory protocol) or as determined by [CONTACT_737]. 
A laboratory abnormality may meet the criteria to  qualify as an AE as described in this 
protocol (see Section [IP_ADDRESS].1 ).  In these instances, the AE corresponding to the laboratory 
abnormality will be recorded on the Adverse Event CRF/eCRF. 
For laboratory abnormalities meeting the criteria of SAEs (see Section [IP_ADDRESS].2 ), the site 
must electronically transmit the SAE report including the laboratory report to the Sponsor using the SAE form (see Section [IP_ADDRESS] ). 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 37  
CONFIDENTIAL 
 [IP_ADDRESS].4 V ITAL SIGNS 
Vital sign (pulse rate, systolic and diastolic blood pressure, respi[INVESTIGATOR_697], and body 
temperature) measurements will be taken after the subject has been seated for at least 
5 minutes at Screening (Visit 1), Day 5 (Visit 6), Day 8 (Visit 7), Day 15 (Visit 8), Day 29 (Visit 9), and Day 57 (Visit 10) ( Table 1 ).  Serial vital signs may be obtained to confirm 
accurate readings.  
[IP_ADDRESS].5 P HYSICAL EXAMINATIONS  
A complete PE will be performed at Scre ening (Visit 1) and Day 57 (Visit 10) ( Table 1 ). 
A complete PE will include weight and an as sessment of head, eyes, ears, nose, and throat 
(HEENT), integumentary, gastrointestinal, ca rdiovascular, respi[INVESTIGATOR_696], muscular-skeleton, 
and neurological systems. 
Documentation of the PE will be included in the source documentation at the site.  Only 
changes from screening PE findings that meet the definition of an AE will be recorded on the 
Adverse Events CRF/eCRF. 
[IP_ADDRESS].6 E LECTROCARDIOGRAMS  
A 12-lead ECG will be completed at Screen ing (Visit 1), Day 8 (Visit 7), and Day 57 
(Visit 10) ( Table 1 ).  ECGs may be performed at a convenient time during the visit.  Subjects 
must be in the recumbent position for a period of 5 minutes prior to the ECG.  The ECG data 
recorded on the CRF/eCRF must include rate, rhythm, intervals, and QTc/QTcF. 
ECG changes and associated clinical symptoms determined to be clinically significant by [CONTACT_548015]. 
[IP_ADDRESS].7 P REGNANCY TESTING  
Serum pregnancy tests will be obtained in females of childbearing potential at Screening 
(Visit 1), Day 8 (Visit 7), and Day 57 (Visit 10) ( Table 1 ). 
A urine pregnancy test will be performed  on females of childbearing potential before study 
medication application on Day 1 (Visit 2).  Visit [ADDRESS_717376] be reviewed 
before dosing. 
[IP_ADDRESS].8 O THER ASSESSMENTS  
Concomitant Medications 
Concomitant medications will be assessed at all clinic visits ( Table 1 ).  Any medication 
(including nonprescription medications) or therap y administered to the subject during the 
course of the study (starting at the date of informed consent) will be recorded on the 
Concomitant Medication CRF/eCRF.  The Investigator will record any AE on the Adverse Events CRF/eCRF for which the concomitant medication/therapy was administered. 
Clinical Study Protocol KX01-AK-[ADDRESS_717377]-Screening clinic visit through Day 57 (Visit 10), the Investigator or trained 
designee will assess any LSR on the treatment area for signs: 
x Before study medication application (on dosing days) 
x After the assessment of adverse events 
The LSR assessment is the Investigator‚Äôs (or trained designee‚Äôs ) assessment of the following 
signs on the treatment area:  erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration.  Th ese signs will be assessed using a grading 
scale ranging from 0 (not present) to 4 (worst) (Table 5) . 
Table 5 Local Skin Reaction Grading Criteria 
 Grading Criteria 
Local Skin 
Response 0 1 2 3 4 
Erythema  Not present Slightly pi[INVESTIGATOR_8745] 
<50% Pi[INVESTIGATOR_22764] 
>50% Red, restricted to 
treatment area Red extending 
outside treatment 
area 
Flaking / 
Scaling  Not present Isolated scale, 
specific to lesion Scale <50%  Scale >50%  Scaling extending 
outside treatment 
area 
Crusting  Not present Isolated crusting Crusting <50%  Crusting >50% Crusting 
extending outside 
treatment area 
Swelling  Not present Slight, lesion 
specific edema Palpable edema 
extending beyond 
individual lesions Confluent and/or 
visible edema Marked swelling 
extending outside 
treatment area 
Vesiculation / 
Pustulation Not present Vesicles only Transudate or 
pustules, with or 
without vesicles 
<50% Transudate or 
pustules, with or 
without vesicles 
!50% Transudate or 
pustules, with or 
without vesicles 
extending outside 
treatment area 
Erosion / 
Ulceration Not present Lesion specific 
erosion Erosion extending 
beyond individual 
lesions Erosion >50% Black eschar or 
ulceration  
 
Examples of LSR signs are shown in photographs in  Appendix 2 . 
Application site reactions not classified as LSRs (eg, pruritus, pain, infection) will be 
reported as adverse events. 
All application site reactions and LSRs will be followed to resolution, or if resolution is 
unlikely, to stabilization. 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 39  
CONFIDENTIAL 
 Treatment for any LSR or interruption/discontinua tion of study treatment for an LSR will be 
recorded on the CRF/eCRF. 
LSRs will be reported separately from adverse events. 
Pi[INVESTIGATOR_547963]- and hyper- pi[INVESTIGATOR_547964] e treatment area will be assessed by [CONTACT_3786] (or a trained designee) as being present or absent.   
Pi[INVESTIGATOR_547991]-Sc reening clinic visit through Day 57 (Visit 10) 
(Table 1 ). 
Standardized Photography 
Standardized photography will be performed at Screening (Visit 1), Day 1 (Visit 2), Day 8 
(Visit 7), Day 57 (Visit 10), and during the Recurrence Follow-up (at 3, 6, 9, and [ADDRESS_717378]-Day 57).  Before study medication application on Day 1, the Investigator or a qualified staff member must obtain standardized photograph y of each subject‚Äôs treatment area before 
application of study medication. 
Care must be taken to ensure the same ligh ting, background, subject positioning relative to 
the camera and camera settings are used for  each photograph.  Equipment, supplies and 
detailed instructions for obtaining and managin g the photographs will be provided to the 
investigational center prior to the initiation of subject enrollment. 
The photographs are to document the appearance of the subjects‚Äô treatment area and to assist 
with the identification and confirmation of the location of the treatment area throughout the 
study ( Section 9.1.1 ). 
Equipment, supplies and detailed instructions for obtaining and managing the photographs 
will be provided to the investigational center prior to the initiation of subject enrollment.  
9.5.[ADDRESS_717379], will be collected (ie, Day 57 plus 30 days).  These SAEs will be discussed in the 
clinical study report.  Any SAE event judged by [CONTACT_548042]. 
Deaths and life-threatening events should be  reported immediately by [CONTACT_756].  The 
immediate report should be followed up within [ADDRESS_717380] information for reporting of SAEs is provided in the Safety 
Management Plan, located in the Investigator File. 
It is very important that the SAE report form be  filled out as completely as possible at the 
time of the initial report. This includes the Investigator ‚Äôs assessment of causality.  All 
supporting documents should be sent de-identified and should contain the assigned subject number. Send only supporting documents directly related to the event. 
Any follow-up information received on SAEs should be forwarded within 1 business day of 
its receipt.  If the follow-up information changes the Investigator ‚Äôs assessment of causality, 
this should also be noted on the follow-up SAE form. 
Preliminary SAE reports should be followed as soon as possible by [CONTACT_3582][INVESTIGATOR_3103], autops y reports, and other documents requested by 
[CONTACT_1034]. 
 Reporting of Pregnancy and Exposure to Study Drug through Breastfeeding 
Any pregnancy for which the estimated date of c onception was either before the last visit or 
within [ADDRESS_717381] be reported. 
If an adverse outcome of a pregnancy is suspected to be related to study drug exposure, this 
should be reported regardless of the length of ti me that has passed since the exposure to study 
treatment. 
A congenital anomaly, death during perinatal period, an induced abortion, or a spontaneous 
abortion are considered to be an SAE and should  be reported in the same timeframe and in 
the same format as all other SAEs (see Section [IP_ADDRESS] ). 
Pregnancies must be reported by [CONTACT_548035] 
[ADDRESS_717382] 
[IP_ADDRESS].1 R EPORTING OF ADVERSE EVENTS ASSOCIATED WITH STUDY DRUG OVERDOSE , 
MISUSE , ABUSE , OR MEDICATION ERROR  
Study drug overdose is defined as the accidental or intentional use of the drug in an amount 
higher than the dose being studied. 
Any study drug overdose should be noted on the Study Medication CRF/eCRF. All AEs associated with overdose, or medicati on error should be captured on the Adverse 
Event CRF/eCRF and also reported using the procedures detailed in Section [IP_ADDRESS] even if 
the AEs do not meet serious criteria.  If th e AE associated with an overdose or medication 
error does not meet serious criteria, it must still be reported using the SAE form and in an 
expedited manner but should be noted as nonserious on the SAE form and the Adverse Event CRF/eCRF. 
 Expedited Reporting 
The Sponsor (or its designee) must inform In vestigators and regulatory authorities of 
reportable events, in compliance with appli cable regulatory requirements, on an expedited 
basis (ie, within specific timeframes).  For th is reason, it is imperative that sites provide 
complete SAE information in the manner described above. 
In determining what SAEs meet criteria for ex pedited reporting, the current version of the 
Investigator ‚Äôs Br ochure will be used for reference safety information. 
 Breaking the Blind 
Not applicable 
 Regulatory Reporting of Adverse Events 
Adverse events will be reported by [CONTACT_548020] a third party acting on behalf of the 
Sponsor to regulatory authorities in compliance with local law and established guidance.  The format of these reports will be dictated by [CONTACT_119663]. 
9.5.4 Completion/Discontinuation of Subjects 
A subject may elect to discontinue from the study at any time for any reason.  See 
Section 9.3.[ADDRESS_717383] document the actual reason(s ) why they decided to discontinue subjects, 
or why subjects withdrew consent, as appli cable.  Study disposition information will be 
collected on the Disposition CRF/eCRF. 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 42  
CONFIDENTIAL 
 Subjects who withdraw from study treatment (w ith the exception of death or withdrawal of 
consent) will be encouraged to complete th e Early Termination assessments at the time of 
withdrawal as indicated in Table [ADDRESS_717384] who has ceased to return for visits will be 
followed up by [CONTACT_2319], phone, or other means to gather information such as the reason for failure to return, the status of treatment comp liance, the presence or absence of AEs, and 
clinical courses of signs and symptoms.  This i nformation will be recorded in the CRF/eCRF.  
9.5.[ADDRESS_717385] 
whether he/she has received medical care by  [CONTACT_3212].  When the subj ect is going to receive medical care by [CONTACT_3213], the Investigator, with the consent of the subject, will inform the other physician that the subject is participating in the clinical study. 
9.6 Data Quality Assurance 
This study will be organized, performed, a nd reported in compliance with the protocol, 
SOPs, working practice documents, and applicab le regulations and guidelines.  Site audits 
may be made periodically by [CONTACT_1034]‚Äôs or the CRO‚Äôs qualified compliance auditing team, which is an independent function from the study team responsible for conduct of the study. 
9.6.[ADDRESS_717386] source documentation, 
collected on the CRF/eCRFs and entered into a validated data management system that is 
compliant with all regulatory requirements.  A CRF/eCRF or a select CRF/eCRF page may be used as a source document.  CRF/eCRFs used as source documents will be listed in the Data Management Plan.  As defined by [CONTACT_12212] E6 guidelines (Section 1.11), the CRF is a 
printed, optical, or electronic document design ed to record all of the protocol-required 
information to be reported to the Sponsor on each study subject.  In this study, the CRF may 
refer to either a paper (CRF) or electronic data collection form (eCRF), or both. 
Data collected on the CRF/eCRF must be comple ted following the instructions described in 
the CRF/eCRF Completion Guidelines, which will be based on the Data Management Plan.  The Investigator has ultimate responsibility for  the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRF/eCRF.  The PI [INVESTIGATOR_547966]/eCRF to attest to its accuracy, authenticity, and completeness. 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 43  
CONFIDENTIAL 
 Completed, original CRFs/eCRFs are the sole property of the Sponsor and should not be 
made available in any form to third parties without written permission from the Sponsor, 
except for authorized representatives of the Sponsor or appropriate regulatory authorities. 
Responsible site personnel will enter the information required by [CONTACT_548021]/eCRFs in accordance with the CRF/eCRF Completion Guidelines that are provided.  A CRA will visit each site as documented in the monitoring plan to re view the CRF/eCRFs for 
completeness and accuracy against the source documents. They will identify any discrepancies and ensure that appropriate site personnel address the discrepancies. 
The original CRFs/eCRFs will be maintained at the site in a central document repository. If 
used, a copy of the CRF will be forwarded to the Sponsor. 
At the end of the study an electronic copy of the database along with appropriate system 
version will be archived. 
Uniform procedures will be discussed at the Investigator meetings or at site initiation and/or 
will be documented in the CRF/eCRF Completion Guidelines. 
9.6.2 Clinical Data Management 
All data, both CRF/eCRF and external data, will be loaded into a clinical system as specified 
in the Data Management Plan. 
Quality control and data validation procedures w ill be applied to ensure the validity and 
accuracy of the clinical data. 
All software applications used in the collec tion of data will be properly validated following 
standard computer system validation that is compliant with all regulatory requirements. 
9.[ADDRESS_717387] deviation (SD), median, 
minimum, and maximum.  Categorical variable s will be summarized by [CONTACT_548022].  All raw data obtained from the 
CRF/eCRF, as well as any derived data  will be included in data listings. 
For all analyses, study Day [ADDRESS_717388] dose of study drug. 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 44  
CONFIDENTIAL 
 9.7.1 Statistical and Analytical Plans 
 Study Endpoints 
[IP_ADDRESS].1 P RIMARY ENDPOINTS  
The primary endpoint is activity. 
Activity will be evaluated by [CONTACT_547995].  Complete response rate will be 
defined as the proportion of subjects achieving 100% complete clearance of all treated AK 
lesions on the face or scalp at Day 57.  Sustained response will be defined as the proportion of subjects achieving 100% (complete) cleara nce at Day [ADDRESS_717389]-Day 57.
  
[IP_ADDRESS].2 S ECONDARY ENDPOINTS  
Activity 
Reduction in lesion counts at each visit during Days 1-57 will be assessed as the secondary 
endpoint for activity. 
Safety 
Safety will be evaluated primarily by [CONTACT_548023].  The 
results of other safety assessments (vital si gns, PEs, ECGs) will also be evaluated. 
Pharmacokinetic  
Secondary endpoints include the following PK  parameters derived by [CONTACT_548024]-time data of KX2-391:  C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
[IP_ADDRESS].3 E XPLORATORY ENDPOINTS  
The exploratory endpoint in the study is recurrence rate. 
Recurrence rate will be defined as the proportion of subjects who achieved 100% complete 
clearance at Day 57 (Visit 10) with any identified AK lesions on the face or scalp at 3, 6, 9, and [ADDRESS_717390] evaluations including the Day 57 Follow-up Visit. 
The Safety Analysis/Full Analysis Set is the group of subjects who receive at least one dose 
of study treatment. 
Clinical Study Protocol KX01-AK-[ADDRESS_717391] Disposition 
All subjects will be tabulated as to study di scontinuation and the reasons for discontinuation 
as described in Section 9.3.3 . 
 Demographic and Other Baseline Characteristics 
Demographic and baseline characteristics will be summarized.  For continuous demographic 
variables, results will be summarized and pr esented as N, mean, SD, median, and minimum 
and maximum values.  For categorical (no minal or ordinal) variables, the number and 
percentage of subjects will be used.  No statistical testing will be performed. 
 Prior and Concomitant Therapy 
All Investigator terms for medications recorded in the CRF/eCRF will be coded to an 
11-digit code using the World Health Orga nization Drug Dictionary drug codes. 
Prior medications will be defined as medicati ons that stopped before the first dose of study 
drug. 
Concomitant medications will be defined as med ications that (1) started before the first dose 
of study drug and were continuing at the time of the first dose of study drug, or (2) started on 
or after the date of the first dose of study drug.  Prior and concomitant medications will be 
further coded to the appropriate Anatomical-T herapeutic-Chemical (A TC) code indicating 
therapeutic classification.  A listing of prior and concomitant medications by [CONTACT_548027]. 
All medications will be presented in subject data listings. 
 Activity Analyses 
AK lesion counts will be summarized at Da y 1 (pretreatment) and at each subsequent 
timepoint for subjects in the Full Analysis Set and the Per-Protocol Set. 
A 95% confidence interval (CI) for the comp lete clearance (response rate) at Day [ADDRESS_717392]-Day 57 will be estimated in the Evaluable Set. 
Recurrence rates for all subjects who achieved  complete clearance at Day 57 will be 
summarized by [CONTACT_548043]. 
Clinical Study Protocol KX01-AK-002
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 46  
CONFIDENTIAL 
 
 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker 
Analyses 
[IP_ADDRESS].1 P HARMACOKINETIC ANALYSES  
PK analyses will be performed on the PK Analysis Set. 
Plasma concentrations of KX2-391 will be analyzed to determine C max, and where applicable, 
AUC t, Cmin, and accumulation ratio R. 
Individual timepoints will be tabulated and displa yed graphically and listed for all subjects.  
Summary PK parameters will be analyzed as applicable. 
[IP_ADDRESS].2 P HARMACODYNAMIC , PHARMACOGENOMIC , AND OTHER BIOMARKER ANALYSES  
Not applicable 
 Safety Analyses 
All subjects in the Safety Analysis Set will be included in the safety analyses. 
Safety data will be summarized using desc riptive statistics (eg, n, mean, SD, median, 
minimum, maximum for continuous variables; n [%] for categorical variables).  Safety 
variables include AEs, clinical laboratory pa rameters, weight, vital signs, 12-lead ECG 
results, and physical examination findings 
[IP_ADDRESS].[ADDRESS_717393] will be summarized. 
[IP_ADDRESS].2 A DVERSE EVENTS  
For AEs, verbatim terms on the CRFs/eCRFs wi ll be mapped to preferred terms (PTs) and 
system organ classes (SOCs) using the Medi cal Dictionary for Re gulatory Activities 
(MedDRA; version 16.0 or higher).  Subject incidence of AEs will be displayed by [CONTACT_2946].  Adverse events will also be summarized by [CONTACT_548044].  Subject 
incidence of SAEs will also be displayed. 
Only those AEs that were treatment-emergent  will be included in summary tables.  
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after dosing or  
x those pre-existing AEs that worsen after dosing 
All AEs, treatment emergent or otherwise, will be presented in subject data listings. 
The number (percentage) of subjects with TEAEs leading to death will be summarized by 
[CONTACT_55366].  A subject data listing of all AEs leading to death will be provided. 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 47  
CONFIDENTIAL 
 The number (percentage) of subjects with TEAEs leading to discontinuation from study drug 
will be summarized by [CONTACT_55366].  A subject data listing of all AEs leading to 
discontinuation from study drug will be provided. 
[IP_ADDRESS].3 L ABORATORY VALUES  
Laboratory parameters will be summarized using de scriptive statistics at baseline and at each 
subsequent timepoint.  Changes from baseline will also be summarized. 
In addition, shift tables (ie, low-normal-high at baseline versus low-normal-high at follow-up 
in a 3-by-3 contingency table) will be provided to assess change s in laboratory values from 
baseline to follow-up. 
[IP_ADDRESS].[ADDRESS_717394].  Abnormal vital sign 
values will be identified as those outsi de (above or below) the reference range. 
[IP_ADDRESS].[ADDRESS_717395]. 
[IP_ADDRESS].[ADDRESS_717396]. 
[IP_ADDRESS].7 P REGNANCY TESTS  
Results of pregnancy tests will be lis ted for all subjects, as applicable. 
[IP_ADDRESS].[ADDRESS_717397] a 100% complete clearance rate at Day 57 
greater than 20% with 80% power, based on a two-sided (alpha=0.05) binomial test, assuming a response rate of 35%, and less than  a 25% dropout rate.  This corresponds to a 
two-sided 95% CI with a half-width of less th an 15% (ie, lower boundary of the CI above 
20%). 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 48  
CONFIDENTIAL 
 9.7.3 Interim Analysis 
Since this is an open-label study, after each group of 20 subjects completes Day 57 
assessments, activity data will be tabulated. 
9.7.4 Other Statistical/Analytical Issues 
Not applicable 
9.7.[ADDRESS_717398] 
1. ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance, 
US Department of Health and Human Service s, Food and Drug Administration, April 
1996. 
2. Marks R, Rennie G, Selwood TS.  Malign ant transformation of solar keratoses to 
squamous cell carcinoma.  Lancet 1988;1(8589):795-7. 
3. Criscione VD, Weinstock MA, Naylor MF, et  al. Actinic keratoses: natural history 
and risk of malignant transformation in the Veterans Affairs Topi[INVESTIGATOR_201562]. Cancer 2009;115(11):2523-30. 
4. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 
2000;42(1 Pt 2):23-4. 
5. Salasche SJ. Epi[INVESTIGATOR_231743]. J Am 
Acad Dermatol 2000;42(1 Pt 2):4-7. 
6. Guidelines for the Management of Acti nic Keratoses.  2004/2005 European 
Dermatology Forum.  Available from: http://www.euroderm.org  [Accessed 02 July 
2012]. 
7. Drake LA, Ceilley RI, Cornelison RL, et al. Gu idelines of care for actinic keratoses. 
Committee on Guidelines of Care. J Am Acad Dermatol 1995;32(1):95-8. 
8. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in 
hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37(3 Pt 1):392-4. 
9. Ehrig T, Cockerell C, Pi[INVESTIGATOR_229748] D, et al. Actinic keratoses and the incidence of 
occult squamous cell carcinoma: a clinical- histopathologic correlation. Dermatol Surg 
2006;32(10):1261-5. 
10. Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; 
[LOCATION_007] Academy of Family Physicians. Acti nic keratoses: sequelae and treatments. 
Recommendations from a consensus panel.  J Fam Pract 2006;55([ADDRESS_717399]):1-8. 
11. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Ac tinic keratosis: how to differentiate the 
good from the bad ones? Eur J Dermatol 2006;16(4):335-9. 
12. Marks R, Foley P, Goodman G, et al.  S pontaneous remission of solar keratoses:  the 
case for conservative management. Br J Dermatol 1986;115(6):649-55. 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 50  
CONFIDENTIAL 
 11 APPENDICES 
 
 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 51  
CONFIDENTIAL 
 Appendix 1 Fitzpatrick Skin-Type Classification 
 
Clinical Study Protocol KX01-AK-002 
 
 
Kinex Pharmaceuticals, Inc. 
FINAL v1.0_23 Jan 2016  Page 52  
CONFIDENTIAL 
 Appendix 2 Photographs of Local Skin Reactions 
 
 
Source:  (CDER) Clinical Review NDA 202833 PI[INVESTIGATOR_411190]‚Ñ¢ (ingenol mebutate gel, PEP005 Gel) November 
30, 2011. 
 
